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Abstract 
Emerging zoonotic viruses pose an increasing threat, causing outbreaks with high rates of 
morbidity and mortality and frequently significant economic implications. Often, there is a lack or 
shortfall of effective prophylaxis and diagnostic capabilities. Research towards their development, 
together with improved surveillance activities are high priority activities to prepare and respond to 
outbreak threats. Yet handling these viruses commonly requires high containment levels. This can 
be circumvented by the use of replication defective pseudotyped viruses (PVs), incorporating the 
viral envelope protein of interest which constitutes the primary surface antigen. This permits the 
serological detection of neutralising antibodies without the need to handle live virus, as well as 
other viral entry studies. Hence, PVs are increasingly proving to be a valuable tool for emerging 
virus research. The aim of this study was to exploit novelties in the unique flexibility of the PV 
platform to allow the serological assessment of emerging viruses and evaluate technical aspects 
towards standardisation.   
 
Current prophylaxis provides robust protection against rabies virus, yet only confers limited 
protection against other lyssavirus species, which have a near 100% fatality rate. It is thought 
protection is afforded against isolates of phylogroup I rabies virus, yet there is limited biological 
data for the Arctic-like rabies virus (AL RABV) lineage which is endemic across the Middle East 
and Asia. Although other lyssaviruses pseudotype efficiently, titres of AL RABV PV were low. 
Within this study, high titre PV was produced by constructing chimeric envelope proteins, splicing 
the AL RABV ecto-transmembrane domain with the cytoplasmic domain of vesicular stomatitis 
virus. Comparisons showed this did not alter the serological profile of the AL RABV and they were 
effectively neutralised by vaccines and antivirals. It could therefore be concluded that they do not 
pose a significant public health risk. However it is recognised broadly neutralising prophylaxis 
needs to be developed to protect against more divergent lyssaviruses. In a further study, again 
utilising the flexibility to manipulate the envelope protein, PV was produced switching the five 
known antigenic sites of the envelope protein between a phylogroup I (rabies virus) and III (West 
Caucasian bat virus) isolate. Screening polyclonal sera via a neutralisation assay, the 
immunologically dominant sites for phylogroup I and III were identified as III and I respectively. 
This can act to inform future development of more broadly neutralising vaccines.  
 
The 2013-16 outbreak of Ebola virus focused global efforts towards the urgent need for effective 
vaccines and antivirals. To permit low containment level serology studies to assist their 
development, a panel of filovirus PVs were rapidly produced. Work was carried out to optimise 
their method of production; determining lentiviral core PV produced by transfecting HEK 293T/17 
cells was most efficient. Efforts to repeat the use of chimeric envelope proteins to increase titre 
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proved unsuccessful. The evaluation of target cell lines permissive to infection and appropriate for 
neutralisation assays identified that the CHO-K1 cell line produced the clearest data. The PV 
neutralisation assay was subsequently applied to a range of projects to assess candidate prophylaxis 
and demonstrated the value of the platform to respond to emerging virus outbreaks. 
 
Given the increasing prominence in the use of PV, work was undertaken to expand their utility and 
methods for standardisation. An assessment of new reporter genes found a red fluorescent protein, 
with a nuclear localisation signal, improved the clarity of data collection and output in additional 
spectrum to the current repertoire. To be able to correlate the disparate readout units of fluorescent 
and luminescent reporters, recorded as infectious units (IFU) and relative light units (RLU) 
respectively, a new construct was produced to integrate and equally express two reporters from 
cells transduced with PV. It was determined that approximately 1260 RLU equates to 1 IFU, 
although future work to determine how this fluctuates between cell lines is required. Finally, 
alternative methods to quantify PV were evaluated, measuring the number of particles, genome 
copies and reverse transcriptase (RT) activity, in addition to the currently used biological titre. It 
was found that measures of genome copies and RT activity, in combination with biological titre 
provides information on the quality of PV preparations and could be used to standardise assay 
input.  
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Chapter 1. Introduction 
 
1.1. Emerging Zoonotic Viruses 
1.1.1. History and Processes of Zoonotic Virus Emergence 
Emerging infectious diseases (EIDs) present a continuing threat to human, animal and crop health, 
constituting a source of great global burden and economic demand (Jones et al., 2008; Weiss & 
McMichael, 2004). Little over half a century ago there was widespread belief among the medical 
community that EIDs were moving towards eradication, a view which was rumoured to be shared 
by the US Surgeon General of the time, Dr. William Stuart (1965-1969), with the largely cited 
quote “It is time to close the book on infectious diseases”, although this has more recently been 
reported as inaccurate (Spellberg & Taylor-Blake, 2013). Advances in sanitation and disease 
surveillance along with increased vaccine availability and use of antibiotics had given rise to a 
decline in infectious disease occurrence in the developed world, yet this phenomenon was short 
lived. Within the last 40 years there has been a marked, steady increase in the incidence of EIDs 
which is reflected in the current and continuing demand for research advances coupled with ever 
heightening media attention (Jones et al., 2008; Meslin et al., 2000; Reperant & Osterhaus, 2017; 
Smith et al., 2014).  
 
Zoonotic pathogens, causing infections in animals which are capable of transmission to humans, 
are accountable for around 65% of EIDs, with zoonosis caused by viral pathogens regarded as one 
of the most significant threats (Jones et al., 2008; Smith et al., 2014; Taylor et al., 2001). Indeed, a 
list has been culminated by the World Health Organisation (WHO) of diseases which are a priority 
for research and development purposes. This is based on a lack of diagnostic and prophylactic 
treatments as well as the public health risk and epidemic potential they pose. It is comprised only of 
zoonotic viruses, all of which first emerged within the last century, distributed over four continents 
(Figure 1.1) (WHO, 2017). Zoonotic virus (re-)emergence, as either a newly recognised infection 
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or the rapidly increasing incidence and geographic range of an existing virus, is attributable to 
changes in ecological, social and environmental factors (Daszak et al., 2000; Morse, 1995; Morse 
et al., 2012). Scientific advances bringing an initial period of decline in EIDs could not compensate 
for other dramatic, fast moving changes which arose in the developing global community. 
Deforestation, rural-to-urban migration and displacement in zones of conflict, along with an 
increase in international connectivity through air travel and trade links, culminates in bringing 
humans into closer proximity with animal host reservoirs and the ability of emerging virus species 
to rapidly spread across continents (Gortazar et al., 2014; Pybus et al., 2015; Weiss & McMichael, 
2004).  
 
An example is the 1994 and 1999 emergence of henipavirus outbreaks in the Australasian region. 
Farming into previously uncultivated land allowed transmission to humans from equine and swine 
intermediary amplifying hosts, of Hendra and Nipah virus respectively, after exposure to Pteropid 
bats, the viral reservoir (Field et al., 2001; Kuzmin et al., 2011; Weiss & McMichael, 2004). 
Further, the 2002-3 emergence of severe acute respiratory syndrome coronavirus (SARS-CoV) 
rapidly resulted in an epidemic involving cases in over 30 countries, demonstrating the significance 
of air travel in abolishing the natural containment effect of geographical boundaries (Chan et al., 
2013; Cheng et al., 2007). This has been further corroborated by the rapid spread of Middle East 
respiratory syndrome coronavirus (MERS-CoV) from the Middle East to Europe in 2012 and the 
proceeding nosocomial outbreak in South Korea during 2015, with air travel responsible for the 
introduction into each location (Anderson & Baric, 2012; Su et al., 2015; de Wit et al., 2016). 
Additionally, during the 2013-16 West African Ebola virus outbreak, the worldwide threat posed 
from its spread via international air travel drew much attention and saw the implementation of air 
travel restrictions, along with exit and entry screening (Bogoch et al., 2015; To et al., 2015). These 
events act to highlight the need for global collaboration on epidemiology and surveillance in order 
to rapidly respond to developing pandemic threats. 
 
  
 
3
 
 
Figure 1.1 Timeline Mapping the Emergence of Viruses Considered a Research and Development Priority by the WHO 
The year of first isolation, location and key host reservoirs/vectors are indicated for emerging viruses which are currently considered a priority by the WHO due to the 
potential to cause a public health emergency, requiring urgent research and development to produce effective diagnostic tests and prophylaxis. The timeline is representative 
of the past century (1917 – 2017) and arrowheads indicate the region where the virus emerged. * Likely host reservoir.  
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It is not only mankind’s encroachment and technological advances that have exacerbated the 
burden caused by emerging viruses, but also the ability of the viruses themselves to adapt and 
evolve to these anthropogenic drivers of emergence. Chikungunya virus, an arbovirus spread by the 
Aedes aegypti mosquito, was first documented in the 1950s in Africa but has re-emerged in the last 
decade to cause a series of major epidemics in Africa, Asia and more recently Europe (Caglioti et 
al., 2013). During outbreaks in the Reunion Islands (2005-6) and Kerala, India (2009) the virus has 
evolved to contain specific mutations in its envelope glycoprotein that allow it to now be 
effectively transmitted by the Aedes albopictus mosquito (Tsetsarkin et al., 2007; Tsetsarkin & 
Weaver, 2011), thereby giving it access to new environmental niches and increasing the severity of 
outbreaks in existing endemic areas. Similarly, it has recently been suggested that co-evolution of 
Zika virus with its Aedes mosquito host species, acquiring a mutation in a non-structural protein, 
lead to its enhanced infectivity and prevalence within mosquitoes, which may have contributed to 
its recent re-emergence and spread (Liu et al., 2017). First isolated in Uganda in 1947, Zika virus 
caused only sporadic cases prior to outbreaks in western, followed by southern, Pacific islands and 
the French Polynesia between 2007-13. Then, geographical expansion in 2015 led to its emergence 
in the Americas and the resulting epidemic which spread across three continents. It was declared a 
public health emergency of international concern by the WHO in February 2016 due to its 
association with an alarming increase in cases of microcephaly (Baud et al., 2017; McCloskey & 
Endericks, 2017). In each of these cases, economic growth in the developing countries driving 
urbanisation gave rise to an increase in mosquito populations and human contacts. A higher 
number of transmission events fuel the probability of the virus evolving genetically favourable 
adaptations. 
 
The majority of emerging zoonotic viruses, and indeed those accountable for some of the most 
threatening outbreaks, are RNA viruses. High error rates of virus-encoded RNA polymerase allows 
for frequent mutations during genome replication, with additional genetic recombination or 
reassortment possible in positive-sense RNA viruses and those with segmented genomes 
respectively in particular (Chan et al., 2013; Nichol et al., 2000). The ability to rapidly adapt and 
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exploit the evidenced environmental and social worldwide developments has facilitated their 
successful transmission. They are further able to overcome selective pressures of the immune 
response and adaptation of the host. An additional feature advantageous to their success is 
asymptomatic carriage in reservoir host species, demonstrated by bat species which are implicated 
as the reservoir of many zoonotic RNA viruses. Bats demonstrate persistent viral shedding despite 
a lack of notable pathology, a phenomenon tentatively accounted for by characteristics of their 
immune system (Chan et al., 2013; Kuzmin et al., 2011; Zhang et al., 2013). There is additional 
speculative theory on the role of flight, unique to these mammals, which is metabolically 
demanding resulting in body temperatures in the range of those seen during fever, associated with 
shortened disease duration and improved recovery, yet studies to substantiate this further are 
needed (O’Shea et al., 2014; Wang et al., 2011). Indeed there is constant evolutionary pressure 
between viruses and their hosts, adapting to have temporary genetic advantages through 
interactions known as arms races (Daugherty & Malik, 2012). A phenomenon defined under the 
Red Queen hypothesis of organisms continually evolving to gain both reproductive and status 
advantages over both opposing organisms and the changing environmental landscape. 
 
Influenza A virus is a prime example of a zoonotic virus which undergoes continual evolution 
events, producing new antigenic variants to evade host immune recognition under a diverse 
environmental and host landscape, with global transmissibility (Pybus et al., 2015; Smith et al., 
2014). Aquatic birds are considered the primary host reservoir of influenza A viruses, which also 
circulate between humans and several other mammalian and avian hosts (Webby & Webster, 
2001). Annual human influenza epidemics arise from antigenic drift events within circulating 
strains, whereby mutations occur primarily in the haemagglutinin (HA) but also neuraminidase 
(NA) envelope proteins driven by an error prone RNA polymerase. More critical, although less 
frequent, are antigenic shift events which arise upon co-infection of a cell with two or more 
influenza viruses, leading to re-assortment of the segmented RNA genome to form an antigenically 
distinct variant. Such antigenic shift events gave rise to pandemic events in 1918, 1957, 1968 and 
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2009; with the 1918 (Spanish) influenza pandemic causing a devastating 50-100 million deaths 
(Johnson & Mueller, 2002). Signifying how devastating such pandemic events can be. 
 
1.1.2. Significance and Future Direction of the Emerging Virus Field 
Outbreaks of emerging zoonotic viruses have repeatedly demonstrated catastrophic implications for 
human and animal populations, with a significant economic burden. The 2002-3 SARS-CoV 
outbreak infected more than 8,000 people and caused 774 deaths, with an estimated cost of 
USD$40 billion. It has been estimated that the cost of a pandemic scenario during the 21
st
 century 
could amount to more than USD$60 billion per year (National Acadamey of Medicine, 2016). 
Animal losses can also be high; between 2006-9 OIE-WAHID veterinary services reported that 
55% of livestock loss was a result of zoonosis (The World Bank, 2012). A response to the 1999 
emergence of Nipah virus in Malaysia was the mass culling of more than 1 million pigs, causing 
significant economic implications (Lam & Chua, 2002). As a consequence of evolutionary 
pressures and the drivers of emergence, the threat of further emerging virus outbreaks is constant. 
Indeed, since a framework was introduced in 2007 for WHO epidemic alert and response activities, 
detailed under International Health Regulations (IHR), there have been 4 public health emergencies 
of international concern (PHEIC), with 3 attributed to zoonotic emerging viruses. The third 
declared PHEIC was in response to the 2013 Ebola virus outbreak, which devastatingly resulted in 
more than 11,000 deaths (WHO, 2016). Despite recognising the need to direct a coordinated, 
international, response to an outbreak threatening global public health, improvements are needed. It 
has also been widely recognised that having a responsive approach alone is limited in effectiveness, 
and the capacity to mitigate future threats will be greatly improved by investing in relevant public 
health infrastructure and research. 
 
It is proposed that an investment of USD$4.5 billion a year should be made towards a framework 
building global capabilities to counter the threats of infectious diseases, which is a relatively small 
sum when compared to the predicted cost of a pandemic (National Acadamey of Medicine, 2016).  
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The key aims are outlined as strengthening and regularly assessing public health capabilities and 
infrastructure under IHR legal regulations, with improved WHO leadership of better integrated 
global and regional activities, along with an accelerated research and development programme 
overseen by a dedicated committee. Public health strategies to reduce threats include surveillance 
programmes supported by robust high-throughput diagnostic capabilities for early diagnosis and 
clear infection control and isolation measures (Reperant & Osterhaus, 2017; Welfare & Wright, 
2016). Contact tracing to isolate, monitor and control further transmissions is also fundamental. A 
tremendous example of the value of such a system was set when Ebola virus spread to Lagos, 
Nigeria during the recent outbreak. The country rapidly implemented intense and sustained contact 
tracing and control procedures, monitoring 894 contacts linked to the index case, to effectively 
prevent what could have been a serious outbreak in such a densely populated and connected city 
(Fasina et al., 2014).  
 
Active surveillance for the early detection and monitoring of these emerging zoonotic threats, 
which occur at the transboundary of people, animals and the ecosystem, requires a cross-sectorial, 
One Health approach. The benefits have been evaluated both economically, showing cost 
effectiveness, and in terms of public health benefits, measuring a reduction in Disability Adjusted 
Life Years (DALYs) as a result of disease burden (Baum et al., 2017; The World Bank, 2012).  
Such an approach can help towards preventing outbreaks at the source and work towards predicting 
their occurrence (Morse et al., 2012; Reperant & Osterhaus, 2017). A basic intervention was 
implemented to help prevent the spill-over of Nipah virus, from their fruit bat reservoir to humans 
within Bangladesh. This involved adding bamboo skirts to date palms (Khan et al., 2012) to 
prevent bat saliva coming into contact with sap collected for human consumption, after it became 
clear harvests coincided with outbreaks. The control and surveillance of influenza virus is another 
good example of effective One Health measures. Live poultry markets were identified as a major 
transmission route for avian influenza within the crowded city of Hong Kong during an outbreak in 
1997. Subsequent market closures, as well as implementing better cleaning practices and 
inspections has led to a greatly reduced risk of emergence (Sims & Peiris, 2013). Further, 
 8 
 
surveillance of poultry as well as wild birds and swine for evidence of avian and swine influenza 
respectively, including molecular evolution, helps pre-empt potential pandemics and contributes 
towards guidance on which subtypes to include in seasonal vaccines (Peiris et al., 2012; Sims & 
Peiris, 2013).  
 
The PREDICT project, initiated in 2009 as part of the United States Agency for International 
Development’s (USAID) Emerging Pandemic Threats program, is using a One Health approach 
towards strengthening global capacities to detect known and unknown zoonotic viruses within 
wildlife reservoirs (Kelly et al., 2017; Morse et al., 2012; PREDICT, 2017). The project is vast in 
scale, working with over 30 countries, with surveillance programmes in many developing nations 
which are considered hotspots for emergence. It has collected thousands of wildlife and animal 
samples, identifying known and novel viruses (PREDICT, 2017). The sampling of bats is 
particularly prominent, due to their implication as a reservoir for many zoonotic viruses and a 
desire to better understand their ecology, as well as the diversity of viruses they may harbour. 
Projects have included identifying cost-effective strategies to quantify diversity and reviewing 
sample collection in bats to optimise discovery (Anthony et al., 2013; Young & Olival, 2016). One 
outcome was the early isolation of a MERS-CoV sequence from a bat that was identical to that of 
the human index case during the 2012 outbreak (Memish et al., 2013), with further studies 
providing evidence for the evolutionary mechanisms behind its possible emergence from a bat 
reservoir host (Anthony et al., 2017). Analysis also looks at high-risk patterns of human behaviour 
and identifies intervention points, while providing training to the local workforce to improve 
continuing surveillance and diagnosis capabilities. Works include a recent review into wildlife 
hosts of OIE listed diseases, to encourage better documentation and surveillance of increasing 
global wildlife trade activities (Smith et al., 2017). Further, a mobile-phone based reporting system 
was implemented in Uganda under an Animal Morbidity and Mortality Monitoring programme to 
allow local rangers to provide rapid dissemination of information to enhance surveillance of 
potential risks (Machalaba & Karesh, 2015). Ultimately it is hoped the improvements in zoonotic 
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emerging virus recognition achieved under the PREDICT programme will help inform strategy and 
policy to lower the risks of future pandemic events.  
 
Finally, given many emerging viruses lack appropriate diagnostic tools and prophylaxis, there is a 
fundamental need to undertake research towards their development. This has been recognised in the 
previously mentioned blueprint established by the WHO in 2015 as a response to the Ebola virus 
outbreak and revised in 2017; listing diseases which require priority research and development 
(WHO, 2017) (Figure 1.1). Prioritisation is based on a lack of, or insufficient countermeasures, 
taking into account the public health risk posed and potential to cause an epidemic. A target 
product profile is issued with the aim to fast-track the development of a pipeline of products 
fulfilling the set requirements. As set out in a case study on the WHO consultation activities for 
MERS-CoV research and product development, success requires a global dialogue between public 
health agencies, scientists, product developers and funders (Modjarrad et al., 2016). The Ebola 
virus vaccine development field greatly benefitted from this coordinated, global collaboration. 
Working in PHEIC scenario, the accelerated regulatory and ethical approval of clinical studies, 
along with the provision of funding and manufacturing support, enabled several phase I and II 
clinical trials to be undertaken and impressively, the completion of a phase III clinical trial (Lambe 
et al., 2017; Venkatraman et al., 2017). This clearly demonstrated the potential of working to fast-
track development when public health risks are high and acted to offer the necessary focus towards 
vaccine development for other high priority emerging viruses.  
 
1.1.3. Lyssaviruses 
Rabies is one of the oldest and most deadly zoonotic diseases of mankind, causing an invariably 
fatal encephalitic disease in all warm-blooded mammals. It is caused by members of the Lyssavirus 
genus, belonging to the Rhabdoviridae family, with rabies virus (RABV) constituting the type 
species and thought to be responsible for the majority of human cases. Bats are considered the 
reservoir host of lyssaviruses, with all but two species having been associated with a species of bat 
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(Banyard & Fooks, 2017). However, RABV is only detected in bats within the Americas (New 
World), yet circulates globally within terrestrial carnivores (Figure 1.2). Indeed bites from rabid 
dogs is the principle transmission reservoir, responsible for 99% of human cases and causing 
almost 60,000 deaths a year, which predominantly occur in Africa and Asia (Fooks et al., 2014; 
WHO, 2013). The theory is that RABV emerged within terrestrial mammals following a spill-over 
event, which led to its subsequently geographic expansion (Badrane et al., 2001). Distinct lineages 
of RABV are also maintained within various wildlife carnivores, such as racoons and foxes in 
certain geographic locations (Troupin et al., 2016). Canine rabies is estimated to cost 3.7 million 
DALYs and USD8.6 billion annually (Hampson et al., 2015). It is considered that under reporting 
of rabies, partly due to the lack of effective surveillance and laboratory infrastructure (Banyard et 
al., 2013; Sudarshan et al., 2007), resulted in a lack of realisation as to its burden and historical 
policies were insufficient towards its elimination.   
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Figure 1.2 Diversity with the Lyssavirus Genus 
Representation of the current global diversity within the Lyssavirus genus, divided into antigenically distinct 
phylogroups I, II and III with a human silhouette representing species associated with human fatalities. 
Species marked by a red boarder are awaiting classification. Adapted from (Banyard & Fooks, 2017). 
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Although efforts to control canine rabies have seen it successfully eliminated across many 
developed countries, it remains endemic across large regions of the developing world. Effective 
vaccines derived against RABV are available and post-exposure prophylaxis can prevent rabies if 
administered promptly before the onset of symptoms, however it is not always available in endemic 
regions and both have a high cost implication (Fooks et al., 2014; Hampson et al., 2008). 
Improving access to therapeutics certainly goes some way towards limiting its burden. Yet, the key 
priority towards the control of human rabies is the mass vaccination of domestic dogs, adopting a 
coordinated One Health approach. Investing in dog vaccination is both ethical and economically 
viable and effective provided at least 70% coverage is achieved (WHO, 2013; Zinsstag et al., 
2007). It works to avert future human exposures, decreasing medical costs and also presents a 
feasible method towards elimination. The cost effectiveness is calculated to be USD$837 per 
averted human exposure (Zinsstag et al., 2007). Such efforts have successfully eliminated dog 
rabies in Europe and the Americas (Muller et al., 2012; Vigilato et al., 2013). Further, wildlife 
rabies control via oral vaccination schemes has progressed towards eliminating rabies from foxes 
within Europe (Freuling et al., 2013). In 2015, a joint WHO-OIE global framework was set for the 
elimination of canine rabies by 2030 (WHO & OIE, 2015). Key obstacles include the need to 
collect high quality surveillance data, with in-field diagnostic capabilities and the maintenance of 
political and social awareness (Banyard et al., 2013; Fahrion et al., 2017; Fooks et al., 2014). 
Further, surveillance to better document and understand rabies circulation within wildlife species 
will remain important to assessing the human rabies risk.  
 
A different challenge is posed by the non-RABV lyssaviruses, which have been detected within 
bats across Africa, Europe and Asia (Old World) but have rarely been documented in non-flying 
species (Fooks et al., 2014) (Figure 1.2). The first to be identified was Lagos bat virus (LBV), 
isolated in 1956 in Nigeria (Boulger & Porterfield, 1958) and since then an increasing number of 
novel lyssaviruses continue to be discovered, circulating in distinct geographical regions. Currently 
14 species are classified within the Lyssavirus genus, which are separated within 3 phylogroups 
based on antigenic and genetic distance, with a further three putative species awaiting classification 
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(Banyard & Fooks, 2017; Dietzgen et al., 2011) (Figure 1.2). While both Mokola virus (MOKV) 
and Ikoma virus (IKOV), isolated form a shrew and civet respectively, have not be detected in bats, 
their ecology and circumstances of detection mean a bat reservoir is likely (Evans et al., 2012; 
Horton et al., 2014). These novel lyssaviruses cause an indistinguishable clinical disease, and 
although only a small number of human cases have been documented, routine diagnosis does not 
differentiate the causative species and thus the disease burden could be higher (Evans et al., 2012; 
Fooks, 2004). Significantly, it has been shown that existing vaccines and post-exposure 
prophylaxis are ineffective at affording protection against more divergent species in phylogroups II 
and III (Brookes et al., 2005; Hanlon et al., 2005; Horton et al., 2010). Consequently there is a 
drive towards the urgent development of more broadly neutralising prophylaxis. The number of 
human rabies cases caused by non-RABV lyssaviruses also needs to be better characterised. Given 
the maintenance of lyssaviruses within bats, there is an inability to eradicate rabies and once again 
bats are constituting a risk for spill-over events leading to infectious disease emergence (Fooks, 
2004; Kuzmin et al., 2011). As ever, there is a need for improved knowledge of the ecology of bats 
and their role in the maintenance and circulation of lyssaviruses to fully understand future risks of 
rabies emergence, particularly after elimination from the canine reservoir.  
 
1.1.4. Filoviruses 
Members of the Filoviridae family have been a known cause of severe haemorrhagic fever in 
humans since first emerging as the etiological agent responsible for an outbreak in 1967. 
Laboratory workers in Germany had become infected handling African green monkeys imported 
from Uganda, there were 31 cases with a 23% fatality rate and the species responsible falls within 
the Marburgvirus genera (Leroy et al., 2011; Smith et al., 1967). The second defined genus, 
Ebolavirus, emerged 10 years later in almost simultaneous outbreaks in Sudan and the Democratic 
Republic of Congo. They were each responsible for over 200 cases and found to be caused by the 
species Sudan ebolavirus and Zaire ebolavirus, with an 88% and 53% fatality rate respectively 
(Leroy et al., 2011; WHO, 1978a, b). Since their emergence there have been numerous sporadic 
outbreaks of Marburg and Ebola virus disease (M/EVD) across remote villages in Central Africa, 
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limited to at most a few hundred cases, with variable fatality rates (Leroy et al., 2011; To et al., 
2015). EVD has occurred most frequently and of the five species within the Ebolavirus genus, 
Sudan and Zaire ebolavirus are often responsible. Of the other species, just one human case has 
been associated with Tai Forest ebolavirus, when an ethnologist fell sick after performing an 
autopsy on a chimpanzee (Le Guenno et al., 1995) and Bundibugyo ebolavirus has caused two 
outbreaks, in 2007 and 2012 which had relatively low fatality rates (To et al., 2015; Towner et al., 
2008). Distinctly, the Reston ebolavirus species circulates within the Philippines and has not 
caused human disease (Leroy et al., 2011; Miranda et al., 1999). 
 
All the filoviruses originating in Africa cause haemorrhagic fever of varying severity within 
humans and have shown a similarly high pathogenicity in non-human primates (NHPs). A large 
epizootic outbreak of Zaire ebolavirus has contributed to a decline in great ape numbers in Gabon 
and the Republic of Congo (Bermejo et al., 2006; Walsh et al., 2003). Frequently, the emergence of 
M/EVD within human populations has been linked to contacts with infected NHPs, acting as an 
intermediate host. For a long time the natural reservoir of these filoviruses has remained elusive, 
however it seems likely that bats act as a reservoir following the isolation of Marburgvirus from a 
bat species (Towner et al., 2007, 2009) and demonstration that others harboured antibodies and 
genetic material specific to Zaire ebolavirus (Leroy et al., 2005). It has also been shown that during 
an outbreak of Zaire ebolavirus in 2007, humans were likely directly infected following contact 
with migratory fruit bats which were hunted for consumption (Leroy et al., 2009). Although a 
better understanding of the transmission cycle is required, it has become clear that direct contact 
with tissues of infected wildlife also constitutes a risk for human infection. Subsequent 
transmission between humans occurs via direct contact with bodily fluids of symptomatic 
individuals. As for Reston ebolavirus, it was identified after causing a haemorrhagic fever outbreak 
with high mortality in NHPs imported to the US, which were traced back to the Philippines 
(Miranda et al., 1999). The source of infection was not identified, yet it has subsequently been 
found that domestic swine within the Philippines act as a host (Barrette et al., 2009) and it has also 
been detected in pigs in China (Pan et al., 2014). Humans in contact with the infected NHPs and 
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swine were found to have antibodies against the virus without clinical disease, thus asymptomatic 
infection is assumed. Perhaps unsurprisingly, bats seropositive for Reston ebolavirus have been 
implicated as a reservoir in the Philippines (Taniguchi et al., 2011). Intensified studies into bat 
ecology have further found evidence of species seropositive for both Zaire and Reston ebolavirus 
in Bangladesh (Olival et al., 2013) and China (Yuan et al., 2012). Lastly, following a large die-off 
of bats in Spain they were found to be infected with a novel, genetically distinct, filovirus (Negredo 
et al., 2011). The species, Lloviu cuevavirus has been classified under the Cuevavirus genus. There 
is speculation as to whether it was the cause of the bat deaths.  
 
The recent, historical, outbreak of EVD within West Africa is suspected to have infected more than 
28,000 people (WHO, 2016). The index case occurred in Guinea in December 2013 and by March 
2014, when the WHO was notified of a communicable disease outbreak, there were already 111 
suspected cases and Zaire ebolavirus was identified as the cause (Baize et al., 2014). By this time 
the virus was already spreading to highly populated and well connected areas in bordering Liberia 
and Sierra Leone, which went on to report EVD cases in March and May 2014 respectively (To et 
al., 2015). When, on 8
th
 August 2014 the WHO declared a PHEIC, there were already 1,070 
confirmed cases within the three countries (WHO, 2014). The West African region was eventually 
declared free of EVD in June 2016 (WHO, 2016). Some of the implications of this outbreak 
included the pandemic risks associated with international connectivity and the lack of available 
prophylaxis. As mentioned (Section 1.1.2), the establishment of the WHO blueprint of priority 
pathogens helped coordinate and facilitate vaccine clinical trials during the outbreak. Efforts to 
mitigate the risk of future outbreaks should include strengthening the healthcare infrastructure 
within the regions affected, including differential diagnosis of cases of viral haemorrhagic fever 
given Lassa virus is endemic in the same region (Baize, 2015). The location of the recent outbreak 
was of interest, given that it was so far from the central African regions where EVD outbreaks had 
until now occurred and the spill-over event that lead to the outbreak is unknown. The role of bats in 
filovirus ecology needs to be better understood, which has been outlined in a review by the 
PREDICT consortium (Olival & Hayman, 2014). Several questions also remain to be answered 
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towards vaccine development, such as determining the immune correlate of protection by which to 
measure vaccine efficacy and the durability of protection afforded by vaccines (Lambe et al., 2017; 
Venkatraman et al., 2017). Given that the recent outbreak has expanded the geographic area 
associated with EVD outbreaks, with predictive mapping estimating 22 countries are at risk of 
outbreaks (Pigott et al., 2014), further research efforts to widen the understanding of filoviruses are 
prudent.  
 
 
1.2. The Viral Envelope Protein 
1.2.1. Importance and Structure of the Viral Envelope Protein 
Structurally, many mammalian RNA viruses and all zoonotic RNA viruses consist of a viral 
envelope, a lipid membrane acquired during budding from host cell intracellular or extracellular 
membranes, which surrounds the core proteins. Protruding from this lipid membrane are viral 
envelope proteins, involved in attachment to host cell receptors and mediating viral entry during 
the process of infection, which is the initial stage of the viral replication cycle. Following 
conformational changes leading to irreversible binding of receptors to envelope proteins, the viral 
genome and capsid enters after membrane fusion has occurred, either at the host cell surface or 
internally after endocytosis. Envelope proteins comprise two properties to mediate this, domains 
which recognise and bind specifically to cell receptors and a specialised fusion domain. These are 
generally the same within a viral family and are responsible for initiating membrane penetration 
and entry of the viral genetic material post-fusion (Cosset & Lavillette, 2011). Based on structural 
features three classes of fusion protein have been described, class-I, II and III. The fusion domain is 
often hidden, becoming exposed as a result of conformational changes. This is either a direct result 
of envelope protein binding to the host cell receptor, allowing membrane fusion at the cell surface, 
or in a pH-dependent fashion, requiring entry via endocytosis with conformational changes by 
acidification (Cosset & Lavillette, 2011). As a result of their central role in attachment and entry 
into the host cell, they are considered to play a major role in determining pathogenicity. Further to 
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this, being the most exposed protein on the surface of the virus results in them being the major 
target of the humoral immune response. 
 
Structurally, viral envelope proteins are generally type I transmembrane proteins, spanning the lipid 
envelope and comprising an N-terminal ectodomain, transmembrane domain and C-terminal 
cytoplasmic tail. It is thought an interaction between the cytoplasmic tail and the underlying matrix 
protein of the core may guide incorporation of the envelope protein during viral budding at the 
plasma membrane (Harrison, 2013). They can also contain trafficking signals, directing the 
envelope protein to the site of viral budding, and contribute to the fusion process (Cosset & 
Lavillette, 2011; White et al., 2008). The ectodomain of envelope proteins directs the functions of 
receptor binding and fusion. For most viruses these functions are combined onto a single envelope 
protein, such as those of the Rhabdoviridae and Filoviridae family. However for the 
Paramyxoviridae they are split between two proteins with one directing receptor binding (H) and 
the other carrying out fusion activities (F). All three classes of fusion protein act to bring about 
fusion of the viral and host cell membranes in the same sequence; upon activation by receptor 
binding, a low pH, or a combination of both, a conformational change exposes a fusion domain 
which interacts with the cell membrane, the protein then refolds into a post-fusion structure to bring 
the membranes into a hemifusion state before further refolding results in the formation of a fusion 
pore (Figure 1.3) (Harrison, 2008; White et al., 2008). The three classes are based on distinct 
structural features of the pre- and postfusion proteins. A key feature of class I fusion proteins is 
their synthesis as a precursor with two subunits, which often requires proteolytic cleavage in the 
producer cell for activation, as with the well characterised influenza virus HA. Alternatively, as has 
been demonstrated for the envelope protein (GP) of ebolavirus, cleavage of the GP1 and GP2 
subunits is not required for cell entry (Neumann et al., 2007; White et al., 2008). However, rather 
uniquely, proteolysis of GP1 by endosomal cathepsin proteases is a necessary priming step for exit 
from the endosome (Schornberg et al., 2006). Class I fusion proteins are trimers in both pre- and 
post-fusion states with an α-helical structure and refold into a stable rod like structure to mediate 
fusion (Figure 1.3A). On the other hand, class II fusion proteins are anti-parallel dimers in their 
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pre-fusion state, folded low on the virion surface, and upon activation refold as trimers extending 
towards the cell membrane and are formed of β-sheets (Figure 1.3B). They are synthesised in 
association with a chaperone protein, which regulates folding and transport and is proteolytically 
cleaved during maturation. In the absence of cleavage viral infectivity is reportedly reduced (Cosset 
& Lavillette, 2011). The class III proteins share features of the previous two; however do not 
undergo proteolytic processing. Like class I proteins, they are trimers in the pre-fusion state, yet 
have a fusion domain resembling that of class II proteins and both α-helix and β-sheets (Figure 
1.3C). Envelope proteins of the Rhabdoviridae family are class III fusion proteins.  
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Figure 1.3 Schematic Representation of Conformational Rearrangements for Different 
Classes of Viral Fusion Protein during Viral and Cell Membrane Fusion 
Fusion between viral and cell membranes, creating a fusion pore for viral entry follows the same sequence 
for each class of fusion protein but their conformational rearrangements differ. (A) Class I fusion proteins are 
trimers in the virus envelope pre-fusion, which upon activation directs the fusion peptide to the cell 
membrane. Initial refolding brings the membranes into a hemifusion state, before further folding opens a 
fusion pore with the fusion protein anchored as a trimer in a stable rod like structure. (B) Class II fusion 
proteins are presented in an anti-parallel dimer formation in the viral envelope, which transitions to a trimer 
formation and extends towards the cell membrane on activation, before folding back to create a fusion pore. 
(C) Class III fusion proteins are trimers pre- and post-fusion, like class I proteins, and present a fusion 
domain similar in conformation to class II proteins following activation, which also folds back to create a 
fusion pore for viral entry. (Cosset & Lavillette, 2011) 
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1.2.2. The Viral Envelope Protein as a Target  
Studying these envelope proteins, which constitute the primary viral surface antigen, can provide 
important information to assist development of prophylaxis. For example, current rabies vaccines 
only afford protection against lyssaviruses within phylogroup I, with studies finding no cross-
protection is provided against those in phylogroups II and III (Brookes et al., 2005; Fooks, 2004; 
Hanlon et al., 2005). This is due to the antigenic distance of these lyssaviruses from the vaccine 
strain. By comparing identified antigenic sites mapped to the envelope protein, which are important 
immune targets to block functionality, it is possible to gather information to assist with the 
development of a vaccine which affords a greater level of cross-protection (Evans et al., 2012). 
This also feeds into new approaches to evaluate vaccine protection, with knowledge of the 
envelope protein antigenic variation helping predict the level of protection afforded (Horton et al., 
2010). Efforts to develop an efficacious vaccine against Ebola virus have focused on methods of 
presenting the GP envelope protein to the immune system, as a key antigenic target for the 
development of immunity. Many vaccine regimes have entered clinical trials, which are 
predominantly based on using recombinant viral vectors to present the GP, with others employing 
virus like particles as well as DNA based vaccines which work to deliver the GP envelope protein 
in isolation of other viral presentation components (Gilbert, 2015; Lambe et al., 2017; Wang et al., 
2017). Assessment of the magnitude and durability of the response evoked against the GP envelope 
protein, along with how the response correlates with protection, informs suitability of a vaccine 
regime to progress through development.  
 
In addition to raising an antibody response via vaccination, the envelope protein also constitutes a 
target for the development of antiviral drugs. The administration of convalescent serum post-
infection has long been used as a passive immunisation route, which can afford immediate 
protection in previously unvaccinated individuals. However, replacing these polyclonal 
preparations with monoclonal antibody (mAb) can offer a more potent and specific response (Both 
et al., 2013a). It is during the development and isolation of mAb targeting the envelope protein, 
that a detailed assessment of antigenic sites is used to construct an antigenic map. The antigenic 
 21 
 
structure of the rabies virus envelope protein was initially defined by Lafon et al., (1983) and 
current antigenic maps evolved over several development studies (Kuzmina et al., 2013; Marissen 
et al., 2005). Structural studies of mAb bound to the ebolavirus envelope protein have helped the 
understanding of important targets to prevent infection, as well as the receptor binding and fusion 
mechanisms of the envelope protein (Bale et al., 2012; Lee et al., 2008a; Murin et al., 2014). 
Additionally, knowledge of the receptor binding and fusion processes of an envelope protein can 
also be exploited to develop chemical and peptide inhibitors of entry. By targeting these viral 
processes, rather than being specific to a viral species, offers a broad spectrum antiviral approach 
(Vigant et al., 2015). Inhibitors of the cathepsin proteases, which are required for envelope protein 
cleavage and activation for the entry of filoviruses, coronaviruses and henipaviruses, is an example 
of an antiviral that could have a broad spectrum mode of action (Vigant et al., 2015; Zhou & 
Simmons, 2012). Careful assessment of the therapeutic index of such antivirals is required due to 
the risk of side effects from their broad action as well as often having a low potency. However, 
they are considered less susceptible to the development of resistance owing to not being encoded 
by the viral genome, and if developed, have value in rapidly offering an effective treatment for a 
newly emerging virus.  
 
 
1.3. Serology 
1.3.1. Serological Investigations 
Serum antibodies are produced as part of the adaptive humoral immune response either to infection 
or following vaccination. Serological methods for their detection can be used to provide indirect 
evidence of acute, current infection with a pathogen or past exposures and immune status. IgM 
class antibodies are produced during the acute phase of infection, before a transition to IgG class 
antibodies which provide longer-lasting protection and can persist for a life-time. Diagnosis of an 
acute viral infection can be made by detecting virus specific IgM, or by detecting a four-fold rise in 
antibody titres between an acute and convalescent serum sample. Detecting IgG antibodies alone 
 22 
 
signifies past infection or vaccination. However, the onset of antibody responses can occur at 
variable time points during acute infections and so serology may not always be appropriate for 
diagnosis. Further, the advent of molecular techniques such as real-time PCR to give direct 
evidence of current viral infection has led to a gradual reduction in the use of serology. Both of 
these situations are true for rabies and EVD, with molecular detection of virus RNA being 
employed for diagnosis (Broadhurst et al., 2016; Fooks et al., 2009). Although this is only 
recommended for rabies intra vitam, with antigen detection in tissue samples the gold standard OIE 
prescribed test. Despite this, in instances where viremia is transient and virus isolation is either 
impractical or slow the detection of virus specific antibodies is highly valuable (Storch & Wang, 
2013). As a result serology still remains useful to assist diagnosis and allows identification of the 
risk of viral infection. 
 
When deciphering the immune status of individuals to identify the risk of infection and evaluate the 
efficacy of vaccines, the detection and quantification of neutralising antibodies (NAbs) is 
fundamental. NAbs act to block infectivity and for enveloped viruses are targeted towards the 
envelope protein - blocking receptor binding and/or fusion and therefore the processes of entry and 
uncoating within the cell. They are often the best correlate of protection following vaccination 
(Klasse, 2014). During the ongoing development of a vaccine against EVD, assessment of its 
efficacy in producing a humoral immune response and the power of NAbs against the envelope 
protein in preventing infection are essential (Feldmann et al., 2003; Lambe et al., 2017; Ye & 
Yang, 2015). Further, studies investigating the efficacy of current rabies vaccines against novel 
lyssaviruses by quantifying NAbs has been key to determining the lack of protection afforded to 
those in phylogroups II and III (Brookes et al., 2005; Hanlon et al., 2005). Their quantification will 
also be a key part of studies being carried out towards the development of new, broadly 
neutralising vaccine formulations.  
 
Serology also provides the ability to track the spread of emerging viruses, with the advantage of 
detecting antibodies when the symptomatic stage of infection and viral clearance has occurred. 
 23 
 
Such serosurveillance provides valuable epidemiological and public health information on 
emerging viruses, such as the health risk posed, geographic distribution and prediction of its 
epidemic potential. As examples, a serosurveillance study highlighted the longstanding disease 
burden of important emerging viruses circulating in Sierra Leone and the need for better 
surveillance as well as differential diagnosis (O’Hearn et al., 2016). In others, the frequency of 
Ebola virus seropositive, asymptomatic individuals, was shown to be low during the recent 
outbreak (Glynn et al., 2017), even though it has previously been suggested to occur at a high 
frequency (Becquart et al., 2010). Further, upon the recent emergence of Schmallenberg virus, a 
member of the Bunyaviridae family causing congenital malformations in ruminants, development 
of a serological assay was required for serosurveillance studies. This helped to quickly establish it 
had a high prevalence among livestock in the Netherlands (Beer et al., 2013; Elbers et al., 2012). It 
was also possible to determine it posed a low zoonotic risk, with no detectable antibodies in a 
serosurvey of farmers known to be exposed to the virus (Tarlinton et al., 2012). Serology is also 
frequently applied to studying the circulation of emerging viruses in their wildlife reservoir hosts, 
where sample volumes can be limited (Gilbert et al., 2013). Several studies into bat populations 
which are an important reservoir of emerging viruses have been carried out, including isolating 
NAbs to henipaviruses (Peel et al., 2012) and lyssaviruses (Arguin et al., 2002; Kuzmin et al., 
2006; Schatz et al., 2014).  
 
1.3.2. Serological Assays 
Several different formats of serological assay are available for the detection of virus specific 
antibody within serum. Most typically they can be divided within two categories, either binding or 
functional assays. Binding assays measure the attachment of antibody to viral antigen which has 
been attached to a solid surface. Common formats include the indirect immunofluorescent antibody 
assay (IFA) and the enzyme-linked immunosorbent assay (ELISA). Using the IFA, viral antigen is 
attached to a microscope slide and incubated with serum to allow binding of antiviral antibody. A 
fluorescently labelled secondary antibody, which has specificity to the species being tested, is then 
 24 
 
added and binding detected using a fluorescent microscope. The ELISA works in a similar way, but 
is performed in a microtiter plate and uses enzyme-conjugated antibody requiring the addition of a 
substrate, which most commonly emits a colourimetric or fluorescent signal. Signal intensity 
indicates the presence or absence of antibody depending on which format of ELISA is used. 
Binding assays can be used to differentiate between IgM and IgG antibodies by using a class 
specific secondary antibody.  
 
Functional assays work on the basis of measuring specific activities resulting from the binding of 
antibody to viral antigen. This could be agglutination, such as with the haemagglutination-
inhibition assay (HI) whereby antibodies to viruses which are able to agglutinate erythrocytes are 
measured from the action of preventing agglutination. This is usually operated on the basis of 
testing acute and convalescent sera in parallel to detect a rise in antibody titres. Yet the most 
important functional assay is the virus neutralisation assay (VNA), which measures the ability of 
antibodies to block viral infectivity. The assay is performed by preparing serial dilutions of serum 
for incubation with a standardised quantity of virus. Following a short incubation the mixture is 
added to a confluent monolayer of permissive cells and incubated for a period sufficient for 
infection to have occurred. Virus infection is either observed as plaques of virus-induced cytopathic 
effect, or using fluorescently labelled virus specific antibodies to detect infected cells for viruses 
which do not cause cytopathic effect. The value in being able to quantify NAbs makes this widely 
regarded as the serological assay to which others should be measured (Storch & Wang, 2013).  
 
Serology to assist diagnosis is mainly undertaken with binding assays, commonly ELISA, based on 
the fact they are relatively low cost and rapid. They also have utility in differentiating antibody 
responses raised to infection or vaccination as part of the Differentiating Infected from Vaccinated 
Animals (DIVA) approach when a subunit vaccine has been used, with the ability to select the 
target viral antigen (Mather et al., 2013; Uttenthal et al., 2010). However, in comparison to the 
VNA their specificity is limited by potential cross-reactivity of secondary antibodies, as well as the 
use of purified or recombinant proteins as antigen, which may not have authentic conformation.  
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Overall, when evaluating vaccine efficacy the VNA is considered a gold standard and information 
on the protective capacity of antibodies is highly valued for serosurveillance studies. Indeed, two 
variations of a VNA, the rapid fluorescent focus inhibition test (RFFIT) (Smith et al., 1973) and 
fluorescent antibody virus neutralisation test (FAVN) (Cliquet et al., 1998), are the OIE endorsed 
gold standard serological tests for rabies. However limitations in performing a VNA include its 
cost, a laborious technique as well as often needing several days incubation for virus growth, which 
slows the collection of results, and most importantly the requirement to use infectious virus. This 
presents a major limitation in the ability to measure NAbs for pathogenic viruses which require 
high biosafety level (BSL) 3 or 4 containment facilities, hampering the performance of vaccine 
efficacy and serosurviellance studies. This is a particular constraint for emerging viruses which are 
often highly pathogenic and endemic is less developed countries which do not have access to high 
containment facilities. This is true of both lyssaviruses and filoviruses which are BSL 3 and 4 
pathogens respectively. Consequently, a robust serological assay to measure NAbs which does not 
require handling live virus is of great value.   
 
 
1.4. Pseudotyped Virus 
1.4.1. Pseudotyped Virus Definition 
Pseudotyped viruses (PVs) are defined as viral particles which consist of a core (matrix, capsid, 
nucleocapsid) originating from one virus, which is surrounded by a lipid envelope comprising 
envelope proteins protruding from the outer surface. In most cases the genome is engineered to 
incorporate a transfer/reporter gene and lacks the genetic elements required for replication. This 
offers a safe system to study properties related to the viral envelope proteins, with the ability to act 
as surrogates to pathogenic viruses. Upon PV transduction of susceptible cells, detection of reporter 
gene expression can be used to infer envelope protein interaction with cell receptors and viral entry.  
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With an equivalent serological profile, PV has proven to be a robust alternative to wildtype 
emerging viruses when applied to serological assays and addresses the limitations to their use 
(Mather et al., 2013). They can be handled in low containment BSL 1 or 2 laboratories to measure 
NAbs as part of vaccine efficacy and serosurveillance investigations, with a lower associated cost 
as well as result turnaround time than some VNAs using live virus. This enables them to be used in 
a wider range of laboratory environments, including those in less developed countries where 
emerging viruses are often endemic. Consequently, PV has established itself as an attractive 
alternative to live virus within the emerging virus field.  
 
1.4.2. History of Pseudotyped Virus 
Retroviruses have widely been used as cores for PVs and current production protocols are based on 
several decades of retroviral vector development (Temperton et al., 2015a). This development is 
closely allied to the gene therapy field, where retroviral vectors are favoured due to the ability to 
stably integrate transfer genes into the cell genome without transferring viral genes (Naldini, 1998; 
Sakuma et al., 2012). This is attributable to the unique property of retroviruses to reverse transcribe 
their single stranded RNA genome to a double stranded DNA provirus, with viral integrase 
subsequently directing its integration into the chromosome of target cells. Early retroviral vectors 
were based on gammaretroviruses, often murine leukemia virus (MLV); however their utility was 
restricted by only being able to transduce dividing cells. Consequently, the system was soon 
expanded to include lentiviruses, most commonly human immunodeficiency virus (HIV), which 
due to infecting non-dividing tissue macrophages has evolved the ability to infect cells in the 
absence of division. This would allow in vivo integration into non-dividing cells such as 
hepatocytes, haematopoietic stem cells and neurons (Naldini et al., 1996).  
 
Initial efforts in the use of retroviral vectors for gene therapy applications in the early 1990s were 
based on the use of stable cell lines. These cells expressed packaging components, with the 
retroviral genome being introduced within a plasmid by transfection, where the packaging genes 
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were replaced by a transfer gene (Miller, 1990; Pear et al., 1993). Unfortunately, recombination 
events between the newly produced retroviral vectors and the integrated packaging genes meant 
replication-competent viruses could be detected. Safety of the system was greatly improved by 
moving away from stable cell lines and instead adopting a method which separated the structural 
and enzymatic genes, envelope protein and transfer genes onto three separate plasmids, which were 
transiently transfected into producer cells (Naldini et al., 1996; Soneoka et al., 1995). Their 
simultaneous expression produced replication-defective retrovirus which would require at least two 
recombination events to revert to a pathogenic variant. Lentiviral vector systems based on HIV 
have undergone several rounds of development to further improve upon the safety of the ‘first-
generation’ vectors (Sakuma et al., 2012). 
 
Safety precautions employed within the first-generation vector system involved only including the 
cis-acting elements required for packaging () and the long terminal repeats (LTRs) and rev-
response element (RRE) required for reverse transcription and integration on the transfer gene 
plasmid, excluding the expression of lentiviral proteins within target cells (Figure 1.4) (Naldini et 
al., 1996; Sakuma et al., 2012). Pseudotyping the vectors, including an envelope protein from an 
unrelated virus, further reduced the chance of recombination by removing homologous sequences 
with the transfer plasmid. Second-generation vectors offered enhanced safety by removal of 
lentiviral accessory protein genes (Vif, Vpu, Vpr and Nef) from the lentiviral structural plasmid 
(Figure 1.4). Although required during natural infection, they were found to be dispensable during 
replication (Zufferey et al., 1997). This left only four (gag, pol, tat and rev) of the nine lentiviral 
genes within the system when incorporating a foreign envelope. This system was further adapted 
by the introduction of self-inactivating (SIN) transfer vectors. LTRs contain three regions (U3, R 
and U5) and flank the transfer gene, becoming integrated within the target cell genome and 
regulating transcription and polyadenylation of transfer gene mRNA. A deletion in the 3’-LTR U3 
region was found to disrupt the generation of potentially packageable transfer RNA as genomes in 
progeny virions (Sakuma et al., 2012; Zufferey et al., 1998). Further, risks associated with rescue 
of the transfer gene into new viral particles if subsequent infection with wild-type lentivirus occurs, 
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and the possibility of insertional activation of nearby proto-oncogenes (Hacein-Bey-Abina et al., 
2003) by residual promoter activity of the LTR, were also prevented. Finally, a third-generation 
vector system was developed where the rev gene on the lentiviral structural plasmid, which is 
involved in nuclear export of transcripts, was placed on a separate plasmid (Figure 1.4) (Dull et al., 
1998). Additionally the tat regulatory gene, required for viral transcription, was removed by 
replacing the 5’-LTR U3 promoter region on the transfer gene plasmid with a strong viral promoter 
(Dull et al., 1998). This system results in at least three recombination events being required to 
generate replication competent virus, which would still lack active LTRs and accessory proteins. 
However, lower pseudotyped vector yields as a consequence of transfecting an additional plasmid 
are a disadvantage and have limited its use (Sakuma et al., 2012).  
 
Further modifications to improve the performance of the transfer gene plasmid, which are widely 
used, include the addition of a central polypurine tract (cPPT) (Demaison et al., 2002) and the 
woodchuck hepatitis virus post-transcriptional regulatory element (WPRE) (Zufferey et al., 1999). 
They function to increase vector transduction efficiency by facilitating nuclear import and enhance 
transfer gene expression in targets cells, respectively. Additionally alterations to improve safety 
and performance are continually being proposed (Sakuma et al., 2012). Within this work, the three 
plasmid lentiviral vector system is used for PV production. While not conforming to the defined 
four plasmid third-generation system, the transfer gene plasmid employs additional safety features 
and improvements introduced beyond the second-generation system (Figure 1.4).  
 
When producing PV with different viral envelope proteins, the efficiency of production with 
different vector systems alters dependent on factors such as the site of envelope protein 
accumulation and parental virus budding, and the ability of the envelope protein to interact with the 
viral core component (Sandrin & Cosset, 2006; Steffen & Simmons, 2016). The generation of a 
rhabdoviral vector system based on vesicular stomatitis virus (VSV), is so far proving to be the 
second most popular system to retroviral vectors for pseudotyping. While acclaimed for having 
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superior pseudotyping efficiency, with the ability to readily incorporate envelope proteins of 
different viruses, establishment of the system is far more complex (King et al., 2016; Whitt, 2010). 
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Figure 1.4 Schematic Representation of the Lentiviral Genome and Vector System 
(A) The lentiviral viral genome encodes three structural (gag, pol and env), two regulatory (rev and tat) and 
four accessory (vif, vpr, vpu and nef) genes which are flanked by LTRs. The gag gene encodes the matrix 
(MA), capsid (CA), nucleocapsid (NC) and p6 proteins and the pol gene encodes the enzymatic proteins to 
process them; protease (PR), reverse transcriptase (RT) and integrase (IN). The rev-response element (RRE) 
A 
B 
C 
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located in the env gene is also depicted. (B) First-generation lentiviral vectors include all elements of the 
genome, except env which is depicted here as a VSV envelope protein. The LTRs and packaging signal () 
are on the transgene plasmid, so viral genes are not packaged or expressed in target cells. Genes are 
expressed under strong viral promoters (PRO). Second-generation vectors lack the lentiviral accessory genes 
on the structural plasmid. Third-generation vectors include a separate plasmid encoding the rev gene and the 
tat gene is removed after including a strong viral promoter in place of the 5’ LTR U3 promoter. Additionally, 
the system is self-inactivating (SIN) after including a deletion in the 3’ LTR U3 region. (C) The lentiviral 
vector system used in this study employs a second generation packaging plasmid and an upgraded SIN 
transfer plasmid which includes a central polypurine tract (cPPT) and the woodchuck hepatitis virus post-
transcriptional regulatory element (WPRE) to enhance transduction and expression of the transfer gene. 
Adapted from (Sakuma et al., 2012). 
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1.4.3. Pseudotyped Virus Production 
The production of retroviral PV is achieved by the concurrent transfection of plasmids separately 
comprising retroviral structural genes, envelope protein and transfer genes, such as detailed for the 
lentiviral vector system in Section 1.4.2, into a readily transfectable producer cell line (Figure 
1.5A). The human embryonic kidney 293 T-cell line (HEK 293T) is highly transfectable and thus 
commonly used for this purpose (Pear et al., 1993; Temperton et al., 2015a). The retroviral 
structural plasmid encodes the structural proteins of the viral core (matrix, capsid and 
nucleocapsid) along with the enzymatic proteins to process them on the gag and pol genes 
respectively; with the regulatory tat and rev genes also expressed from this plasmid. The retroviral 
core component (depicted in grey, Figure 1.5B) may be produced without supplying the envelope 
protein (∆env) for use as a transduction control. The transfer gene, commonly encoding a reporter 
protein, is incorporated within the PV core as an RNA dimer (depicted in pink, Figure 1.5B), 
facilitated by a packaging signal () which is included only on the transfer plasmid so that 
packaging of viral sequences supplied on other plasmids does not occur. The PV core, 
incorporating two copies of a RNA reporter gene, is trafficked to the producer cell plasma 
membrane which contains the foreign viral envelope protein, introduced via the plasmid expressing 
the envelope protein gene. Following extracellular budding, the retroviral PV becomes encased in 
the producer cell plasma membrane, studded with the foreign viral envelope protein (depicted in 
orange, Figure 1.5B). Released into the producer cell culture medium, the supernatant containing 
PV can be harvested and titrated onto a permissive target cell line.  
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Figure 1.5 Schematic Representation of the Three Plasmid Transfection System for 
Retroviral Pseudotyped Virus Production and Use in a Neutralisation Assay 
(A) As part of the retroviral vector system for PV production, three plasmids separately expressing retroviral 
genes (gag-pol)  required for core formation, a viral envelope protein (env) and a reporter gene for packaging 
() within the PV core are concurrently transfected into a producer cell line such as HEK 293T cells. (B) PV 
is harvest from the producer cell culture medium and can then be titrated onto permissive target cells, where 
reporter gene expression is measured to assign a titre. (C) Used in a PV neutralisation assay (PVNA), the 
correlation between reporter gene expression and cell transduction can be used to detect for the presence of 
neutralising antibodies (NAb) in serum samples. 
 
A 
B 
C 
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Transduction of target cells is dependent upon envelope protein interaction with appropriate cell 
receptors, which leads to membrane fusion and internalisation (Temperton et al., 2015a). The PV 
reporter gene becomes integrated within the target cell genome; facilitated by the LTRs and the 
reverse transcriptase and integrase of the retroviral core. Given that only the reporter gene is 
included within the PV core; viral proteins required for replication are not able to be produced 
within the target cell, preventing replication. This is the central reason for their safety in 
comparison to working with wildtype virus. Detection of reporter expression from the target cells 
acts to provide a quantitative measure as to the level of PV transduction, allowing a titre to be 
assigned which can be used to control input into downstream assays. When undertaking serological 
evaluation via a PV neutralisation assay (PVNA), this positive correlation between reporter 
expression and cells transduced can be used to infer the presence of NAbs (Figure 1.5C).  
 
There is inherent flexibility in this retroviral pseudotype system to tailor for end user requirements, 
with the nature of the three plasmid system facilitating simplicity in altering the various 
components. A variety of reporter genes have been incorporated within the platform, which offer 
outputs over a range of time, cost and sensitivity constraints (Figure 1.6) (Wright et al., 2009). The 
use of luciferase and green fluorescent protein reporters is popular due to their high throughput 
capabilities as well as offering good sensitivity; however they both require expensive reagents or 
equipment. Using the lower cost lacZ reporter gene, which doesn’t require advanced laboratory 
equipment or expensive reagents, expands the utility of PV to resource limited settings, such as 
within less developed countries where outbreaks of highly pathogenic emerging viruses have 
frequently occurred. Further, PV has previously demonstrated good stability, with a half-life of 1-2 
or 2-4 weeks at room temperature or 4°C respectively, as well as withstanding lyophilisation 
(Mather et al., 2014; Wright et al., 2009). This permits its use in settings with less reliable 
infrastructure. 
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Figure 1.6 Representation of Cost and Time Constraints of Reporter Genes Incorporated 
with the Retroviral Pseudotyped Virus Platform 
The LacZ reporter gene is low cost and colourimetric readouts can be provided via addition of X-gal, CRPG 
or ONPG β-gal substrates. The green fluorescent reporter gene (GFP) is a mid-range reporter, while the 
luciferase (luc) reporter has the highest cost and also offers high-throughput results. The readout in the 
presence of high and low neutralisating antibody concentrations [NAb] is represented, luciferase only offers 
quantitative results. Image drawn by E. Wright. 
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As has already been mentioned, the efficiency of viral envelope protein incorporation into PV 
produced based on different vector systems can vary. Producing PV via the retroviral system has 
generally proven successful for RNA viruses which bud from the plasma membrane, with lentiviral 
vectors proving to be those most commonly used (Temperton et al., 2015a). In some cases a source 
of protease is required for envelope protein cleavage during maturation to become fusion 
competent. This is the case for the production of influenza PV, with a protease encoding plasmid 
commonly being transfected during production (Carnell et al., 2015; Ferrara et al., 2012). Efforts to 
produce PV for internally budding viruses, which traffic envelope proteins to the golgi complex 
rather than the cell plasma membrane, have proven to be problematic. This includes viruses within 
the Flaviviridae and Bunyaviridae families, with only hepatitis C virus successfully producing PV 
using a retroviral core (Bartosch et al., 2003b; Tarr et al., 2007; Urbanowicz et al., 2016a). Using 
alternative cores, such as those based on VSV which has been used to produce Crimean-Congo 
haemorrhagic fever PV (Shtanko et al., 2014), may offer a way to overcome difficulties in their 
production.  
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1.4.4. Pseudotyped Virus Applications 
The use of PV to study serological aspects of emerging viruses is becoming well established, 
offering a low containment platform to answer important research and development questions, 
which is both efficient and accessible. Yet their use is not limited to serological evaluation, they are 
also applicable to studies of viral entry or exit, elucidating cell surface receptors or investigating 
innate antiviral responses. This includes the screening of antiviral drugs targeting entry or exit 
processes. Additionally, the use of PV as a vaccine immunogen has been explored. Several reviews 
highlight these various applications (Cosset & Lavillette, 2011; King et al., 2016; Steffen & 
Simmons, 2016; Temperton et al., 2015a).Overall, the flexibilities of PV allow it to be exploited to 
undertake high-throughput screening of neutralising antibodies and antivirals towards the 
development of both natural and artificial therapeutics.  
 
The use of PV for serological evaluation is widely reported and increasing, with neutralisation 
assays to detect NAbs targeted towards the viral envelope protein having been developed for many 
species, providing both sensitive and specific results which correlate with live virus assays (Mather 
et al., 2013; Temperton et al., 2015a). Pseudotypes have previously been produced for different 
Lyssavirus species, acting as surrogates for live virus to evaluate levels of cross-neutralisation 
afforded by current rabies virus vaccines against the emerging European bat lyssavirus (EBLV) -1 
and -2, using sera from vaccine recipients (Wright et al., 2008). The assay was further applied in a 
larger serosurveillance study in Africa, a developing country where rabies is endemic, detecting 
rabies antibodies within field serum samples from vaccinated dogs. Further to this a further three 
lyssaviruses, LBV, MOKV and Duvenhage lyssavirus (DUVV) were incorporated into the 
pseudotype platform to increase its specificity (Wright et al., 2009). In each case, the PVNA was 
shown to be able to distinguish between lyssavirus species and results were found to correlate with, 
or in some cases were more sensitive than, the validated live virus FAVN assay (Wright et al., 
2008, 2009). Additionally, it was demonstrated how serological studies via a PVNA only require a 
small volume of serum for each assay, which is 5-10 fold lower than assays with live virus, with 
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further benefits attributed to their relative low cost and suitability to be used in a wide range of 
laboratory environments (Wright et al., 2009).  
 
Further serological studies, applying a PVNA to detect NAbs and demonstrating correlation with 
the corresponding wildtype virus assay, showing good sensitivity and specificity, have been 
performed for SARS-CoV, MERS-CoV, influenza virus and hepatitis C virus, which included 
evaluating suitability for serosurveillance (Bartosch et al., 2003a; Molesti et al., 2013; Perera et al., 
2013; Temperton et al., 2005, 2007; Yang et al., 2014). The ease of PV production, along with the 
speed, reproducibility and safety of the PVNA make it amenable to a high-throughput format when 
conducting serological investigations, such as serosurveillance or vaccine clinical trials which 
involve a large number of samples. An automated PV production system, which can produce one 
litre of cell culture supernatant containing PV a week under Good Clinical Laboratory Practice 
(GCLP) guidelines, has been described to meet this purpose (Schultz et al., 2012). These same 
features make PV a valuable resource in the response to outbreaks of novel, highly pathogenic 
viruses. Once the sequence of the viral envelope protein is known, it can be rapidly synthesised and 
PV produced, providing an accessible platform to begin serological screening. This was applied in 
response to the 2012 emergence of MERS-CoV, with a PVNA being rapidly produced and used to 
evaluate seroprevalence in both livestock and human populations within Saudi Arabia (Gierer, et 
al., 2013; Hemida, et al., 2013). Additionally, maintaining a library of emerging virus pseudotypes 
for important strains of circulating species, such as that being developed for influenza virus 
(Bentley et al., 2015), provides an outbreak preparedness resource.  
 
By exploiting the flexibility of the pseudotype system a further advantage has been demonstrated in 
the ability to develop a multiplex PVNA, detecting NAbs directed against two viral envelope 
proteins in a single volume of sera. In one study the PVNA was used to detect NAbs against the 
lyssaviruses LBV and MOKV from a single sample of bat sera by using PV incorporating a renilla 
and firefly luciferase reporter gene respectively (Wright et al., 2010). This helps maximise the 
amount of data that can be collected in serosurviellance studies, such as those of bats, where only 
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small volumes of sera can be collected. The multiplex platform has also been adapted to the 
detection of antibodies directed towards different subtypes of influenza PV (Molesti et al., 2014a). 
Further, it was used to include PV with unrelated envelope proteins as internal controls for a high-
throughput PV assay screening for entry inhibitors of SARS-CoV (Zhou et al., 2011). 
 
The high-throughput format of the PVNA has also seen it widely applied to the screening of 
antiviral drugs against emerging viruses (Steffen & Simmons, 2016; Temperton et al., 2015a; 
Wang et al., 2014; Zhou & Simmons, 2012). Not long before the 2014 Ebola virus outbreak a study 
was undertaken using PV to screen >1000 FDA approved compounds for antiviral activity against 
Ebola virus, Marburg virus and Lassa virus, in an effort to identify therapeutic options against these 
high-priority bioterrorism agents (Madrid et al., 2013). The study identified 24 compounds that 
were broadly active against two or more of the viruses. During the outbreak a further study was 
rapidly undertaken, looking to confirm the mechanism of entry inhibition for currently licenced 
drugs which had shown therapeutic potential against Ebola virus to help inform their safe 
administration (Long et al., 2015). This screening approach has also recently been applied to 
identify monoclonal antibodies (mAbs) which could broadly neutralise non-RABV lyssaviruses in 
phylogroup I, as well as having activity across the other phylogroups (De Benedictis et al., 2016). 
A panel of 22 PVs incorporating the envelope protein of one or more isolates of each Lyssavirus 
species were used to screen 16 mAbs. As well as identifying entry inhibitors, PV has been applied 
to a study looking at influenza virus neuraminidase inhibitors (NAI) to prevent virus release from 
cells (Su et al., 2008). Given PV with a HA envelope protein requires NA cleavage of surface sialic 
acid molecules for their release, a different approach was taken, measuring the inhibition of PV 
production at different concentrations of NAI.  
 
Further work demonstrating advantages of the inherent flexibility provided by the pseudotype 
system has been in the ability to manipulate envelope proteins incorporated within PV. The 
interaction of rabies mAbs with epitopes on the envelope protein has been characterised by 
incorporating envelope protein with mutated antigenic sites into PV and evaluating its effect on 
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neutralisation (De Benedictis et al., 2016; Both et al., 2013b). This allowed the epitope specificity 
of mAbs undergoing development to be better defined. Taking this further, a study by Evans, et al., 
(2013) switched each of the five defined antigenic sites of the lyssavirus envelope protein between 
a phylogroup I and II species and investigated the effect on PV neutralisation by polyclonal sera. 
The evaluation of the immunological importance of the antigenic sites between different lyssavirus 
phylogroups will act to assist the development of more broadly neutralising vaccines.  
 
Viral tropism and cell surface receptor interactions with viral envelope proteins, initiating target 
cell entry, can also be elucidated using the pseudotype system. Much of the work into filovirus 
virus entry has been undertaken with PVs, alleviating the need for BSL 4 containment of this 
highly pathogenic virus. Measurement of PV transduction was initially used to identify cell lines 
susceptible and refractory to infection, revealing filoviruses to have a broad host range with only 
lymphoid cells being resistant to infection (Chan et al., 2000; Wool-Lewis & Bates, 1998). They 
were then further used to screen cells to assist in eliminating the involvement of cell receptors 
initially thought to be involved in entry. This provided confirmation that the Niemann-Pick C1 
receptor is required for exit from the late endosome (Côté et al., 2011; Simmons et al., 2003a, b). A 
significant study, again using the flexibility of the pseudotype system to mutate the envelope 
protein, looked at the impact on viral tropism of lineage-defining amino acid substitutions 
circulating during the recent Ebola virus outbreak (Urbanowicz et al., 2016b). Using a panel of PV 
with mutant envelope proteins representative of the lineages, specific amino acid changes were 
experimentally shown to have increased tropism in human cells which in turn reduced in bat cells. 
Moving on, in addition to studies of virus entry, PV has utility in elucidating the action of innate 
antiviral responses targeted against the envelope protein. Studies have recently been conducted 
using PV with lyssavirus and influenza virus envelope proteins to investigate activity of the 
restriction factor interferon-inducible transmembrane protein 3(IFITM3), which acts to block 
cytosolic entry of these and other enveloped viruses, in chickens, bats and pigs (Benfield et al., 
2015; Smith et al., 2013).  
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While the use of PV to study the serological aspects of vaccine efficacy, antiviral activity and 
serosurveillance, as well as properties of the envelope protein is well established; select studies 
have shown PV can be used as a platform for antigen delivery in order to stimulate an immune 
response. Concentrated influenza PV, when injected into mice, lead to seroconversion of the 
animals and the production of humoral and cellular neutralising responses against homo- and 
heterotypic influenza HA moieties (Powell et al., 2012; Szécsi et al., 2006). Therefore, PV not only 
provides a valuable platform for undertaking studies that elucidate data on epitope antigenicity and 
the generation of antigenically optimised antigens, but also as a vehicle for the administration of 
these proteins as vaccine immunogens.  
 
Each study reported PVs as a robust tool to study highly pathogenic emerging viruses, urgently 
requiring therapeutic interventions at low containment levels. Thus having applicability to enable a 
wider range of research groups to undertake such work and offering a flexible platform for future 
research, including use in less developed countries where emerging zoonotic viruses often occur.    
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1.5. Aims and Objectives 
Given the continuing threat posed by the emergence of zoonotic viruses, which are often highly 
pathogenic with a lack of effective prophylaxis and validated diagnostic assays, there is an 
unquestionable need for research advances aimed at mitigating the resulting social and economic 
burdens. More recently there has been an increasing recognition in the need to strengthen global 
capabilities to respond and be better prepared to prevent outbreaks. To this end, PVs are proving to 
be a valuable tool, circumventing the need to handle highly pathogenic emerging viruses, and thus 
increasing accessibility to serology studies detecting NAbs and assessing antivirals, as well as 
being applicable to answering cell biology questions. In working to continue expanding the utility 
of the pseudotype platform, studying aspects relating to the flexibility of the system and efforts 
towards the standardisation of PV based assays will help inform validation of its use.  
 
Therefore, the first aim of this project was to exploit novelties in the flexibility of the pseudotype 
system to develop neutralisation assays for emerging zoonotic viruses and quantify NAb responses 
raised against the envelope protein, including determining the importance of antigenic sites.   
Objectives: 
 To generate new PV incorporating the envelope protein of important emerging zoonotic virus 
species.  
 Develop a neutralisation assay to evaluate the efficacy of available prophylaxis, or that 
undergoing development, against the newly generated PV. 
 Continually monitor the status of emerging viruses, responding to the Ebola virus outbreak to 
generate a filovirus PVNA, making it available for serological studies. 
 Investigate the manipulation of lyssavirus and filovirus envelope proteins to produce a higher 
titre of PV for serological evaluation. 
 To use PV incorporating lyssavirus envelope proteins with altered antigenic sites to investigate 
their immunological importance via a PVNA. 
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The second aim of this project was to expand the repertoire of reporter genes incorporated within 
the pseudotype platform and evaluate alternative ways to quantify PV, to assist the standardisation 
of input into downstream assays. 
Objectives: 
 To incorporate and test new PV reporter genes against the existing repertoire. 
 Investigate whether the disparate readout units of fluorescent and luminescent reporter genes 
can be correlated. 
 Test alternative methods for PV quantification, which measure different structural components, 
in addition to biological titre that is currently used.  
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Chapter 2. Materials and Methods 
 
2.1. Materials 
2.1.1. Bacterial Strains and General Media 
Table 2.1 Escherichia coli Strain and Associated Genotype 
Strain Genotype Source 
OneShot
TM
 TOP10 F- mcrA Δ( mrr-hsdRMS-mcrBC) Φ80lacZΔM15 Δ 
lacX74 recA1 araD139 Δ( araleu)7697 galU galK 
rpsL (StrR) endA1 nupG 
Invitrogen 
 
 
Table 2.2 Bacterial Culture Media 
Name Composition Source 
Luria Broth (LB), Miller 10 g/L Tryptone, 10 g/L NaCl, 5 g/L yeast 
extract 
Sigma 
LB Agar Luria Broth supplemented with 15 g/L agar Sigma 
SOC Media 20 g/L Tryptone, 5 g/L yeast extract, 10 mM 
NaCl, 2.5 mM KCl, 10 mM MgCl2, 10mM 
MgSO4, 20 mM glucose 
Sigma 
 
2.1.2. Virus Envelope Protein and Reporter Protein Sequences 
Full details of the accession number, source and sequence of the virus envelope proteins and 
reporter proteins used within this study are provided partially within the relevant results chapter 
and in full in Appendix I. 
 
2.1.3. Plasmids and Primers 
Envelope protein genes used in this study were inserted into multiple cloning sites within the pI.18 
or pCAGGS expression plasmid (Table 2.3 and 2.4). Both are pUC-based plasmids, encoding a 
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bacterial origin of replication and an ampicillin resistance gene for growth and selection in E. coli. 
The pI.18 plasmid comprises a human cytomegalovirus promoter, truncated enhancer region, intron 
A gene and terminator sequence (Cox et al., 2002). The pCAGGS plasmid has a full chicken β-
actin promoter and an efficient poly(A) signal from a rabbit β-globin gene (Niwa et al., 1991). 
Plasmid maps are available in Appendix I. 
 
New reporter protein sequences were inserted into the pCS[reporter]W plasmid (Appendix I) using 
primers detailed in Table 2.5. Expression of the reporter protein is driven by the U3-LTR and 
spleen focus forming virus (SFFV) promoter, which is enhanced by a Woodchuck hepatitis virus 
posttranscriptional regulatory element (WPRE) lacking the oncogenic X protein (Demaison et al., 
2002). Constructs with a firefly luciferase (FLuc), enhanced green fluorescent protein (GFP), 
emerald GFP (emGFP) and LacZ reporter protein which had previously been cloned were used and 
referred to as pCSFLW (Wright et al., 2008), pCSGW (Demaison et al., 2002), pCSemGW (kindly 
provided by Greg Towers, UCL) and pCSLZW (Wright et al., 2009) respectively. A second 
reporter protein expression plasmid, pDUAL, was used within this study (Table 2.6). Based on 
pCS[reporter]W, a ubiquitin promoter is incorporated to create a dual promotor expression plasmid 
(Escors et al., 2008). These reporter protein plasmids form part of the self-inactivating (SIN) 
system for pseudotyped virus production applied within this study and used in combination with 
the plasmid p8.91 which provides the retroviral gag and pol genes (Zufferey et al., 1997). When 
producing pseudotyped virus with a gammaretroviral core, the plasmid pCMVi was used to provide 
gag and pol genes (Towers et al., 2000) and a pCNC[reporter] plasmid to supply the reporter 
protein, where expression is driven by a human cytomegalovirus promoter (Beeck et al., 2004). 
Confirmation of genes cloned within expression plasmids was carried out using the appropriate 
sequencing primers (Table 2.7) as detailed in Section 2.2.8. 
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Table 2.3 Primers and Cloning Sites for Envelope Protein Genes Inserted into the pI.18 Expression Plasmid 
   Flanking Primers (5’  3’) 
Construct Gene Cloning Site Forward (F) Reverse (R) 
C1.1 CVS-11 KpnI/XhoI GCGCGCGGTACCGCCACCATGGTTCCTCAAGTTCTT GCGCGCCTCGAGTTACAGTCTGATCTCACCTC 
C1.2 RV61 KpnI/XhoI GCGCGCGGTACCGCCACCATGGTTCCTCAAGTTCTT GCGCGCCTCGAGTCACAGTCTGGTCTCACC 
C1.3 RV193 KpnI/XhoI GCGCGCGGTACCGCCACCATGGTTCCTCAGGTTCTT GCGCGCCTCGAGTCACAGTCTGGTCTCACC 
C1.4 RV250 KpnI/EcoRI GCGCGCGGTACCGCCACCATGGTTCCTCAAGCTCTT GCGCGCGAATTCTCACAGTCTGGTCTCACC 
C1.5 RV277 KpnI/XhoI GCGCGCGGTACCGCCACCATGGTTCCTCAGGTTCTT GCGCGCCTCGAGTCACAGTCTGGTCTCACC 
C1.6 WCBV KpnI/XhoI GATCATGGTACCGCCACCATGGCTTCCTACTTTGCG GATCATCTCGAGTTATTGGGCAGTTTGTCCCT 
C1.7 CVStoWCBV FSS KpnI/XhoI *C1.1 *C1.1 
C1.8 WCBVtoCVS FSS KpnI/XhoI *C1.6 *C1.6 
   Flanking Primers (5’  3’) Internal (int) Primers  (5’  3’) 
   Forward (F) Reverse (R) Fint Rint 
C1.9 RV61etmCVS-11c KpnI/XhoI *C1.2 *C1.1 ACATGTTGC 
AGAAGAGCCAAT 
GGCTCTTCT 
GCAACATGTTAT 
C1.10 RV193etmCVS-11c KpnI/XhoI *C1.3 *C1.1 ACATGTTGC 
AGAAGAGCCAAT 
GGCTCTTCT 
GCAACATGTTAT 
C1.11 RV250etmCVS-11c KpnI/EcoRI *C1.4 GAGCGCGAATTCTTAC 
AGTCTGATCTCACCTC 
GACATGTTGT 
AGAAGAGCCAA 
GGCTCTTCT 
ACAACATGTCATT 
C1.12 RV277etmCVS-11c KpnI/XhoI *C1.5 *C1.1 ACATGTTGC 
AGAAGAGCCAAT 
GGCTCTTCT 
GCAACATGTCATT 
C1.13 CVS-11etmVSVc KpnI/XhoI *C1.1 GATCATCTCGAGTTAC 
TTTCCAAGTCGGTTCA 
GACATGGTGC 
CGAGTTGGTATCCAT 
TACCAACTCG 
GCACCATGTCATTAG   
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C1.14 RV61etmVSVc KpnI/XhoI *C1.2 *C1.13 AACATGTTGC 
CGAGTTGGTATCCAT 
TACCAACTCG 
GCAACATGTTATTATG   
C1.15 RV193etmVSVc KpnI/XhoI *C1.3 *C1.13 AACATGTTGC 
CGAGTTGGTATCCAT 
TACCAACTCG 
GCAACATGTTATTATG   
C1.16 RV250etmVSVc KpnI/EcoRI *C1.4 GATCATGAATTCTTAC 
TTTCCAAGTCGGTTCA 
GACATGTTGT 
CGAGTTGGTATCCAT 
TACCAACTCG 
ACAACATGTCATTAAG 
C1.17 RV277etmVSVc KpnI/XhoI *C1.5 *C1.13 GACATGTTGC 
CGAGTTGGTATCCAT 
TACCAACTCG 
GCAACATGTCATTATG 
C1.18 CVStoWCBVIIb KpnI/XhoI *C1.1 *C1.1 ACAACTGAACAAAGCATAA
CCTACATGGAACTCAAAG 
GCTTTGTTCAGTTGTACAA
TATTCATCCTCCACAACCA
GG 
C1.19 CVStoWCBVIIa KpnI/XhoI *C1.1 *C1.1 GCAGAGGGAAACTAGTC 
TCCAAAGG 
CCTTTGGAGACTAGTTT 
CCCTCTGC 
C1.20 CVStoWCBVI KpnI/XhoI *C1.1 *C1.1 ATATGCGGTAGGCAG 
GGACTTAGACTTATGG 
CCTACCGCATATTGA 
GAGCCTGCATGCTCCT 
C1.21 CVStoWCBVIV KpnI/XhoI *C1.1 *C1.1 ACATCAAGTC 
AGACGAGATTGAGC 
GACTTGATGT 
CGTGCAAATTCACC 
C1.22 CVStoWCBVIII KpnI/XhoI *C1.1 *C1.1 GTAGAGAATTGGTCAGAGG
TCATCCCCTCAAAAG 
TGACCAATTCTCTACCTTG
ATGTAGTGAGCATCAG 
C1.23 WCBVtoCVSIIb KpnI/XhoI *C1.6 *C1.6 ACCAACCTGTCCGAGTTCT
CCTACACAGAGTTGAAGG 
CTCGGACAGGTTGGTACAT
CCAGAGGCATCAGTATAA 
C1.24 WCBVtoCVSIIa KpnI/XhoI *C1.6 *C1.6 GCAGAGGGAAACTAGTC 
TCCAAAGG 
CGGTTCCTTGCTCTCTT 
CCCTCTAC 
C1.25 WCBVtoCVSI KpnI/XhoI *C1.6 *C1.6 TTATGTGGAGTTCTT 
GGAATCCGTTTAGTGG 
AACTCCACATAACTT 
TATTTTGCATGCTCCT 
C1.26 WCBVtoCVSIV KpnI/XhoI *C1.6 *C1.6 ATCAACACGCACGAC 
TTTCACTCGATGAGCTGG 
CCAGCTCATCGACGTGAAA
GTCGTGCGTGTTGAT 
C1.27 WCBVtoCVSIII KpnI/XhoI *C1.6 *C1.6 GTCCGGACCTGGAATGAGA
TCATCCCACACAAAG 
ATTCCAGGTCCGGACTGAC
TTGTAGTGAGCATCTG 
* Indicates when the primer used is the same as that detailed for another construct 
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Table 2.4 Primers and Cloning Sites for Envelope Protein Genes Inserted into the pCAGGS Expression Plasmid 
   Flanking Primers (5’  3’) 
Construct Gene Cloning Site Forward (F) Reverse (R) 
C2.1 EBOV/MAY KpnI/XhoI GATCATGGTACCGCCACCATGGGCGTTACAGGAATATTGC GATCATCTCGAGCTAAAAGACAAATTTGCA 
C2.2 EBOV/MAK KpnI/XhoI GATCATGGTACCGCCACCATGGGCGTGACCGGAAT GATCATCTCGAGTCAGAACACGAACTTGCAG 
C2.3 BDBV KpnI/XhoI GATCATGGTACCGCCACCATGGTTACATCAGGAATTC GATCATCTCGAGTTAGAGTAGAAATTTGC 
C2.4 TAFV KpnI/BglII GATCATGGTACCGCCACCATGGGGGCTTCAGGGATTCT GATCATAGATCTTCACAGCATAAACTTACAG 
C2.5 SUDV KpnI/NheI GATCATGGTACCGCCACCATGGAGGGTCTTAGCCTACT GATCATGCTAGCTCAACAAAGCAGCTTGCA 
C2.6 RESTV EcoRI/XhoI GATCATGAATTCGCCACCATGGGGTCAGGATATCAACT GATCATCTCGAGTCAACACAAAATCTTACATA 
C2.7 EBOV/MAYetmRAVVc KpnI/BglII *C2.1 
GATCATAGATCTTCATCCAATGTATTTAGTGAAGATACG
GCATATACAGAATAAAGCG 
C2.8 EBOV/MAKetmRAVVc KpnI/BglII *C2.2 *C2.7 
C2.9 SUDVetmRAVVc KpnI/NheI *C2.5 
GATCATGCTAGCTCATCCAATGTATTTAGTGAAGATACG
GCAGACGCAAAGAAGAGCA 
C2.10 EBOV/MAYetm KpnI/BglII *C2.1 GATCATAGATCTCTAGCATATACAGAATAAAGCGAT 
C2.11 EBOV/MAKetm KpnI/BglII *C2.2 *C2.10 
C2.12 SUDVetm KpnI/NheI *C2.5 GATCATGCTAGCTCAGCAGACGCAAAGAAGAGCA 
C2.13 EBOV/MAKetmHAc KpnI/BglII *C2.2 GATCATAGATCTTTAAATGCAAATTCTGCATTGTAACGA
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CCCATTGGAGCAGCATATACAGAATAAAGC 
C2.14 SUDVetmHAc KpnI/NheI *C2.5 
GATCATGCTAGCTTAAATGCAAATTCTGCATTGTAACGA
CCCATTGGAGCAGCAGACGCAAAGAAGAGC 
   Flanking Primers (5’  3’) Internal (int) Primers  (5’  3’) 
   Forward (F) Reverse (R) 
C2.15 EBOV/MAYetmVSVc KpnI/XhoI *C2.1 
GATCATCTCGAGTTAC 
TTTCCAAGTCGGTTCA Fint Rint 
C2.16 EBOV/MAKetmVSVc KpnI/XhoI *C2.2 *C2.15 
CTGTATATGC 
CGAGTTGGTATCCAT 
TACCAACTCG 
GCATATACAGAAT   
C2.17 SUDVetmVSVc KpnI/NheI *C2.5 
GATCATGCTAGCTTACTTTC
CAAGTCGGTTCA 
*C2.15 *C2.15 
C2.18 EBOV/MAKetmHIVc KpnI/NheI *C2.2 
GATCATGCTAGCTTATAGCA
AAATCCTTTCC 
TTGCGTCTGC 
CGAGTTGGTATCCAT 
TACCAACTCG 
GCAGACGCAAAG 
C2.19 SUDVetmHIVc KpnI/NheI *C2.5 *C2.18 
CTGTATATGC  
AATAGAGTTAGGCA 
TAACTCTATT  
GCATATACAGAATAA 
* Indicates when the primer used is the same as that detailed for another construct 
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Table 2.5 Primers and Cloning Sites for Reporter Protein Sequences Inserted into the pCS[insert]W Expression Plasmid 
   Flanking Primers (5’  3’) 
Construct Gene Cloning Site Forward (F) Reverse (R) 
C3.1 
Cypridina 
Luciferase 
BamHI/NotI GATAGGATCCGCCACCATGAAGACCTTAATTCT GATAGCGGCCGCCTATTTGCATTCATC 
C3.2 
NanoLuc 
Luciferase 
BamHI/NotI GATCGAGGATCCGCCACCATGGTCTTCACACTCGAAG GATCGAGCGGCCGCTTACGCCAGAATGCGTTCGC 
C3.3 SEAP BamHI/NotI GATCGAGGATCCGCCACCATGCTGCTGCTGCTGCTGCT GATCGAGCGGCCGCTTAACCCGGGTGCGCGGCGT 
C3.4 SEAP2 BamHI/NotI *C3.3 GATCGAGCGGCCGCTCATGTCTGCTCGAAGC 
C3.5 
Dual-Nuclear 
Localised GFP 
(dNG) 
BamHI/NotI GATCGAGGATCCGCCACCATGCCCAAGAAAAAGCG GATCGAGCGGCCGCTTAGCCGCTCTTATACAG 
C3.6 
Dual-Nuclear 
Localised tdTomato 
(dNT) 
BamHI/NotI GATCGAGGATCCGCCACCATGGTGAGCAAGGGCGAGG GATCGAGCGGCCGCTTATCTTGATCCGGTCGATCCTACCT 
   Flanking Primers (5’  3’) Internal (int) Primers  (5’  3’) 
   Forward (F) Reverse (R) Fint Rint 
C3.7 FLuc – T2A – GFP BamHI/NotI 
GATCATGGATCCACCGGTCG
CCACCATGGAAGATGCC 
GATCATGCGGCCGCTTT
ACTTGTA 
AGGAAGTCTTCTAACATGCGGT
GACGTGGAGGAGAATCCCGGCC
CTTCCGGGCATTTAAATGTGAG
CAAGGGCGAGG 
CTCCTCCACGTCACCGCATG
TTAGAAGACTTCCTCTGCCC
TCTCCAGACCCGTTAATTAA
CACGGCGATCTTGCC 
C3.8 GFP – T2A – FLuc BamHI/NotI 
GATCATGGATCCACCGGTCG
CCACCATGGTGAGCAAGG 
GATCATGCGGCCGCTTA
CACGGCGATC 
AGGAAGTCTTCTAACATGCGGT
GACGTGGAGGAGAATCCCGGCC
CTTCCGGGCATTTAAATGAAGA
TGCCAAAAACATTAAG 
CTCCTCCACGTCACCGCATG
TTAGAAGACTTCCTCTGCCC
TCTCCAGACCCGTTAATTAA
CTTGTACAGCTCGTCC 
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Table 2.6 Primers and Cloning Sites for Reporter Protein Sequences Inserted into the pDUAL Expression Plasmid 
   Flanking Primers (5’  3’) 
Construct Gene Cloning Site Forward (F) Reverse (R) 
C4.1 LacZ KpnI/XhoI GATCGAGGTACCGCCACCATGGCGCCAAAAAAGAAGAGAA GATCGACTCGAGTTATTTTTGACACCAGACCAACT 
C4.2 FLuc KpnI/XhoI GATCGAGGTACCGCCACCATGGAAGATGCCAAAAACATTAAGA GATCGACTCGAGTTACACGGCGATCTTGCCGCCCTTC 
C4.3 GFP KpnI/XhoI GATCGAGGTACCACCGGTCGCCACCATGGTGAGCAAGGGCGA GATCGACTCGAGTTACTTGTACAGCTCGTCCATGC 
 
Table 2.7 Sequencing Primers 
 Primers (5’  3’)  
Plasmid Forward (F) Reverse (R) 
pI.18 GGTGGAGGGCAGTGTAGTCT GAAGACACGGGAGACTTAGT 
pCAGGS TTCGGCTTCTGGCGTGTGA CAGAAGTCAGATGCTCAAGG 
pCS[reporter]W AAAGAGCTCACAACCCCTCA AAGCTTGCATGCCTGCAGGT 
pDUAL (KpnI/XhoI site) GGTCAATATGTAATTTTCAGTG GCTAAGATCTACAGCTGC 
pCSFLuc-T2A-W TTGCACGAGATCGCCAG  
pCS-T2A-FLucW ATAGCTTGCAGTTCTTCATGC  
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2.2. Methods 
2.2.1. Chemically Competent TOP10 E. coli Cell Preparation 
An LB agar plate streaked with a loop of competent TOP10 E. coli cells was incubated overnight at 
37°C. The following day, several colonies were inoculated into 10 mL LB broth in a sterile 50 mL 
falcon tube and incubated overnight at 37°C, 330 rpm. On day three, 1 mL of the overnight culture 
was inoculated into 50 mL of pre-warmed LB broth in a sterile conical flask. This was left to grow 
at 37°C, 220 rpm until the O.D.600nm reached 0.3 – 0.4. At this point the culture was transferred to a 
pre-chilled 50 mL falcon tube and left to chill on ice for 20 minutes. Cells were harvested via 
centrifugation for 5 minutes at 3,000 rpm, 4°C. After discarding the supernatant the cell pellet was 
gently resuspended in 5 mL ice cold, filter sterile 0.1 M CaCl2 and left on ice for 30 minutes. After 
a repeat centrifugation, the supernatant was discarded and the cell pellet gently resuspended in 2 
mL ice cold, filter sterile 0.1 M CaCl2 and 15% glycerol and left on ice for a minimum of 30 
minutes. 100 μL aliquots were prepared in pre-chilled eppendorfs and stored at -80°C. 
 
2.2.2. Agarose Gel Electrophoresis 
Agarose gels were prepared by dissolving 1g agarose (Sigma) in 100 mL 1x TAE buffer (40 mM 
Tris, 1 mM EDTA, 20 mM acetic acid) to give a 1% w/v ratio and heating in a microwave until 
dissolved. Prior to pouring, SYBR
TM
 Safe DNA gel stain (Life Technologies; used at 50,000x) was 
added to the gel. Gels were submerged in 1x TAE buffer and Quick-Load® purple 2-log DNA 
ladder was loaded as a marker (as per the manufacturer’s instructions; New England Biolabs 
(NEB)). Where gel bands were cut for purification, gels were briefly visualised on a Safe Imager
TM 
2.0 Blue Light Transilluminator (Invitrogen) and the correct size bands excised using a sterile 
scalpel blade. DNA was purified from the gel using the QIAquick Gel Extraction kit (Qiagen) or 
GeneJet Gel Extraction kit (Thermo Scientific), eluting in 25 – 35 μL elution buffer. 
Concentrations and A260/A280 purity ratios were assessed using a NanoDrop Lite (Thermo 
Scientific). Where bands were not excised, gel images were captured using an Omega Fluor
TM
 Gel 
Documentation system (Aplegen). 
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2.2.3. cDNA PCR Amplification 
The constructs listed in Table 2.3 – 2.6 were amplified using flanking oligonucleotide primers 
designed to incorporate a 5’ overhang followed by a restriction enzyme site for sub-cloning, which 
in the forward primer was followed by a Kozak consensus sequence (GCCACCATG). PCR 
reactions were performed using the high fidelity, proofreading enzyme AccuPrime
TM
 Pfx SuperMix 
(Life Technologies,) or Q5® Hot Start High-Fidelity 2x Master Mix (NEB). Following 
manufacturer instructions, 25 μL reactions were set up and run following the cycling conditions in 
Table 2.8 and 2.9. A gradient of four temperatures with 5°C increments, selected according to the 
melting temperature (Tm) of the primer pair, was used at the annealing step. Reactions were run on 
a Veriti® Thermal Cycler (Applied Biosystems). To confirm amplicon size, PCR products were 
resolved by agarose gel electrophoresis, loading with 10x loading dye (0.25% bromophenol blue, 
50% glycerol) and purified as detailed in Section 2.2.2. 
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Table 2.8 PCR Cycling Conditions for AccuPrime Pfx SuperMix 
Step Temperature Time 
Initial Denaturation 95°C 5 minutes 
35 Cycles of: 
Denaturation 95°C 15 seconds 
Annealing 50 - 70°C 30 seconds 
Extension 68°C 1 minute per kb 
 
 
Table 2.9 PCR Cycling Conditions for Q5 Hot Start High-Fidelity 2x Master Mix 
Step Temperature Time 
Initial Denaturation 98°C 30 seconds 
30 Cycles of: 
Denaturation 98°C 10 seconds 
Annealing 50 - 70°C 30 seconds 
Extension 72°C 30 seconds per kb 
Final Extension 72°C 2 minutes 
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2.2.4. Splicing by Overlap Extension (SOE) PCR Amplification 
The modification of gene sequences, to produce chimeric genes, splice together gene segments and 
carry out site-directed mutagenesis was undertaken via an adapted SOE PCR protocol, working on 
the basis of extending overlapping gene segments (Heckman & Pease, 2007) (Figure 2.1). All PCR 
reactions were performed as detailed in Section 2.2.3 unless stated otherwise.  
 
To produce chimeric constructs C1.9 – 1.17 (Table 2.3) and C2.15 – C2.19 (Table 2.4), internal 
oligonucleotide primers b and c (Figure 2.1A) were designed with a 5’ overhang of 8 – 12 
nucleotides complementary to the gene sequence being introduced. Flanking primers a and d 
(Figure 2.1A) were designed as per standard PCR amplification, described in Section 2.4. Initial 
PCR reactions were performed to separately amplify gene segments through the pairing of 
oligonucleotide primers a with b and c with d, as depicted in Figure 2.1A, producing two gene 
fragments with a region of complementary nucleotides spanning their junction. In a second PCR, 
50 ng of each of the complementary gene fragments was added as template, hybridisation of the 
overlapping regions brought together the entire open reading frame and amplification was 
facilitated by the flanking primers a and d (Figure 2.1A). 
 
The production of the linked constructs C3.7 and 3.8 (Table 2.5) and site-directed mutations of the 
constructs C1.18 – 1.27 (Table 2.3) followed the same protocol as that detailed to produce the 
chimeric constructs above; however the design of internal primers differed. To insert a nucleotide 
sequence (red broken line in Figure 2.1B) between two genes, internal primers b and c were 
designed with 5’ overhangs of equal lengths of the sequence to be inserted with a complementary 
region spanning the central section of the insert sequence (Figure 2.1B). Internal primers to 
generate specific nucleotide substitutions were designed as a complimentary pair, with nucleotide 
sequence flanking the substituted nucleotides, when the region containing the substitutions was less 
than 10 nucleotides in length (Figure 2.1C). When the region containing the substitutions was 
greater than 10 nucleotides, internal primers b and c were designed with a complementary 5’ 
overhang comprising the substituted nucleotides. 
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Figure 2.1 Primer Design for Splicing by Overlap Extension (SOE) PCR 
PCR amplification using primers a-d extends overlapping gene segments to produce chimeric genes, spliced 
gene segments or site directed mutagenesis. (A) Chimeric genes are produced by designing internal primers b 
and c with overlapping sequences spanning the junction of the two sequences to be joined. The first PCR 
uses primers a + b and c + d to produce intermediate sequences with complementary regions. Both products 
are used as template in a second PCR where they denature and hybridise at the complementary region and the 
chimeric sequence is amplified by flanking primers a + d. (B) Spliced gene segments are also produced by 
two PCRs, except internal primers b and c have an overhang of equal length to a sequence to be inserted, 
including a complementary region that will allow the PCR products to hybridise in the second PCR. (C) Site 
directed mutagenesis follows the same PCR protocol, yet uses a complementary pair of internal primers c and 
b with sequence either side of the substituted nucleotides to produce intermediate products with a 
complementary region containing the mutated site.  
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2.2.5. Restriction Enzyme Digestion and Cloning into Plasmid Vector 
To create sticky ends for ligation, gene sequences with PCR inserted restriction enzyme sites were 
double-digested with 1 μL/μg FastDigestTM restriction enzyme per μg of DNA in 10x Green buffer 
(Thermo Scientific) at 37°C for 30 minutes. 2 – 3 μg plasmid DNA was digested in parallel. 
Digested gene inserts and linearised plasmid DNA were gel purified following agarose gel 
electrophoresis as detailed in Section 2.2.2.  
 
Ligations were set up with T4 DNA ligase (1 Unit/μL) in 10x T4 DNA ligase buffer (Thermo 
Scientific) with 50 – 100 ng linearised plasmid DNA and 100 – 300 ng digested insert sequence in 
a 1:3 plasmid-to-insert ratio, incubating for 1 hour at room temperature and heat inactivating at 
70°C for 5 minutes. Ligation products were transformed into competent TOP10 E. coli cells. 
 
2.2.6. Transformation of Chemically Competent Cells 
Competent TOP10 E. coli cells were removed from -80°C storage and thawed on ice for at least 5 
minutes. 5 μL (10% v/v) ligation product, or 10 ng plasmid DNA, was added to 50 μL of 
competent cells and incubated on ice for 30 minutes. The cells were heat shocked at 42°C for 42 
seconds and placed back on ice for 2 minutes. Cells were then incubated with 200 μL SOC media 
(Sigma) at 37°C, 300 rpm for 30 – 60 minutes. 150 μL of transformed cells were then plated onto 
an LB agar plate containing antibiotic corresponding to the plasmid’s resistance marker 
(Ampicillin-Nafcillin 50 μg/mL; Sigma) and left to grow at 37°C for 20 hours, or room temperature 
for 72 hours.  
 
2.2.7. Plasmid Propagation 
To screen clones following transformation, three colonies were picked from the LB agar plate and 
inoculated into separate 6 mL LB broth cultures containing antibiotic (Ampicillin-Nafcillin 50 
μg/mL; Sigma). Cultures were incubated overnight at 37°C, 300 rpm (Incubating Mini Shaker, 
VWR). The following day glycerol stocks were prepared for long term storage at -80°C, mixing 
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800 μL of the overnight culture with 200 μL of 50% filter (0.2 μM) sterile glycerol solution. Cells 
in the remaining culture were pelleted by centrifugation at 3,000 rpm for 10 minutes (Heraeus 
Megafuge 1.0R) and plasmid DNA purified using the PureLink® Quick Plasmid Miniprep kit 
(Invitrogen), eluting into 30 – 40 μL dH2O (Molecular Grade, Eppendorf). Concentrations and 
A260/A280 purity ratios were assessed using a NanoDrop Lite (Thermo Scientific).  
 
To prepare plasmid DNA from glycerol stocks, a loop of the frozen culture was inoculated into a 1 
mL LB broth starter culture containing antibiotic (Ampicillin-Nafcillin 50 μg/mL) and incubated 
for 5 – 7 hours at 37°C, 300 rpm. An overnight culture was then prepared by transferring 0.5 – 1 
mL of the starter culture to a 6 mL pre-warmed LB broth culture and incubating at 37°C, 300 rpm 
as detailed above.  
 
2.2.8. Confirmation of Cloned Gene Sequences 
To confirm the correct gene sequences were cloned into expression plasmids, following plasmid 
DNA purification 300 ng was double-digested with the restriction enzymes used for cloning as 
detailed in Section 2.2.5. A gel image captured following agarose gel electrophoresis was used to 
establish the presence and size of the insert gene sequence (Section 2.2.2). Finally, 100 ng/μL of 
plasmid DNA containing the correct size insert gene was sequenced using 3.2 pmol/μL of plasmid 
sequencing primers (Table 2.7) (SourceBioscience). Chromatogram files were analysed to confirm 
the correct gene sequence using DNADynamo software (v.1.387, Blue Tractor Software Ltd). 
 
2.2.9. Cell Culture 
All cell lines except CHO-K1 cells (Table 2.10) were cultured in Dulbecco’s Modified Eagles 
Medium (DMEM) high glucose (Gibco), supplemented with 10% heat inactivated foetal bovine 
serum (FBS; Gibco) and 1% penicillin-streptomycin (10,000 Units/mL penicillin, 10,000 μg/mL 
streptomycin; Sigma):complete media. The CHO-K1 cell line was cultured in Ham’s F-12 medium 
(Gibco), supplemented with 10% FBS and 1% penicillin-streptomycin. When reviving cells from 
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liquid nitrogen, vials were quickly thawed in a 37°C, 5% CO2 incubator (Sanyo MCO-15AC Incu-
Safe) and washed in 10 mL cold complete media followed by centrifugation at 2,000 x g for 10 
minutes (MSE Centaur 2). Cell pellets were re-suspended in 7 mL complete media and seeded into 
a 6-cm culture dish (TPP) before incubating at 37°C, 5% CO2 until confluent.  
 
Cells were passaged tri-weekly or frozen for storage upon reaching 80 – 90% confluence. To 
passage, cells were briefly washed and subsequently incubated with pre-warmed 0.05% Trypsin-
EDTA (1x; Sigma) for 5 minutes at 37°C, 5% CO2 or until detached from the culture dish. The 
trypsin was neutralised with pre-warmed complete media and cells seeded into a fresh 10-cm 
culture dish (TPP or Nunc for HEK 293T/17 cells only) with 8 mL complete media. Depending on 
the cell line growth rate, they were passaged between 1:5 and 1:12. When freezing cells for storage, 
cells were pelleted by centrifugation at 2,000 x g for 10 minutes and re-suspended in FBS 
containing 10% DMSO (Hybri-Max
TM
, Sigma) and 1 mL aliquots prepared. Cells were frozen 
gradually, at -80°C in a cryo-freezing container for a minimum of 48 hours, before transferring to 
liquid nitrogen.  
 
Table 2.10 Cell Lines 
Cell Line Description ATCC® Number 
HEK 293T/17 Human embryonic kidney 293T clone-17 CRL-11268 
BHK-21 Baby hamster kidney-21 clone-13 CCL-10 
CHO-K1 Chinese hamster ovary CCL-61 
CRFK Feline kidney CCL-94 
A549 Human lung carcinoma CCL-185 
Vero-E6 African green monkey kidney clone-E6 CRL-1586 
HeLa05
1
 Human cervix adenocarcinoma  
E-SIAT MDCK (EBOV GP)
2
 Canine kidney overexpressing sialic acid, 
stably expressing Ebola glycoprotein 
 
1
Cell line kindly provided by Greg Towers, UCL. 
2
Cell line kindly provided by Alain Townsend, University 
of Oxford. 
 
 60 
 
2.2.10. Transfection for Pseudotyped Virus Production 
HEK 293T/17 cells were seeded 24 hours prior to transfection into a 6-well culture plate (~ 2 x 10
5
 
cells/well; TPP) or 10-cm culture dish (~ 2 x 10
6
 cells; Nunc) to be 60 – 80% confluent at the point 
of transection. Prior to transfection cell media was replaced, adding 1.5 mL and 5 mL complete 
media to cells on a 6-well plate and 10-cm dish respectively. Either polyethylenimine (PEI; Sigma) 
or FuGENE® 6 transfection reagent (Promega) was used. A plasmid DNA mix was prepared as 
detailed in Table 2.11 along with the transfection reagent which was prepared separately, as 
detailed in Table 2.12. Both the plasmid DNA mix and transfection reagent were left to incubate at 
room temperature for 5 minutes before combining and incubating for a further 15 or 20 minutes for 
Fugene-6 or PEI transfection reagent respectively. The resulting solution was frequently mixed. 
The transfection mix was then added dropwise to the cells to evenly distribute and the cells left to 
incubate at 37°C, 5% CO2. After 18 – 20 hours the cell media was replaced with the equivalent 
volume of complete media. At 48 and 72 hours post-transfection cell media containing 
pseudotyped virus was harvest, filtering through a 0.45 μM filter (Millipore), replacing with the 
equivalent volume of complete media at 48 hours. The two harvests were combined and stored 
short term (up to 4 weeks) at 4°C and long term (no maximum) at -80°C. 
 
Table 2.11 Plasmid DNA Mix for Transfection 
  Transfection Reagent 
Culture dish Plasmid DNA PEI Fugene-6 
 Gag-pol Reporter Envelope OptiMEM dH2O 
6-well 0.6 μg 0.9 μg 0.6 μg 100 μL Up to 10 μL 
10-cm 1 μg 1.5 μg 1 μg 200 μL Up to 15 μL 
 
Table 2.12 Transfection Reagent 
Culture dish PEI Fugene-6 
 1 mg/mL PEI OptiMEM Reagent OptiMEM 
6-well 20 μL 100 μL 9 μL 100 μL 
10-cm 60 μL 200 μL 18 μL 200 μL 
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2.2.11. Pseudotyped Virus Titration 
2.2.11.1. Infection Assay 
On a 96-well culture plate harvested pseudotyped virus was titrated on a susceptible target cell line 
to assess the infectious titre. A 2-fold serial dilution of pseudotyped virus was prepared starting at a 
1:4 dilution, in duplicate. 100 μL complete media was added to wells 1-12 and 100 μL pseudotyped 
virus serially diluted across the plate from the first well before the addition of 100 μL of target cells 
(2 x 10
5
 cells/mL) to each well. Controls of target cells and pseudotyped virus alone were set up in 
quadruplet, and the infection assay incubated at 37°C, 5% CO2 for 48 hours. Results for infection 
plates were read according to the reporter gene incorporated within the pseudotyped virus (Section 
2.2.12). Titrations of pseudotyped virus with a luminescent reporter gene were prepared in a 96-
well opaque (white) culture plate (Nunc). All other titrations were prepared on clear 96-well culture 
plates (TPP). 
 
For flow cytometry analysis, four replicates of an infection with pseudotyped virus at a 1:4 dilution 
was set up, adding 50 μL of pseudotyped virus to 50μL of complete media on a 96-well culture 
plate. Target cells were added to each well, including six target cell alone controls and the plate 
incubated as described above. 
 
2.2.11.2. Titre Designation Assay 
An assay was set up with pseudotyped virus preparations to determine the 50% tissue culture 
infective dose per mL (TCID50 / mL) which was used to standardise input. A 5-fold serial dilution 
of pseudotyped virus was prepared, starting at a 1:10 dilution, in four replicates across wells A - D, 
1 - 11 of a 96-well culture plate. 100 μL complete media was added to wells A - D, 1 - 12 and 25 
μL pseudotyped virus serially diluted across from well 1 – 11. The titration plate was then 
incubated at 37°C, 5% CO2 for 30 – 60 minutes. Following incubation, 100 μL of target cells (2 x 
10
5
 cells/mL) were added to each well, with wells A12 - D12 acting as target cell alone controls. 
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The TCID50 titration plate was then incubated at 37°C, 5% CO2 for 48 hours and read according to 
the pseudotyped virus reporter gene.  
 
The TCID50/mL value was calculated from the data using the Reed-Muench endpoint method 
(Condit, 2001; Reed & Muench, 1938). Firstly the cumulative number of wells positive or negative 
for pseudotyped virus infection at each dilution was counted and the percentage negative calculated 
for each. The negative cut-off was set at 2.5x the average of the cell alone control wells. The 
proportionate distance between the dilutions either side of the 50% point was then calculated and 
the Reed-Muench formula applied: 
Proportionate distance =  
(% positive above 50%) − 50%
(% positive above 50%) − (% positive below 50%)
 
 
log10 TCID50  =  log10 dilution above 50%
−  (proportionate distance ×  log10 dilution factor ) 
 
2.2.12. Titration Readout  
2.2.12.1. Luminescence 
Pseudotyped virus titrations with a firefly luciferase, NanoLuc or renilla luciferase reporter gene 
were read via the Bright-Glo
TM
, Nano-Glo® and Dual-Glo® assay systems (Promega) respectively, 
prepared following manufacturer’s instructions. After incubation, cell media was removed from the 
96-well culture plate and 50 μL of 50% v/v assay reagent in DMEM added to each well, incubating 
on a shaking platform for 3 minutes. The plate was then read using a GloMax®-Multi+ microplate 
luminometer (Promega) using the manufacturer’s Bright-Glo protocol. Each well of the 96-well 
culture plate was assigned a value in relative light units (RLU) according to the intensity of 
luminescence detected by the luminometer. Data was exported as a Microsoft
TM
 Excel file for 
analysis. 
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Titration data for pseudotyped virus with a cypridina luciferase reporter gene was read using the 
BioLux® cypridina luciferase assay (NEB) prepared following manufacturers instructions. After 
incubation, cell media was carefully removed from the titration and transferred to clean wells on 
the 96-well culture plate. 50 μL of BioLux® reagent was added to each well, incubating on a 
shaking platform for 3 minutes. The plate was read using the GloMax®-Multi+ microplate 
luminometer using the luminescence protocol with the integration time set to 2 seconds. Data was 
collected as described above. 
 
2.2.12.2. Colourimetric 
2.2.12.2.1. β-Galactosidase Assay 
Titrations of pseudotyped virus with a lacZ reporter gene were read by first fixing cells in the 96-
well titration plate by removing cell media and adding 0.5% glutaraldehyde (in 1x PBS) and 
incubating for 10 minutes at 4°C. After discarding, cells were incubated with 1x PBS for 5 minutes 
at 4°C. The cells were then washed twice with 1x PBS before staining by adding 50 μL X-gal (1 
mg/mL) diluted in X-gal buffer for 30 – 60 minutes at 37°C protected from light. After staining, 
cells were washed once with 1x PBS with 100 μL added and left on each well. The plate was read 
using a light microscope (Wilovert, Will Wetzlar) and the 10x objective. Cells infected with 
pseudotyped virus had blue stained nuclei and were counted as positive, recording the total number 
of infected cells for each well. 
 
2.2.12.2.2. Alkaline Phosphatase Enzymatic Assay 
Titrations of pseudotyped virus with a secreted alkaline phosphatase (SEAP) reporter gene were 
read using 2 mg/mL p-Nitrophenyl Phosphate (pNPP) substrate (5 mg pNPP in 2.5 mL Trizma® 
base, 0.2 M, pH 9.8; Sigma). 50 μL cell media was transferred to a clean well in a 96-well culture 
plate and incubated with an equal volume of pNPP substrate for 30 minutes – 1 hour at room 
temperature. The plate was read at A405 on a SpectroStar Nano microplate reader (BMG Labtech, 
Germany). Data was exported as a Microsoft
TM
 Excel file for analysis. 
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2.2.12.3. Fluorescence 
2.2.12.3.1. Microscopy 
Pseudotyped virus titrations with a fluorescent protein reporter gene were read after fixing cells in 
the 96-well titration plate by removing cell media and incubating with 0.5% glutaraldehyde (in 1x 
PBS) for 10 minutes at 4°C. After discarding, cells were incubated with 1x PBS for 5 minutes at 
4°C. The cells were then washed once with 1x PBS with 100 μL added and left on each well. The 
plate was read using an Axiovert S100 inverted microscope with fluorescence (Carl Zeiss), using 
the 10x objective and a blue filter to visualise green fluorescent protein (GFP; Exmax 488 nm, 
EmMax 509 nm) and a green filter to visualise tandem tomato fluorescent protein (tdTomato; ExMax 
554 nm, EmMax 581 nm). Cells emitting fluorescence were counted as positive for infection with 
pseudotyped virus and the total number of infected cells per well recorded. Images were captured 
using AxioCam HRc camera attachment and ZEN v.2.3 (blue addition) software (Carl Zeiss). 
 
2.2.12.3.2. Flow Cytometry 
Following an infection assay (Section 2.2.11.1) cells were prepared for flow cytometry analysis by 
removing the cell media, washing with 50 μL 1x PBS and incubating with 50 μL 0.05% Trypsin-
EDTA (1x; Sigma) for 3 minutes at 37°C, 5% CO2. The trypsin was neutralised with 200 μL 1x 
PBS and the cells resuspended, combining the four replicates. Cells were pelleted by centrifugation 
at 2000 x g for 3 minutes and resuspended in 500 μL 1x PBS. Using a Dako CyAnTM ADP 
cytometer (Beckman Coulter) a total of 100,000 cells were counted for each sample using protocols 
with the flurochrome channel parameters detailed in Table 2.13, using the FITC protocol to detect 
GFP and PE-Texas Red protocols to detect tdTomato. Uninfected cell controls were used to set 
gates for the main cell population, removing cell debris or multiple cell events during acquisition. 
Data was analysed using the Summit
TM
 v.4.4 software (Beckman Coulter).  
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Table 2.13 Flow Cytometry Flurochrome Channel Parameters 
 FITC PE-Texas Red 
Excitation Laser (nm) 488 488 
Emission Filter (nm) 530/40 (FL1) 613/20 (FL3) 
FS Threshold (%) 1.5 1 
FS Gain 10 10 
SS Volts 420
1
 / 460
2
 450 
Channel Volts 460 550 
1
BHK-21 or 
2
HEK 293T/17 cells 
 
2.2.13. Neutralisation Assay 
The ability of mAb or sera samples to neutralise pseudotyped virus with a firefly luciferase reporter 
gene was assessed by a doubling serial dilution of samples in complete media across wells 1 – 12 
of a 96-well culture plate, in duplicate, with a final volume of 50 μL per well. Pseudotyped virus 
was diluted in complete media to add 50 – 100 TCID50 per well in 50 μL. Culture plates were 
centrifuged at 500 rpm for 5 minutes (Heraeus Megafuge 1.0R) before incubating for 30 minutes – 
1 hour at 37°C, 5% CO2. Following incubation, 100 μL target cells were added to each well (2 x 
10
5
 cells/mL) and the plate incubated for a further 48 hours. Controls of pseudotyped virus with 
target cells, along with each alone, were set up in four replicates. Plates were read as described in 
section 2.13.1. Neutralisation titres of the samples tested were recorded as full or half maximum 
inhibitory concentrations (IC100/IC50). Where IC100 end-point titres varied by more than one 
doubling dilution the assay was repeated and the geometric mean recorded. To calculate IC50 titres, 
percentage neutralisation at each dilution was calculated relative to the control of target cells 
infected with pseudotyped virus and plotted in GraphPad Prism® v.5.02 where values were 
interpolated from the non-linear fit of transformed data.  
 
2.2.14. Sucrose Purification 
Prior to RT-qPCR or nanoparticle tracking analysis pseudotyped virus was purified from cell media 
using a sucrose cushion and centrifugation. Samples to be purified were first subject to DNase 
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treatment, incubating 1 mL of the sample with DNase I at a final concentration of 500 U/mL for 1 
hour at 37°C (Life Technologies). Following DNase treatment, 900 μL of the sample was overlaid 
onto 400 μL of 20% filtered sucrose in 1x PBS and centrifuged at 13,000 xg for at least 2 hours at 
4°C. After centrifugation the pellet was resuspended in 900 μL filtered 1x PBS. Samples were 
either analysed immediately or stored overnight at 4°C.  
 
2.2.15. Pseudotyped Virus Genome Analysis 
2.2.15.1. RNA Extraction 
The RNA genome was extracted from purified (Section 2.2.14) and un-purified lentiviral 
pseudotyped virus samples using the QIAamp® viral RNA mini kit (Qiagen). Prior to extraction, 
un-purified pseudotyped virus samples were diluted 1:2 in 1x filtered PBS. Extraction was 
performed using 140 μL of sample following manufacturers instructions, eluting with 60 μL of the 
provided ‘AVE’ buffer.  
 
2.2.15.2. Quantitative Reverse Transcription PCR (RT-qPCR) 
Prior to setting up the reaction, a dilution series of the firefly luciferase expressing reporter 
plasmid, pCSFLW, was prepared for use as a template to generate a standard curve. A 10-fold 
dilution series of the plasmid vector was prepared, diluting in 1 mg/mL UltraPure Salmon Sperm 
DNA solution (Life Technologies)  to achieve 1 x 10
10
 – 1 x 101 plasmid copies/well in the reaction 
(adding 2.5 μL) after calculating copy numbers (plasmids/μL) using the formula: 
molecular weight (g/mol) = Length (bp) x 660 g/mol (av. weight of dsDNA bp)  
moles dsDNA/μL = [Vector] (g/μL) ÷ molecular weight (g/mol) 
plasmid copies/μL = 6.0221 x 1023 molecules/mol (Avogadro's number) x moles dsDNA/μL 
 
RT-qPCR was performed targeting the LTR region of the RNA genome extracted from lentiviral 
pseudotyped virus samples using the RNA UltraSense
TM
 One-Step Quantitative RT-PCR system 
(Life Technologies). 25 μL reactions were set up, using RNA UltraSenseTM 5x master mix 
containing reverse transcriptase and ROX reference dye (0.05 μL) according to the kit guidelines, 
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along with 0.1 μM HIV-LTR TaqManTM probe and 0.2 μM HIV-LTR forward and reverse primers 
(Table 2.14), adding 2.5 μL extracted RNA. Reactions were run on MicroAmp® Optical 96-well 
plates (Applied Biosystems) in triplicate, including no template controls where 2.5 μL of 1 mg/mL 
UltraPure Salmon Sperm DNA solution (Life Technologies) was added in place of extracted RNA. 
The standard was run in duplicate on each plate. A second reaction was prepared as a reverse 
transcriptase negative control, inactivating the enzyme at 75°C for 15 minutes prior to preparing 
the master mix. Reactions were run on a Mx3005p qPCR instrument (Stratagene) following the 
cycling conditions in Table 2.15 and analysed using MxPro v.4.1 software. 
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Table 2.14 HIV-LTR Primer and Probe Sequence for RT-qPCR 
Primer / Probe Sequence (5’  3’) 
HIV-LTR Forward GCTCTCTGGCTARCTAGGG 
HIV-LTR Reverse GTTACCAGAGTCACACAACAGA 
HIV-LTR TaqMan
TM
 probe  
(5’ – FAM and 3’ – BHQ1) 
GCTTCAAGTAGTGTGTGCCC 
 
 
Table 2.15 RT-qPCR Cycling Conditions for RNA UltraSenseTM Master Mix 
Step Temperature Time 
Reverse Transcription
1
 50°C 30 minutes 
Taq Initial Activation 95°C 10 minutes 
40 Cycles of: 
Denaturation 95°C 30 seconds 
Annealing & Extension 60°C 1 minute 30 seconds 
Melt Curve Analysis   
1
Step excluded for reverse transcriptase negative control reaction 
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2.2.16. SYBR Green Product-Enhanced Reverse Transcriptase (SG-PERT) 
Assay 
The reverse transcriptase (RT) activity of lentiviral pseudotyped virus samples was quantified via 
an SG-PERT assay adapted from (Pizzato et al., 2009; Vermeire et al., 2012). Pseudotyped virus 
samples were lysed prior to addition to the reaction by incubating a 50% v/v mix of 10x diluted 
sample (in ultrapure (18 MΩ) H2O) with 2x lysis buffer (100 mM TrisHCl, 50 mM KCl, 0.25% 
Triton X-100, 40% glycerol) supplemented with 0.8 U/μL RiboLock RNase inhibitor (Thermo 
Scientific) prior to use, for 10 minutes at room temperature. Following incubation samples were 
further diluted to give 100x pseudotyped virus lysate.   
 
HIV RT (500U; Merck-Milipore), used to prepare a standard curve, was diluted to 10 mU/μL in 
storage buffer (10 mM potassium phosphate, 1 mM DTT, 20% glycerol, pH 7.4) and 10 μL single 
use aliquots stored at -80°C.  A standard curve was generated by preparing a 10-fold serial dilution 
of 10 mU/μL HIV RT to achieve 1 x 109 – 1 x 103 pU/well in the reaction (when adding 2 μL per 
well). 25 μL reactions were set up, using QuantiTect SYBRTM Green 2x master mix (Qiagen) 
containing 0.2 U/mL RiboLock RNase inhibitor (Thermo Scientific), 3.5 pmol/mL MS2 RNA 
(Sigma) and 0.5 μM MS2 cDNA forward and reverse primers (Table 2.16), adding 12 μL of 100x 
pseudotyped virus lysate. Reactions were run in triplicate on MicroAmp® Fast Optical 96-well 
plates (Applied Biosystems) and master mix, primer and diluent (ultrapure H2O) controls set up in 
duplicate. The HIV RT standard dilution was run in duplicate, adding 2 μL to the master mix along 
with 10 μL of ultrapure H2O. Reactions were run on a 7500 Fast RT-PCR instrument (Applied 
Biosystems) following the cycling conditions in Table 2.17 and analysed using 7500 v.2.3 
software. 
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Table 2.16 MS2 cDNA Primer Sequence for SG-PERT Assay 
Primer Sequence (5’  3’) 
MS2 cDNA Forward TCCTGCTCAACTTCCTGTCGAG 
MS2 cDNA Reverse CACAGGTCAAACCTCCTAGGAATG 
 
Table 2.17 SG-PERT Assay Cycling Conditions 
Step Temperature Time 
Reverse Transcription 42°C 20 minutes 
Taq Initial Activation 95°C 15 minutes 
40 Cycles of: 
Denaturation 95°C 10 seconds 
Annealing 60°C 30 seconds 
Extension & Acquisition 72°C 30 seconds 
Melt Curve Analysis   
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2.2.17. Nanoparticle Tracking Analysis 
Sucrose purified pseudotyped virus samples (Section 2.2.14) were analysed using a NanoSight 
LM10 instrument (Malvern). Before and between sample acquisition the instrument was calibrated 
with polystyrene latex microspheres diluted in 1x PBS. The camera level was set to 15, with a 
detection threshold of 4. As optimal acquisition required a particle concentration of approximately 
10
8
 particles/mL, samples were 10-fold serially diluted in 1x PBS from 100 – 10000x and tested on 
the instrument. Samples 100x diluted had an optimal particle concentration and 1 mL was injected 
for analysis, acquiring 5 times for 90 seconds each. Data was analysed using Nanoparticle Tracking 
Analysis v.2.3 software (Malvern). 
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Chapter 3. Production of Chimeric Arctic-like Rabies 
Virus Glycoproteins to Improve Pseudotyped Virus 
Titres and Permit Serological Studies 
 
3.1. Introduction 
Rabies, a neglected zoonotic disease caused by members of the Lyssavirus genus, poses a 
significant public health threat with a near 100% case fatality rate in individuals who develop 
clinical disease (Fooks et al., 2014). Globally rabies virus (RABV), the type species of the 
Lyssavirus genus, is accountable for approximately 60,000 human deaths per year, having a higher 
mortality rate than any other zoonotic disease (Fooks et al., 2014). Effective pre and post-exposure 
prophylaxes regimens have long been well defined, however high cost implications and the 
geographical distribution of rabies, present on all continents except Antarctica, represents a 
challenge to its control (Fooks, 2004; Warrell, 2012). As such, serological studies, monitoring 
responses to pre and post-exposure treatments and undertaking widespread sero-surveillance, are 
vital aspects in the implementation of control programmes aimed at lowering rabies incidence 
(Banyard et al., 2013; Brookes et al., 2005; Wright et al., 2009). However, as many rabies-endemic 
areas are in the developing world, they lack the infrastructure to be able to undertake these routine 
serological techniques which can require use of BSL 3 containment facilities or specialised 
equipment.  
 
At present, 14 species are classified within the Lyssavirus genus, with a further three putative 
members awaiting classification (Figure 1.2) (Banyard & Fooks, 2017; Dietzgen et al., 2011). They 
cause clinically indistinguishable disease, with techniques to differentiate between causative 
species not routinely employed during diagnosis, particularly in endemic regions, thus the true 
burden of species other than classical RABV remains undefined (Fooks, 2004). Arctic-like rabies 
virus (AL RABV) forms one of seven geographically and genetically distinct viral lineages of the 
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RABV species, determined via phylogenetic analysis (Kuzmin et al., 2008; Nadin-Davis et al., 
2007). Endemic across the Middle East and Asia, AL RABV is likely responsible for a significant 
proportion of rabies cases in this region, which results in greater than 20,000 human fatalities each 
year in India alone (Sudarshan et al., 2007). Yet with inadequate reporting systems and a weak 
healthcare infrastructure across this region, the true burden of rabies could be far higher (Banyard 
et al., 2013; Pant et al., 2013). A lack of accurate data has resulted in the low prioritisation of 
control programmes by policy makers and public health professionals (Fooks et al., 2014; 
Sudarshan et al., 2007). While there is no evidence to indicate AL RABV has an altered 
pathogenicity, its infection dynamics and epidemiology are under studied together with the 
protection afforded by current vaccines and antivirals. Undertaking a comprehensive analysis of 
currently circulating RABVs, as well as monitoring for the emergence of new variants, forms a 
vital aspect in limiting rabies incidence (Matsumoto et al., 2013). Thus, it is important to fully 
understand the public health threat posed by the AL RABV lineage. 
 
The development of a pseudotyped virus neutralisation assay (PVNA) for the measurement of anti-
rabies virus neutralising antibodies (NAbs) in vaccine recipients, along with further large scale in-
field serosurveillance within a developing country has previously been described (Moeschler et al., 
2016; Wright et al., 2008, 2009, 2010). These provided sensitive and specific results which 
correlated with the WHO and OIE endorsed fluorescent antibody virus neutralisation test (FAVN), 
a live virus assay, and distinguished between lyssavirus species. As the use of PV allows 
neutralisation assays to be undertaken in BSL 1 or 2 laboratories, along with having a lower cost 
implication, the serological study of rabies is expanded to resource-limited laboratories in regions 
where the virus is endemic.  
 
While Lyssavirus isolates have previously pseudotyped efficiently, initial attempts to produce AL 
RABV pseudotypes found titres were inadequate to allow downstream neutralisation assay studies 
to be undertaken. The flexibility of using a chimeric envelope glycoprotein to study rabies has been 
demonstrated in a study, albeit based on a recombinant rabies virus system, using a chimeric VSV 
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envelope glycoprotein with a RABV cytoplasmic domain to determine the importance of the 
RABV envelope glycoprotein in eliciting an immune response (Foley et al., 2000). Additionally, 
studies looking at the use of RABV pseudotypes in gene therapy, targeting the central nervous 
system, reported that the pseudotyping efficiency of a RABV envelope glycoprotein could be 
increased by replacing the cytoplasmic domain with that of a VSV glycoprotein, which 
pseudotypes highly effectively (Carpentier et al., 2011; Kato et al., 2011). The work described in 
this chapter aimed to adapt this approach and produce a chimeric AL RABV glycoprotein in an 
attempt to increase PV titre and allow the efficacy of current vaccines and antivirals against the AL 
RABV lineage to be tested via a PVNA. 
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3.2. Results 
3.2.1. Chimeric AL RABV Envelope Glycoprotein Construction 
Chimeric envelope glycoprotein (G) constructs were generated for four AL RABV isolates, RV61, 
RV193, RV250 and RV277 using G cDNA sequences within a pI.18 expression plasmid, 
previously amplified from viral RNA by the Animal and Plant Health Agency (APHA, UK) (Table 
3.1). The isolates were selected to represent three genetically distinct clades of the Arctic-related 
lineage (Table 3.1), which included the isolate (RV61) linked to a clinical, transplant associated, 
outbreak (Ross et al., 2015) as well as two (RV193 and RV277) reported to grow poorly in live 
viral cultures by the reference laboratory source (APHA, UK).  
 
Table 3.1 Arctic-like Rabies Virus Isolates 
Details of the phylogenetically determined Arctic-related clade of the isolates used and GenBank accession 
numbers for the G sequences. All G cDNA sequences were provided by APHA, UK.  
Isolate Arctic-related Clade
1 
GenBank Accession Number 
India.human.87.RV61 Arctic-like 1a KU534939 
Pakistan.dog.89.RV193 Arctic-like 1a KU534940 
Russia.squirrel.RV250 Arctic 2 KU534941 
Pakistan.goat.RV277 Arctic-like 1b KU534942 
1
Determined via phylogenetic analysis (Appendix II) 
 
Using splicing by overlap extension (SOE) PCR (Section 2.2.4) the cytoplasmic (c) domain 
sequence of the four AL RABV isolates was replaced with that of a laboratory strain of RABV, 
challenge virus standard 11 (CVS-11; EU352767), or VSV (J02428) G, which had both previously 
produced high titre PV (Wright et al., 2008). The ecto-transmembrane (etm) domain was not 
altered. Primers used (C1.9 – 1.17, Table 2.3) were designed based on mapping the cytoplasmic 
domain of the AL RABV and CVS-11 G to amino acids 481 – 526 and that of the VSV G to amino 
acids 483 – 512, following those defined in the Carpentier, et al. (2011) study. A chimeric CVS-11 
G with a VSV cytoplasmic domain (CVS-11etmVSVc) G was also produced to act as a control. All 
the constructs produced are depicted in Figure 3.1 and were cloned into the pI.18 expression 
plasmid and sequencing verified (Section 2.2.8).  
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Figure 3.1 Schematic Representation of Chimeric Envelope Glycoprotein Constructs 
The chimeric envelope glycoprotein constructs produced by switching the cytoplasmic domain are depicted. 
Numbers represent the amino acids of the respective full length glycoprotein for the AL RABV and CVS-11 
ecto-transmembrane domain and CVS-11 or VSV cytoplasmic domain. 
 
3.2.2. Production of Arctic-like Rabies Virus Pseudotyped Virus 
Lentiviral PV was produced with a firefly luciferase reporter gene, comprising the wildtype AL 
RABV isolate and CVS-11 G, as well as the chimeric G constructs generated in Section 3.2.1, by 
transfecting HEK 293T/17 cells (Section 2.2.10). To determine whether the chimeric G had 
increased the PV titre, an infection assay was set up (Section 2.2.11.1) with four replicates of 1:4 
diluted PV titrated onto the BHK-21 cell line, previously determined to be permissive to lyssavirus 
infection (Wright et al., 2008). The level of infection was recorded in relative light units (RLU; 
Section 2.2.12.1). It was found that PV with a chimeric CVS-11 cytoplasmic domain G caused a 
decrease (RV61: -15.7 fold, p = 0.2; RV250: -10.6 fold, p = 0.0007; RV277: -1.4 fold, p = 0.7) or 
insignificant increase (RV193: 1.2 fold, p = 0.7) in titre (Figure 3.2). However, PV with a chimeric 
VSV cytoplasmic domain G gave a significant increase (p < 0.0005) in titre for three of the AL 
RABV isolates (RV61, RV193 and RV277) and CVS-11 control (Figure 3.2). The fold increase in 
titre between PV with a wildtype and chimeric VSV cytoplasmic domain G was calculated (Table 
3.2), showing a small (1.1 fold, p = 0.3) increase in titre for the RV250etmVSVc G PV.  
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Figure 3.2 Comparison of Pseudotyped Virus Titres using Wildtype and Chimeric 
Envelope Glycoproteins 
PV with a luciferase reporter gene titrated on BHK-21 cells, with titres calculated as relative light units per 
ml (RLU/ml) to determine if a chimeric glycoprotein with a CVS-11 or VSV cytoplasmic domain increased 
titres. (*p < 0.0005; two-tailed t-test) Error bars show SD (n = 4). 
 
Table 3.2 Fold Increase in Pseudotyped Virus Titre using a Chimeric VSV Cytoplasmic 
Domain Envelope Glycoprotein 
Fold increase calculated in comparison to PV with a wildtype glycoprotein using RLU/ml values plotted in 
Figure 3.2. 
Envelope Glycoprotein Fold Increase 
CVS-11etmVSVc 11.3 
RV61etmVSVc 24.2 
RV193etmVSVc 67.9 
RV250etmVSVc 1.1 
RV277etmVSVc 83.3 
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To corroborate the increase in titre observed, lentiviral PV was produced with the wildtype and 
chimeric VSV cytoplasmic domain G incorporating an emerald green fluorescent protein (emGFP) 
reporter gene. Infection assays were set up for imaging cells via fluorescent microscopy, as well as 
to undertake flow cytometry analysis. Using fluorescent microscopy a visibly apparent increase in 
cells infected with PV was observed with the chimeric VSV cytoplasmic domain G in comparison 
to those infected with wildtype G PV (Figure 3.3). Analysis of flow cytometry data collected using 
the FITC protocol (Section 2.2.12.3) was carried out by applying a gate to remove cell or other 
debris from the analyses (Figure 3.4A). A second gate was applied to the FITC channel at the end 
of the first log-decade to count the percentage of cells from the population emitting fluorescence 
above the background level (Figure 3.4B). The fold increase in titre values calculated for PV with a 
chimeric VSV cytoplasmic domain G (Table 3.3) were found to be in line with those previously 
calculated for PV with a luciferase reporter gene. This acted to confirm the use of a chimeric VSV 
cytoplasmic domain G to increase the titre of AL RABV PV. 
 
  
 
7
9
 
 
 
Figure 3.3 Comparison of Cell Infection by Pseudotyped Virus Bearing Wildtype versus Chimeric Envelope Glycoprotein 
Fluorescent microscopy images of BHK-21 cells infected with PV bearing wildtype CVS-11 or AL RABV isolate glycoprotein (top row) in comparison to that bearing 
chimeric VSV cytoplasmic domain glycoprotein (bottom row). An emGFP reporter gene was used and images captured using the x10 objective. 
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Figure 3.4 Gating of Cells for Flow Cytometry Analysis 
Example of gates set for analysis of BHK-21 cells infected with an emGFP reporter gene PV with. (A) A gate 
(R1) was placed over the cell population to exclude larger cells or any cell debris from the analysis. (B) 
Using the FITC channel a gate (R2) was from the end of the first log-decade to count the percentage cell 
population expressing fluorescence above background. 
 
Table 3.3 Fold Increase in Titre of Pseudotyped Virus with a Chimeric VSV 
Cytoplasmic Domain Glycoprotein Measured Using Flow Cytometry Analysis 
Fold increase calculated in comparison to PV with a wildtype glycoprotein from flow cytometry data on the 
percentage of cells emitting fluorescence. 
Envelope Glycoprotein Fold Increase 
CVS-11etmVSVc 2.2 
RV61etmVSVc 54.5 
RV193etmVSVc 27.0 
RV250etmVSVc 8.0 
RV277etmVSVc 19.0 
A 
B 
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3.2.3. Neutralisation Assays to Evaluate the Efficacy of Existing Prophylaxis 
against the Arctic-like Rabies Virus Lineage 
The increased PV titre achieved for the AL RABV isolates by using a chimeric VSV cytoplasmic 
domain G enabled serology studies to be undertaken via a PVNA to assess the efficacy of currently 
used vaccines and post-exposure prophylaxes. As both receptor-binding domains and antigenic 
sites are known to be mapped to the ectodomain (Evans et al., 2012; Kuzmina et al., 2013), 
switching of the cytoplasmic domain in the generation of the chimeric G constructs should not have 
influenced the serological profile. Further, sequence comparison was undertaken for the etm 
domains of the AL RABV isolates G and that of CVS-11 G, constructing a radial phylogenetic tree 
following ClustalW sequence alignment using the MEGA6 maximum likelihood method, based on 
the JTT matrix model (Figure 3.5A) (Tamura et al., 2013) and nucleotide and amino acid sequence 
identities determined using the BLAST® Global Alignment tool on the NCBI database (Figure 
3.5B). The high levels of homology observed via this analysis acted to suggest the neutralisation 
profiles should be similar, yet only offered a crude estimate due to the potential disproportionate 
effect individual amino acid substitutions can have on antigenic properties. 
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Figure 3.5 Degree of Nucleotide and Amino Acid Sequence Identity Between Arctic-like 
Rabies Virus and CVS-11 Envelope Glycoprotein Ecto-Transmembrane Domain 
(A) Radial phylogenetic tree constructed using the MEGA6 maximum likelihood method, based on the JTT 
matrix model, following ClustalW sequence alignment of the envelope glycoprotein ecto-transmembrane 
domain amino acid sequences. Scale corresponds to amino acid substitutions per site. (B) Nucleotide and 
amino acid percentage sequence identities determined using the BLAST® Global Alignment tool on the 
NCBI database.  
A 
B 
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Initially, a PVNA was performed (Section 2.2.13) testing the chimeric G PV alongside wildtype 
CVS-11 G PV using the OIE standard reference dog serum (0.5 international units per mL 
(IU/mL)), as well as the WHO 2
nd
 international human anti-rabies Ig reference serum (2 IU/mL; 
NIBSC, UK) over a 2-fold serial dilution, starting at 1:20. An input of 50 TCID50 of PV was used 
for neutralisation assays based on the results of a titration assay (Section 2.2.11.2) and results were 
recorded as IC100 end-point titres. Results showed that chimeric CVS-11etmVSVc G PV had an 
IC100 titre matching or within one doubling dilution of that for wildtype CVS-11 G PV for the OIE 
(IC100 = 80) and WHO (IC100 = 269 and 453) standards respectively (Figure 3.6). This suggested 
switching the cytoplasmic domain of the G had not altered the neutralisation profile. Further to this, 
each of the AL RABV chimeric G PV were neutralised at an equivalent or more potent level by 
each standard than that recorded for CVS-11 G PV (Figure 3.6).  
 
Figure 3.6 Neutralisation of Pseudotyped Virus by OIE and WHO Serum Standards 
The OIE is a standard reference dog serum (0.5 IU/mL) and the WHO is the 2
nd
 international human anti-
rabies Ig reference serum (2 IU/mL). Values are reported as IC100 endpoint reciprocal serum dilutions 
(geometric mean ± SD). Where error bars are absent, replicates produced the same IC100 endpoint dilution. 
 
 84 
 
Analysis of the neutralisation afforded against these AL RABV isolates by pre-exposure 
vaccination was undertaken by assessing a blinded panel of serum samples (n = 20) taken from 
RABV-vaccinated humans (Rabipur, Novartis) and domestic animals (dogs and cats) vaccinated 
(Rabvac, Fort Dodge; Nobivac, Intervet; Rabisin, Merial; Quantum, Schering Plough) as part of the 
UK pet travel scheme (PETS) (Ramnial et al., 2010) (Appendix II). The samples had been assigned 
a titre (IU/mL) using the FAVN test method for detecting rabies specific antibodies, a score of 0.5 
IU/mL is considered the cut-off for adequate sero-conversion for protection (Cliquet et al., 1998; 
WHO, 2013). When un-blinded, four human serum samples (H1, H5, H6, H7) with NAb levels of 
0.03 – 0.1 IU/mL, had not neutralised any PV tested (data not presented) and one sample with a 
NAb level just below 0.5 IU/mL (H61, 0.38 IU/mL) had neutralised all PV tested (Figure 3.7A). 
All samples with a NAb titre above 0.5 IU/mL produced good levels of neutralisation for the CVS-
11 and CVS-11etmVSVc G PV (IC100 titres of 160 – 640) along with comparable levels for the 
chimeric AL RABV G PV (Figure 3.7A). The same cut-off is used to assign a satisfactory 
vaccination response in canine and feline recipients. All animal serum samples with an adequate 
level of sero-conversion produced a robust neutralising response (Figure 3.7B). Of the four samples 
tested which had been assigned NAb titres between 0.07 – 0.38 IU/mL on FAVN testing (Figure 
3.7B; PET-5531,-5545,-5734,-5896) a low level of PV neutralisation was detected (IC100 titres of 
12 – 57).  
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Figure 3.7 Pseudotyped Virus Neutralisation IC100 Endpoint Dilutions for Human and 
Animal Serum Samples 
Neutralisation of CVS-11, CVS-11etmVSVc and chimeric AL RABV G PV reported as the reciprocal serum 
dilution of IC100 endpoints. (A) Human serum samples are from RABV vaccine recipients, sample H61 was 
assigned a FAVN titre of 0.38 IU/mL and the remaining samples a titre > 0.5 IU/mL. (B) Animal serum 
samples are from vaccinated dogs or cats, four samples with FAVN titres between 0.07 – 0.38 IU/mL (PET-
5531,-5545,-5734,-5896) are shown. The remaining samples have a titre > 0.5 IU/mL. Values are the 
geometric mean ± SD. Where error bars are absent, replicates produced the same IC100 endpoint dilution. 
 
A 
B 
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Biologics used for post-exposure prophylaxis (PEP) were also tested for their efficacy against the 
AL RABV isolates. Human rabies immunoglobulin (HRIG), in the form of commercial samples 
released for the European market (provided by NIBSC, UK), were tested by PVNA with a starting 
concentration of 2 IU/mL. Results showed each sample provided a good level of neutralisation for 
the PV tested (IC100 titre of 1.9 x 10
-3
 – 7.6 x 10-6 IU/mL; Figure 3.8). In addition, monoclonal 
antibody (mAb) preparations were tested (CR57, CR4098, RVC20 and RVC58), which are directed 
against various neutralising antigenic sites on the RABV G and are being considered for 
development to replace HRIG in PEP (Bakker et al., 2005; De Benedictis et al., 2016). Used at a 
starting concentration of 15 μg/mL, each mAb neutralised the chimeric AL RABV G PV (IC100 titre 
of 1.1 – 662.3 ng/mL), with CR4098 and RVC20 offering the most potent levels of neutralisation 
across all PV preparations (IC100 titres between 1.1 – 35.6 and 1.3 – 106.9 ng/mL respectively; 
Figure 3.8). 
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Figure 3.8 Pseudotyped Virus Neutralisation IC100 Endpoint Dilutions for HRIG and 
mAb Samples 
Neutralisation of CVS-11, CVS-11etmVSVc and chimeric AL RABV G PV reported as IC100 endpoint 
dilutions. (A) HRIG samples were tested at a starting concentration of 2 IU/mL. (B) mAb samples derived 
against different neutralising epitopes were used at a starting concentration of 15 μg/mL. Values are the 
geometric mean ± SD. Where error bars are absent, replicates produced the same IC100 endpoint dilution.  
 
 
 
A 
B 
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To further ensure switching the cytoplasmic domain of the G had not influenced the neutralisation 
profile, IC100 endpoint titres obtained by the PVNA for wildtype CVS-11 G PV were correlated 
with those for CVS-11etmVSVc G PV. Analysis by Pearson’s correlation using GraphPad Prism® 
(v.5.02) showed a strong level of correlation between the PVNA results (r = 0.99, p < 0.0001; 
Figure 3.9) and thus switching the G cytoplasmic domain had not altered its antigenicity.  
 
 
Figure 3.9 Comparison of the Neutralisation IC100 Endpoint Titres for Wildtype CVS-11 
G PV Compared to Chimeric CVS-11etmVSVc G Pseudotyped Virus 
A high correlation (r) is observed between the IC100 endpoint tires for CVS-11 G and CVS-11etmVSVc G 
PV. Pearson’s product-moment correlation was used to calculate r and p values. 
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3.3. Discussion 
Serological studies are required to define NAb titres as part of vaccination and antiviral 
development and treatment schedules, while also allowing surveillance of the epidemiological 
spread of emerging viruses. As PV incorporate envelope proteins representative of the wildtype 
virus in their envelope they are antigenically similar, mimic the action of live virus in neutralisation 
tests and have proven to be a safe, robust and flexible alternative for use in serological assays 
(Mather et al., 2013; Steffen & Simmons, 2016; Temperton et al., 2015b). It has also been shown 
that using a CVS-11 G PV the PVNA proved to be 100% specific and equally sensitive to the 
WHO and OIE endorsed FAVN method of rabies NAb detection (Wright et al., 2008, 2009). The 
results of this study substantiates its use and demonstrates the inherent flexibility of the platform, 
allowing manipulation of the envelope G to increase PV titre, permitting serological studies to 
determine the protection conferred by vaccines and antivirals against AL RABV isolates. 
 
Chimeric AL RABV envelope G sequences were constructed with either a CVS-11 or VSV G 
cytoplasmic domain in an attempt to increase PV titre. As both CVS-11 and VSV G routinely 
produce high titre PV with the pseudotype system used in this study, it was of interest to establish 
if splicing in the cytoplasmic domains from these G could increase PV titre for other G. However, 
it was found that only the chimeric VSV cytoplasmic domain envelope G resulted in a significant 
increase in PV titre for three of the AL RABV isolates (RV61, RV193 and RV277). The lower 
increase in titre for the RV250 isolate is thought to be attributed to a difference in its glycoprotein 
structure, as phylogenetic analysis showed greater sequence homology between the other isolates, 
which formed a separate cluster. Previously, the use of a chimeric CVS (B2c strain) envelope G 
with a VSV cytoplasmic domain was described (Carpentier et al., 2011), reporting a two fold 
increase in titre. In a similar study by Kato, et al. (2011) a 13 fold increase in titre was reported for 
a CVS strain envelope G of RABV. This is in line with that observed for the CVS-11etmVSVc G 
used within this study. The mechanism behind this effect remains to be fully elucidated, yet studies 
have described that the assembly of viable virions requires a direct or indirect interaction between 
the lentiviral matrix protein and envelope protein cytoplasmic domain (Cosson, 1996; Freed, 1998; 
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Sandrin et al., 2004; Yu et al., 1992). Thus it is possible the cytoplasmic domain of VSV G 
interacts more effectively with the lentiviral core compared to that of the CVS-11 G. Alternatively, 
it has been suggested a truncated or shorter cytoplasmic domain, as with VSV G, may cause a 
reduced steric hindrance or allow incorporation into lentiviral particles independent of matrix 
protein interaction (Freed & Martin, 1995). This is further supported by the report that truncation of 
the measles virus fusion (F) protein cytoplasmic domain lead to an increased PV titre (Frecha et al., 
2008). 
 
Both CVS-11 and VSV constitute well studied prototypes of the lyssavirus and vesiculovirus 
genera respectively, within the Rhabdoviridae family. Importantly, there is good consensus within 
the literature of the defined regions of the lyssavirus G domains (Evans et al., 2012; Kuzmina et 
al., 2013). The position of the VSV G cytoplasmic domain is also well defined and the crystal 
structure of the G ectodomain has been derived (Roche et al., 2006; Rose et al., 1980). Due to the 
predictive nature of structural models to define transmembrane and cytoplasmic domains, which 
often are not present in crystal structures, there can be variability in the reported domain regions of 
less studied envelope proteins. It has also been demonstrated that the hydrophobic transmembrane 
domain can affect folding and incorporation into the viral membrane, as well as being involved in 
fusion (White et al., 2008). There are residues in the transmembrane domain of the VSV G which 
are critical for fusion (Cleverley & Lenard, 1998). Further, the membrane proximal region of the 
ectodomain of envelope fusion proteins play a critical role in conformational changes during 
membrane fusion and constitute a target for entry inhibition (Cosset & Lavillette, 2011). 
Consequently, caution is needed when designing chimeric sequences as alterations may result in 
loss of function, particularly the transmembrane domain which is functionally important.  
 
While current vaccines provide protection against RABV, the high level of sequence identity 
between the AL RABV isolates and CVS-11 G is not sufficient to definitively predict their 
neutralisation profile, as the effect of individual amino acid substitutions on antigenic variation has 
in some cases proven substantial (Horton et al., 2010). Also, with the advent of mAbs for PEP, 
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point mutations within the binding sites of mAbs can result in viral escape from neutralisation and 
thus the identification of these critical residues, assessing the neutralisation of generated escape 
viruses, forms a vital aspect in the development of effective, broadly neutralising, therapeutics 
(Bakker et al., 2005; Marissen et al., 2005).  Direct measures of antigenic variation by serology are 
fundamental yet can prove difficult to quantify. The use of antigenic cartography has added power 
to the interpretation of antigenic data, enabling the generation of an antigenic map for a global 
panel of lyssaviruses, instrumental for predicting antigenicity based on the envelope G gene 
sequence (Horton et al., 2010). The PVNA platform has previously been used in the collection of 
antigenic data in a cross-species comparison of lyssavirus neutralisation, showing suitability as a 
high-throughput screening method to complement quantification of antigenic differences (Wright et 
al., 2008, 2009). This study demonstrates the inherent flexibility of the PVNA in the creation of 
chimeric viral envelope protein PV without disruption to the neutralisation profile and therefore the 
envelope protein function. This enabled the determination of sero-status, and by extrapolation, 
protection afforded by current vaccines and prophylaxis against the AL RABV isolates. 
 
The AL RABV isolates were found to be effectively neutralised by human and mammalian serum 
samples, conferring adequate protection by current pre-exposure vaccine formulations. As more 
than 99% of human rabies cases occur from contact with rabid dogs, the control of rabies within 
this population is of high priority (Banyard et al., 2013; WHO, 2013).  The annual economic cost 
of canine rabies alone is estimated to be USD$8.6 billion, highlighting the severe economic and 
societal implications of endemic rabies (Hampson et al., 2015; Pant et al., 2013).  Mass vaccination 
campaigns of dog populations are highly effective and thus monitoring levels of protection 
afforded by animal vaccine formulations is of equal importance to the prevention of human rabies 
infections. All licenced vaccine preparations are derived from inactivated preparations of classical 
RABV, which has shown to confer protection against viruses in phylogroup I but offer limited or 
no protection against those in phylogroups II and III (Evans et al., 2012; Fooks, 2004; Hanlon et 
al., 2005). Since AL RABV is a lineage of classical RABV, the protection observed follows this 
accepted consensus and while rabies cases are poorly characterised in the regions where AL RABV 
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circulate, unexplained vaccine failures have not been reported. However, due to poor growth of 
these AL RABV isolates in live viral cultures, which could suggest a different envelope G 
structure, and the implication of one isolate in a transplant-associated rabies outbreak in Germany 
(Ross et al., 2015), it was important to be able to undertake serological evaluation. Further studies 
into cross-protection of rabies vaccines against more divergent lyssaviruses, such as those within 
phylogroups II and III, using this PVNA could assist in the development of a more broadly cross 
reactive vaccine formulation.   
 
PEP regimes have long been effective in preventing rabies virus infection in the event of exposure. 
For previously un-vaccinated individuals this consists of wound cleansing, vaccination and the 
administration of rabies immunoglobulin (RIG) to provide passive immunity in the interval before 
vaccine induced active immunity is achieved (Fooks et al., 2014). RIG of human (H) or equine (E) 
origin is available. While HRIG is preferred due to its longer half-life, it is expensive compared to 
the more immunogenic ERIG, which is primarily used in the developing world; yet both are in 
short supply (WHO, 2013). The AL RABV isolates were neutralised by all HRIG preparations, 
however alternative means of PEP are now being sought by the development of mAb cocktails. 
This study tested four mAbs, RVC20 and CR57, and RVC58 and CR4098, which target antigenic 
site I and III respectively of the RABV G (Bakker et al., 2005; De Benedictis et al., 2016; Marissen 
et al., 2005). In order to meet WHO guidelines, which suggest RABV PEP should contain at least 
two antibodies to lower the probability of immune escape, CR57 and CR4098 have been combined 
into the CL184 mAb cocktail and undergone phase II clinical trials (Bakker et al., 2008; Nagarajan 
et al., 2014; WHO, 2013). The mAbs RVC20 and RVC58 are in earlier stages of development, 
having demonstrated good broad-spectrum potency by neutralising non-RABV lyssaviruses (De 
Benedictis et al., 2016). In this study, each mAb effectively neutralised the AL RABV isolates, 
which can further serve as an indication that both antigenic sites are conserved across the AL 
RABV lineage. 
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Ultimately, the flexibility of using PV demonstrated within this study can be further extended. The 
generation of antigenic escape mutant envelope protein for incorporation into the PV platform will 
enable evaluation of mAb cocktails undergoing development. Likewise, switching of epitopes 
between lyssavirus envelope G can allow further cross neutralisation studies to be undertaken, an 
important aspect in vaccine design. The ability to switch domains of the lyssavirus envelope G has 
already been explored, highlighting its potential for use in antigenic studies (Jallet et al., 1999). 
This will enable the level of protection afforded against other divergent lyssaviruses in phylogroup 
II and III to be evaluated. This is of great interest from a public health perspective due to their 
unknown disease burden. 
 
Using the approach of generating a chimeric envelope glycoprotein with a VSV cytoplasmic 
domain resulted in high titre PV without affecting their neutralisation profile. These data also 
provide evidence of the flexibility pseudotyped virus-based assays provide when undertaking 
serological studies of highly pathogenic viruses. In conclusion, it was determined the AL RABV 
isolates are not likely to pose a significant public health risk because they are neutralised by 
available vaccines and post-exposure prophylaxis.  
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Chapter 4. Using Pseudotyped Virus to Study the 
Antigenicity of Phylogroup I and III Lyssaviruses by 
Switching Antigenic Sites of the Envelope Glycoprotein 
 
4.1. Introduction 
The Lyssavirus genus, which includes 14 classified species and three putative members awaiting 
classification, is divided into three phylogroups based on genetic and antigenic distance (Figure 
1.2) (Banyard & Fooks, 2017; Dietzgen et al., 2011; Evans et al., 2012). Phylogroup I includes 
rabies virus (RABV), which is the type species for the lyssavirus genus, while phylogroup II 
includes Mokola virus (MOKV), Lagos bat virus (LBV) and Shimoni bat virus (SHIV). 
Phylogroup III comprises the most divergent lyssaviruses, with West Caucasian bat virus (WCBV) 
and Ikoma virus (IKOV) currently classified within this category. All current pre- and post-
exposure prophylaxes are derived against live attenuated strains of classical RABV to produce 
inactivated human vaccines, or anti-RABV antibodies for the development of immunoglobulin 
treatments. Despite lyssaviruses causing an indistinguishable and invariably fatal disease, it has 
been demonstrated that while these prophylaxes confer protection against phylogroup I 
lyssaviruses, they do not effectively neutralise those within phylogroups II and III due to the 
antigenic distance of lyssaviruses from the vaccine strain (Brookes et al., 2005; Evans et al., 2012; 
Fooks, 2004; Hanlon et al., 2005; Horton et al., 2010). As most  lyssaviruses seem able to cause 
rabies, which is invariably fatal following the onset of clinical symptoms (Johnson et al., 2010a, b), 
it is prudent to further understand the antigenicity of the envelope glycoprotein to assist the 
development of more broadly neutralising prophylaxis.   
 
The lyssavirus envelope glycoprotein is the primary surface antigen, involved in cell attachment 
and entry, and the target of neutralising antibodies. Antigenic sites on the envelope glycoprotein 
have been mapped through the use of mutagenesis and monoclonal antibodies (mAbs), identifying 
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both major sites (I - IV) and minor site ‘a’ (Benmansour et al., 1991; Evans et al., 2012; Kuzmina 
et al., 2013). Alignment of these antigenic sites for different lyssavirus species, together with the 
genetic identity at the amino acid level in comparison to RABV, has been used to demonstrate the 
possibility of quantitatively predicting neutralisation efficacy (Badrane et al., 2001; Evans et al., 
2012; Horton et al., 2010). However, as the effect of individual amino acid substitutions can be 
unpredictable, sequence analysis should be used in combination with serology, or the higher 
resolution method of antigenic cartography, which has been used to build an antigenic map for a 
panel of lyssaviruses (Horton et al., 2010). In addition to predicting neutralisation efficacy for 
newly discovered lyssaviruses, identifying the importance of individual antigenic sites in 
neutralisation is also valuable to the development of more broadly neutralising vaccine 
preparations. The importance of individual antigenic sites has previously been assessed using 
mAbs, however not by polyclonal antibodies produced in response to vaccination. The value of 
pseudotyped virus (PV), with the flexibility to readily manipulate the envelope glycoprotein, was 
first utilised to study lyssavirus antigenicity by Evans, et al., (2013); producing a panel of PV with 
antigenic sites switched between the phylogroup I RABV and phylogroup II LBV and investigating 
their pattern of neutralisation by sera samples.  
 
It is equally important to consider phylogroup III lyssaviruses in the production of broadly 
neutralising vaccines and antivirals. As the most divergent lyssaviruses, WCBV and IKOV share 
50% or less amino acid identity with RABV and have both shown significantly reduced or no 
neutralisation by sera samples derived against RABV (Hanlon et al., 2005; Horton et al., 2014; 
Kuzmin et al., 2005). This study looked to expand upon the approach by Evans, et al., (2013), 
switching the antigenic sites between RABV and WCBV envelope glycoprotein and producing PV 
for neutralisation studies by sera samples, identifying antigenic sites of importance for these 
phylogroup I and III lyssaviruses.  
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4.2. Results 
4.2.1. Antigenic Site Swapping and Pseudotyped Virus Production 
The envelope glycoprotein (G) cDNA sequences of the challenge virus standard 11 (CVS-11;) 
isolate of rabies virus (RABV; EU352767) and the single known isolate of West Caucasian bat 
virus (WCBV; RUS-02; EF614258) were within a pI.18 expression plasmid, and represent 
lyssavirus species of phylogroups I and III respectively. Sequence alignment was carried out to 
identify the amino acid residues and corresponding nucleotide sequence at each of the six defined 
antigenic sites which differed between the species (Table 4.1). As previously highlighted (Evans et 
al., 2012), site ‘a’ is conserved yet several residues differ at other sites. Notably, the glycine-
cysteine (GC) sequence at position 34-35 in site IIb of the RABV sequence is almost universally 
conserved between phylogroups (Evans et al., 2012), yet glycine is replaced by a tyrosine (Y) 
within the WCBV site. However, the largest universally conserved motif of leucine/isoleucine-
cysteine-glycine (LCG/ICG) at position 227-229 in site I is present. To switch each of the disparate 
antigenic sites, individually, between the RABV and WCBV envelope glycoprotein, primers were 
designed (C1.18 – C1.27, Table 2.3) to undertake site directed mutagenesis of codons via SOE 
PCR (Section 2.2.4). Additionally, G cDNA sequences with full antigenic site swaps (FSS) were 
obtained via gene synthesis (GeneArt, Invitrogen). Each of the constructs produced, depicted in 
Figure 5.1, were cloned within the pI.18 expression plasmid and sequencing verified (Section 
2.2.8). 
  
 
9
7
 
 
Table 4.1 Sequence Alignment of Rabies Virus and West Caucasian Bat Virus Envelope Glycoprotein Antigenic Sites 
Antigenic sites of the rabies virus (RABV) and West Caucasian bat virus (WCBV) lyssavirus species envelope glycoprotein (G). Amino acid sequences are numbered after 
removal of the signal peptide (19 amino acids), with residues that differ underlined.  
 Antigenic Site 
 
IIb IIa I IV III a 
Virus (34 – 42) (198 – 200) (226 – 231) (263 – 264) (330 – 338) (342 – 343) 
RABV  
(CVS-11) 
GGA TGT ACC AAC CTG TCC GAG TTC TCC 
G   C   T   N   L   S   E   F   S 
AAG AGA GCA 
K   R   A 
AAG TTA TGT GGA GTT CTT 
K   L   C   G   V   L 
TTT CAC 
F   H 
AAG TCA GTC CGG ACC TGG AAT GAG ATC 
K   S   V   R   T   W   N   E   I 
AAA GGG 
K   G 
WCBV  
(RUS-02) 
TAT TGT ACA ACT GAA CAA AGC ATA ACC 
Y   C   T   T   E   Q   S   I   T 
AAA CTA GTC 
K   L   V 
TCA ATA TGC GGT AGG CAG 
S   I   C   G   R   Q 
ATC AAG 
I   K 
ATC AAG GTA GAG AAT TGG TCA GAG GTC 
I   K   V   E   N   W   S   E   V 
AAA GGA 
K   G 
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Figure 4.1 Schematic Representation of the Antigenic Site Swapped Envelope 
Glycoproteins Produced 
(A) The wildtype envelope glycoproteins of the rabies virus (RABV) CVS-11 isolate and West Caucasian bat 
virus (WCBV) RUS-02 isolate, depicting the position of the defined antigenic sites. (B) Constructs produced 
switching each antigenic site individually from the RABV to WCBV sequence and vice-versa, as well as 
envelope glycoproteins with full antigenic site swaps (FSS). 
 
A 
B 
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Each of the envelope glycoprotein constructs (Figure 4.1) was used to produce lentiviral PV 
incorporating a firefly luciferase reporter gene by transfecting HEK 293T/17 cells (Section 2.2.10). 
The titre of each of the PV constructs and the TCID50 was determined via a titration assay (Section 
2.2.11.2) on the BHK-21 cell line. Titres were recoded as relative light units (RLU; Section 
2.2.12.1) and comparisons made to determine whether switching the antigenic sties had negatively 
impacted PV production, which could indicate disruption to the folding of the envelope 
glycoprotein. Results showed that titres >10
7
 RLU/ml were achieved for all PV produced (Figure 
4.2). While some titres were reduced compared to that of PV comprising RABV and WCBV 
wildtype G, with the largest decrease being 6-fold for RABV-WCBV IIb G PV and 64-fold for 
WCBV-RABV IIa G PV, the titres were high enough to demonstrate the envelope glycoprotein 
was still functional.  
 
 
Figure 4.2 Comparison of Titres of Pseudotyped Virus Produced Comprising Wild Type 
and Antigenic Site Swapped Envelope Glycoproteins  
PV with a luciferase reporter gene and comprising wildtype and antigenic site swap G, titrated on BHK-21 
cells with titres calculated as relative light units per ml (RLU/ml) to determine the impact of switching the 
antigenic sites on PV titre. Error bars show SD (n = 4).  
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4.2.2. Characterising Neutralisation of RABV and WCBV Antigenic Variants 
by Serum Samples 
The impact of switching the antigenic sites on neutralisation by serum samples was investigated via 
a PVNA (Section 2.2.13) with an input of 100 TCID50 of PV. Samples tested included a serum 
sample taken from a RABV-vaccinated human (Rabipur, Novartis), which is known to afford 
protection against phylogroup I lyssaviruses, and had previously been assigned a titre of 17.8 IU/ml 
(H85) by a FAVN test, along with a sample with a titre of 0.03 IU/ml (H46) which was used as a 
negative due to previously finding samples with this NAb level failed to neutralise RABV G PV 
(Chapter 3). Further, the WHO 2
nd
 international human anti-rabies Ig reference serum (WHO IS; 
prepared by NIBSC, UK), which is assigned a titre of 2 IU/ml and also known to neutralise 
phylogroup I lyssaviruses was used. Finally, a rabbit serum sample derived against WCBV 
(WCBV #827; produced by CDC) was used, which when previously tested potently neutralised the 
WCBV G PV (E. Wright, unpublished data). Sera were tested over a 2-fold dilution series, starting 
at a 1:40 dilution for the human sera (H85 & H46), a 1:20 dilution for the WHO IS and a 1:640 
dilution for the WCBV serum, with IC100 endpoint titres recorded.  
 
Results showed that after switching individual antigenic sites, a significant drop in the 
neutralisation IC100 endpoint for the RABV G PV occurred when switching site III to that of 
WCBV (RABV-WCBV III), with a 5.7-fold drop (p = 0.05) in neutralisation by the H85 serum 
sample and a 7.9-fold drop (p = 0.03) for the WHO IS serum (Table 4.2, Figure 4.3A). 
Additionally, switching antigenic site IIa caused a small 3.0 and 2.8-fold decrease in the IC100 
neutralisation titre by the H85 and WHO IS sera respectively. The H85 serum had a significantly 
reduced potency (50.7-fold, p < 0.0001) in neutralising the RABV-WCBV FSS G PV and the 
WHO IS serum did not produce an IC100 endpoint titre (Table 4.2, Figure 4.3A). The WCBV #827 
and H46 sera did not give an IC100 endpoint titre with any of the constructs. 
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Table 4.2 Rabies Virus Antigenic Site Swap Pseudotyped Virus Neutralisation by 
Serum Samples 
Neutralisation of wildtype RABV G PV and RABV-WCBV antigenic site swap G PV reported as the 
reciprocal serum dilution of IC100 endpoints. Serum samples known to neutralise phylogroup I lyssaviruses 
include a RABV vaccinated human serum sample, H85 (17.8 IU/ml), along with the WHO IS (2 IU/ml). The 
WCBV #827 is a rabbit serum sample that neutralises WCBV. Sample H46 (0.03 IU/ml) is from a human 
RABV vaccine recipient and was used as a negative control. 
  Serum Sample 
PV Envelope Glycoprotein H85 WHO IS WCBV #827 
H46 
(Negative) 
RABV  5120 453 - - 
RABV - WCBV IIb 3225 403 - - 
 IIa 1810 226 - - 
 I 8127 508 - - 
 IV 4064 320 - - 
 III 905 57 - - 
 FSS 101 - - - 
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The results of individually switching the antigenic sites of the WCBV G showed that the highest 
drop in the IC100 endpoint titre of the WCBV #827 serum occurred for the WCBV-RABV I G PV 
(8-fold; Table 4.3, Figure 4.3B). A drop in neutralisation potency of the WCBV #827 serum was 
also observed when switching antigenic sites IIb and IIa by 2.8 and 4.0-fold, respectively. Similar 
to the results for the RABV G, switching all the antigenic sites of the WCBV G prevented an IC100 
neutralisation titre from being achieved with the WCBV #827 serum; however in this case the H85 
serum consequently gave an IC100 titre at a low, 1:57 dilution (Table 4.3).   
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Table 4.3 West Caucasian Bat Virus Antigenic Site Swap Pseudotyped Virus 
Neutralisation by Serum Samples 
Neutralisation of wildtype WCBV G PV and WCBV-RABV antigenic site swap G PV reported as the 
reciprocal serum dilution of IC100 endpoints. Serum samples known to neutralise phylogroup I lyssaviruses 
include a RABV vaccinated human serum sample, H85 (17.8 IU/ml), along with the WHO IS (2 IU/ml). The 
WCBV #827 is a rabbit serum sample that neutralises WCBV. Sample H46 (0.03 IU/ml) is from a human 
RABV vaccine recipient and was used as a negative control 
  Serum Sample 
PV Envelope Glycoprotein H85 WHO IS WCBV #827 
H46 
(Negative) 
WCBV  - - 5120 - 
WCBV - RABV IIb - - 1810 - 
 IIa - - 1280 - 
 I - - 640 - 
 IV - - 6451 - 
 III - - 4064 - 
 FSS 57 - - - 
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Figure 4.3 Comparison of Serum IC100 Endpoint Neutralisation of RABV and WCBV 
Antigenic Site Swap Glycoprotein Pseudotyped Virus 
The reciprocal serum dilution of IC100 endpoints reported in Table 5.2 – 5.3 for (A) wildtype RABV G PV 
(dot-filled bars) and RABV-WCBV antigenic site swap G PV by the H85 and WHO IS serum samples and 
(B) wildtype WCBV G PV (dot-filled bars) and WCBV-RABV antigenic site swap G PV by the WCBV 
#827 serum sample. The WCBV-RABV FSS G PV was neutralised (IC100 = 1:57) by the H85 serum sample, 
data not shown. *p ≤ 0.05 and ** p < 0.0001 by a one sample t-test comparison of antigenic site swap G PV 
to the respective wildtype G PV endpoint. Values are the geometric mean ± SD, where error bars are absent, 
replicates produced the same endpoint and a t-test could not be performed. 
A 
B 
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4.3. Discussion 
Current vaccines and post-exposure prophylaxis against rabies are derived against strains of the 
phylogroup I, RABV type species, and do not effectively neutralise more divergent lyssavirus 
species which have been classified within phylogroups II and III. While the true burden of non-
RABV lyssaviruses is undefined due to a lack of discriminatory diagnostics and an unclear 
epidemiological picture, they have or are considered capable of causing the same devastating 
clinical disease and pose a continued threat due to the potential for spill-over events from bat 
reservoir species (Banyard & Fooks, 2017; Evans et al., 2012; Fooks, 2004). Thus, to fully 
eliminate the threat of rabies it is prudent to better understand the immunological profile of 
divergent species, which can assist the development of broadly neutralising prophylaxis against 
lyssaviruses in each of the current phylogroups. The low containment level and flexibility of the 
pseudotype platform allows the comprehensive study of individual antigenic sites of the envelope 
protein through evaluation of their immunological importance in neutralisation by polyclonal sera. 
This study further builds upon a recent investigation into the antigenicity of phylogroup I and II 
lyssaviruses (Evans, et al., 2013), by including a phylogroup III lyssavirus, WCBV.  
 
While it has been shown that vaccine efficacy is likely associated with antigenic divergence from 
the RABV species for which they are derived, the relationship remains poorly understood. Even 
within phylogroup I, vaccine efficacy has been found to be reduced against some species such as 
Aravan and Irkut virus, although remains capable of affording protection (Brookes et al., 2005; 
Hanlon et al., 2005). Yet in vivo vaccine challenge experiments have shown protection is not 
afforded against phylogroup II (Badrane et al., 2001), or the phylogroup III WCBV and IKOV 
(Hanlon et al., 2005; Horton et al., 2014). Currently phylogenetic analysis places IKOV within 
phylogroup III, however it has been found that no cross neutralisation occurs between WCBV and 
IKOV (Horton et al., 2014), which supports a more complex relationship between vaccine cross 
protection and sequence identity. Structurally, antigenic sites are proposed to occur on exposed 
sites of the lyssavirus envelope glycoprotein (Buthelezi et al., 2016), although structural models of 
RABV G are based on vesicular stomatitis virus and thus differences in antigenicity cannot be 
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directly linked to differences in folding. The RABV and WCBV antigenic site swap G PV in this 
study were produced to high titres, suggesting that function is not affected by changes which may 
have occurred in envelope glycoprotein folding. Using these PV antigenic variants, levels of 
neutralisation afforded by sera samples from vaccine recipients were measured via a PVNA. 
 
The antigenic sites on the RABV envelope glycoprotein have been defined using mAbs and more 
recently by glycoprotein mutagenesis. Antigenic sites II and III were among the earliest described 
and a large number of mAbs are directed against these sites (Benmansour et al., 1991; Kuzmina et 
al., 2013; Lafon et al., 1983). They have also previously been suggested to be most important for 
neutralisation of RABV (Benmansour et al., 1991). Site II is a discontinuous conformational 
epitope, formed of two domains, IIb and IIa (Prehaud et al., 1988), while site III is a continuous 
conformational epitope, which is considered to be part of a loop on the tertiary structure of the 
protein as mAb is unable to bind the unfolded protein (Benmansour et al., 1991). Additionally, 
antigenic site III contains charged lysine (K) and arginine (R) residues at amino acid positions 330 
and 333 respectively, which have a role in receptor interaction and pathogenicity (Coulon et al., 
1998). These two residues are not conserved within the WCBV G, however compensatory K or R 
residues at amino acid position 331, such as the K within the WCBV G, or at position 334 have 
been found to be sufficient to maintain pathogenicity (Badrane et al., 2001).  
 
Within this study, a significant drop in the potency of the anti-RABV sera was observed when 
antigenic site III of RABV G was replaced with that of WCBV, suggesting this site is important for 
neutralisation of the phylogroup I lyssavirus. Since the reciprocal swap of antigenic site III from 
WCBV G to RABV was not detrimental to neutralisation by the anti-WCBV serum, the same site 
does not have dominance in neutralisation of the phylogroup III lyssavirus. These results confer 
with those reported by Evans, et al., (2013) which also showed site III to be important for the 
neutralisation of a phylogroup I lyssavirus, but similarly found it to be less important for 
neutralisation of the phylogroup II LBV, for which antigenic site II was immunologically 
dominant. Although within this study the switching of site IIa from RABV to WCBV caused a 
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small drop in neutralisation potency by anti-RABV sera, it was not of significance. A small drop in 
the IC100 neutralisation titre was also observed for both sites IIb and IIa when they were switched 
from WCBV to RABV, which may benefit from further investigation; switching both domains to 
generate a WCBV-RABV site II G PV to further evaluate the importance of this antigenic site. 
 
Antigenic site I, which is described to consist of both conformational and linear epitopes (Marissen 
et al., 2005), was found to be immunologically dominant in the neutralisation of the phylogroup III 
WCBV. Work by Evans, et al., (2013) found antigenic site I to be important for the neutralisation 
of RABV, with the site also found to be targeted by a number of mAbs and suggested to share the 
importance of sites II and III (Bakker et al., 2005; Lafon et al., 1983). Yet introducing the WCBV 
site I into RABV G did not cause a reduction in the potency of neutralisation by the anti-RABV 
sera. 
 
Both the results of this study and that by Evans, et al., (2013) have not found antigenic site IV to be 
immunologically dominant. Unlike the other major antigenic sites, site IV is not conformational but 
comprised of overlapping linear epitopes which includes amino acids 263 and 264 (Luo et al., 
1997) used within this study. Although other linear epitopes within this region at amino acid 
positions 251 and 261-262 have been defined (Bakker et al., 2005; Kuzmina et al., 2013).  
 
When evaluating neutralisation against the FSS envelope glycoprotein, the sera either had a 
considerably reduced IC100 neutralisation titre or were unable to fully neutralise the FSS G PV. As 
switching single antigenic sites did not cause a complete loss of neutralisation to an IC100 titre, this 
suggests multiple antigenic sites are targeted by polyclonal sera. However, switching the antigenic 
sites of the RABV G to those of WCBV did not result in neutralisation by the anti-WCBV serum 
and only one of the anti-RABV sera were able to fully neutralise the WCBV FSS G PV. This 
suggests that either changing several antigenic sites causes a big change in folding so that epitopes 
become hidden or that regions of the envelope glycoprotein other than the defined antigenic sites 
are involved in neutralisation by polyclonal sera.  
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Employing antigenic cartography could further assist in the quantification of the immunological 
profile of these divergent lyssavirus species. This technique works on the basis of constructing a 
biological map based on data from assays measuring antigenic differences. It was first used to 
graphically represent binding data from the influenza haemagglutination assay which is now used 
by the World Health Organisation (WHO) as part of their influenza surveillance (Fouchier & 
Smith, 2010; Smith et al., 2004). Antigenic cartography was applied to a global panel of 
lyssaviruses in a study by Horton, et al., (2010), which among other findings demonstrated that 
KHUV is more closely related to RABV antigenically than phylogenetic analysis would suggest. It 
was further employed in the study by Evans, et al., (2013) to look at the relationship between 
RABV, LBV, and LBV FSS G using recombinant viruses and polyclonal sera, which included a 
panel of sera obtained after using the antigenic site swap G PV as a vaccine immunogen. The 
results showed that switching all antigenic sites of the LBV G did not cause a complete phenotypic 
switch, with the glycoprotein instead positioned equally between RABV and LBV (E. Wright, 
personal communication). They also mapped the closeness of polyclonal sera to each of the viruses, 
to demonstrate the shift in immunogenicity caused by each antigenic site. This data supported the 
identification of immunologically important antigenic sites and the hypothesis that sites important 
for broad, cross-neutralisation may be present outside those currently mapped and known to be 
involved in antigenicity. Generating an antigenic map using data collected via the PVNA should be 
explored to allow for enhanced assessment of immunologically important sites via this low 
containment level, accessible platform. 
 
In conclusion, the use of PV comprising envelope glycoprotein with antigenic sites switched 
between RABV and WCBV within this study allowed assessment of their neutralisation by 
polyclonal sera samples raised against each of these lyssavirus species. This led to the 
identification that antigenic site III of the RABV, phylogroup I lyssavirus, and antigenic site I of 
the WCBV, phylogroup III lyssavirus, are likely to be immunologically dominant. Further, it seems 
likely that neutralisation by polyclonal sera involves epitopes other than those identified by mAbs. 
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Future investigation into the importance of other antigenic sites in raising an immune response, 
including more divergent lyssaviruses such as IKOV and incorporating the use of antigenic 
cartography to assess PVNA data, will help to establish immunogens required for a broadly 
neutralising lyssavirus vaccine. 
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Chapter 5. Optimising the Production of Filovirus 
Pseudotypes for Use in Serological Studies 
 
5.1. Introduction 
The recent outbreak of Ebola virus in West Africa, beginning in December 2013 in Guinea before 
spreading to neighbouring Liberia and Sierra Leone, along with imported cases in seven countries, 
resulted in more than 11,000 deaths and was the largest outbreak since being first isolated in 1976 
(Baize et al., 2014; WHO, 2016). All species within the Ebolavirus and Marburgvirus genera of 
the Filoviridae family cause haemorrhagic fever in humans and circulate within Africa, except the 
Reston ebolavirus species which is thought to be asymptomatic and reported to circulate in Filipino 
bat and swine populations (Baize, 2015; Barrette et al., 2009). A third genera, Cuevavirus, was 
more recently described following the isolation of Lloviu cuevavirus from bats in a Spanish cave 
(Negredo et al., 2011). The case fatality rate of Marburg and Ebola virus disease (M/EVD) varies 
between outbreaks and the causative species, with Zaire and Sudan ebolavirus outbreaks having 
occurred most frequently, often with fatality rates >50% (Leroy et al., 2011; To et al., 2015). 
Indeed, Zaire ebolavirus was the species responsible for the recent outbreak which had an 
estimated fatality rate of 40% (WHO, 2016). Following an exponential increase in cases and in 
light of the threat posed by further regional and global transmission, on 8
th
 August 2014 the WHO 
declared the epidemic a public health emergency of international concern (PHEIC), with 
preparedness and response plans implemented globally (WHO, 2014). With no licenced vaccines or 
antiviral drugs available, despite the well-known public health threat ebolavirus poses, there was an 
unprecedented push for their fast-track development by the global public health community. 
 
As handling live filoviruses requires biosafety level (BSL) 4 containment, the development of a 
pseudotyped virus neutralisation assay (PVNA) was highly valuable. It would permit widely 
accessible, low containment, serology studies to be undertaken to assess the efficacy of vaccines 
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and antivirals undergoing development and also to assist in the establishment of serological and 
nucleic acid standards. Further, the relatively low cost and stability of PV, which has previously 
been lyophilised to circumvent cold-chain storage (Mather et al., 2014), means that the PVNA is 
applicable in the resource-limited countries where filoviruses are endemic. Whilst there were 
limited reports of retroviral-based filovirus PV generation prior to the recent EVD outbreak (Chan 
et al., 2000; Simmons et al., 2003a, b; Wool-Lewis & Bates, 1998), their method or components 
for production varied from the three plasmid retrovirus-based PV system used in these studies, for 
which an assay had not been established. The following study aimed to determine the optimal 
method for high titre filovirus PV production along with evaluating the target cell line that ensures 
the most consistent results in the PVNA, in response to the EVD outbreak. 
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5.2. Results 
5.2.1. Optimal Producer and Target Cell Lines 
To optimise the production of filovirus PV a panel of envelope glycoproteins (GP) were used 
representing each genus and species within the Filoviridae family (Table 5.1) and including the 
Zaire ebolavirus (EBOV) Makona isolate responsible for the recent outbreak (Baize et al., 2014). 
This allowed any difference in PV production which could result from the diversity observed 
between the GP sequences of each species to be taken into account. GP identity was assessed via 
ClustalW sequence alignment and construction of a phylogenetic tree using the MEGA7 
maximum-likelihood method, based on the JTT matrix model (Figure 5.1) (Kumar et al., 2016). 
The GP cDNA sequences used had previously been cloned within a pCAGGS expression plasmid, 
which was found to offer superior PV titres in a preliminary experiment (Appendix III). So that 
secreted GP (sGP) could not be produced, the Ebolavirus and Cuevavirus GP sequences were 
derived from an edited mRNA transcript, with eight adenosines in the editing site (Sanchez et al., 
1996).  
 
Table 5.1 Filoviridae Isolates 
Details of the genus and species of the filovirus isolates used and GenBank accession numbers for the GP 
sequences. 
Genus Species Isolate 
GenBank 
Accession Number 
Ebolavirus Bundibugyo ebolavirus BDBV/UGA/2007 FJ217161 
 Reston ebolavirus RESTV/Pennsylvania/USA/1989 AY769362 
 Sudan ebolavirus SUDV/Boniface/SUD/1976 FJ968794 
 Tai Forest ebolavirus TAFV/CIV/1994 FJ217162 
 Zaire ebolavirus EBOV/Mayinga/COD/1976 EU224440 
  
EBOV/Makona/GIN/2014/ 
Kissidougou-C15 
KJ660346 
Cuevavirus Lloviu cuevavirus LLOV/ESP/2003 JF828358 
Marburgvirus Marburg marburgvirus RAVV/KEN/1987/KitumCave DQ447649 
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Figure 5.1 Sequence Homology between Filovirus Envelope Glycoproteins 
Phylogenetic tree constructed using the MEGA7 maximum likelihood method, based on the JTT matrix 
model, following ClustalW sequence alignment of filovirus isolate envelope glycoprotein amino acid 
sequences. Scale corresponds to amino acid substitutions per site.  
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For each of the filovirus isolates, PV were produced with a gammaretroviral or lentiviral core, 
incorporating a firefly luciferase reporter gene, by transfecting HEK 293T/17 cells (Section 2.2.10). 
As a negative control a ∆envelope PV was produced to assess background non-specific uptake, 
along with VSV and CVS-11 G PV as positive controls which pseudotype efficiently to give high 
and medium titres respectively (demonstrated in Chapter 3). To determine the cell line most 
permissive to infection by the gammaretroviral and lentiviral filovirus GP PV, an infection assay 
was performed (Section 2.2.11.1) with four replicates of 1:4 diluted PV titrated onto five different 
target cell lines (HEK 293T/17, A549, Vero-E6, CHO-K1, CRFK; Table 2.10). The level of 
infection was recorded in relative light units (RLU; Section 2.2.12.1). For PV produced with a 
gammaretroviral core, all filovirus GP PV except RAVV failed to infect the target cell lines or had 
very low infectious titres (Figure 5.2A). A cut-off of 10
3
 RLU/ml was considered to represent the 
minimum titre at which a viable level of infection had taken place. The CRFK cell line was most 
permissive to infection by the gammaretroviral RAVV GP PV (3.4 x 10
4
 RLU/ml), closely 
followed by the HEK 293T/17 cell line (3.0 x 10
4
 RLU/ml), and the titres were in line with those of 
the positive control VSV and CVS-11 G PV (Figure 5.2A). However, the infectious titres for 
lentiviral RAVV GP PV on CRFK and HEK 293T/17 cell lines were far greater (3800 and 2000 
fold, respectively), with these cell lines still being the most permissive to infection (Figure 5.2B). 
Viable titres were also achieved on every cell line for each of the other filovirus GP PV when using 
a lentiviral core, with HEK 293T/17 cells being most permissive to infection followed by CRFK 
and CHO-K1 cells (Figure 5.2B). From these results it was noted that GP of the Ebolavirus and 
Cuevavirus genus pseudotyped less efficiently than that of the Marburgvirus genus and also had 
titres lower than those of the CVS-11 G PV control. In addition, the lentiviral ∆envelope PV titres 
were found to be above the threshold set to represent a viable level of infection (10
3
 RLU/ml). 
However, analysis found the titres were significantly lower (p ≤ 0.03; two-tailed t-test) than that of 
the filovirus GP PV with the lowest titre on each of the cell lines most permissive to infection 
(HEK 293T/17: p < 0.0001; CRFK: p = 0.01; CHO-K1: p = 0.03). 
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Figure 5.2 Cell Lines Permissive to Infection by Filovirus Envelope Glycoprotein 
Pseudotyped Virus 
Filovirus envelope GP PV with a gammaretroviral (A) or lentiviral (B) core titrated onto five different target 
cell lines, with titres recorded as relative light units per ml (RLU/ml). Positive controls of VSV and CVS-11 
PV are included, along with a ∆envelope PV (∆env) as a control for background infection levels. A broken 
line at 10
3
 RLU/ml represents the cut-off for a viable PV titre. Error bars show SD (n = 4).  
 
A 
B 
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The lentiviral ∆envelope PV titres were further evaluated to determine if they influenced which 
permissive cell line to use when titrating filovirus GP PV. An infection assay (Section 2.2.11.1) 
was performed, titrating lentiviral ∆envelope PV in parallel to the EBOV/May GP PV on each of 
the three most permissive cell lines, over a 2-fold serial dilution starting at 1:4. Where ∆envelope 
titres were record, they were considerably lower than those measured for the EBOV/May GP PV at 
each dilution on the HEK 293T/17 (166 – 7049 fold; p = 0.0005), CRFK (5 – 80 fold; p < 0.0001) 
and CHO-K1 (7 – 51 fold; p = 0.001) cell lines (Figure 5.3). It was also found that for lower PV 
dilutions the titre of the EBOV/May GP PV remained high, yet ∆envelope PV titres were not 
recorded. This highlighted that the production of high titre PV was advantageous, as lower PV 
input volumes into an assay would omit the potential for presence of ∆envelope PV background 
titres. 
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Figure 5.3 Comparative Titration of Lentiviral Pseudotyped Virus Produced With and 
Without Envelope Glycoprotein on Three Cell Lines Permissive to Filovirus Infection 
Lentiviral PV produced with an EBOV/May GP was titrated in parallel to ∆envelope PV (n = 2) on the HEK 
293T/17 (A), CRFK (B) and CHO-K1 (C) cell lines. Titres were recorded as relative light units per ml 
(RLU/ml). Statistical analysis of the difference between the EBOV/May GP and ∆envelope PV titres on each 
cell line found they were significant (p ≤ 0.001; paired two-tail t-test). 
A 
B 
C 
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After establishing the cell lines most permissive to filovirus GP PV infection, assessment was 
undertaken to determine whether there was a more efficient cell line for PV production than HEK 
293T/17 cells, which are normally transfected in the pseudotype system used within this study 
(Temperton et al., 2015b). Additionally, as HEK 293T/17 cells proved to be most permissive to 
infection by filovirus PV, an alternative producer cell line could alleviate potential issues such as 
non-specific uptake or reduced serum sensitivity in a neutralisation assay (Magre et al., 2004; 
Voelkel et al., 2012). A cell line engineered to stably express EBOV/Mak GP, E-SIAT MDCK, and 
the HeLa05 cell line (Table 2.10) were transfected (Section 2.2.10) alongside HEK 293T/17 cells, 
omitting envelope plasmid DNA for the transfection of the E-SIAT MDCK cells, to produce 
lentiviral EBOV/Mak GP PV with a firefly luciferase reporter gene. An infection assay, titrating 
onto HEK 293T/17 cells, showed transfecting both E-SIAT MDCK and HeLa05 cells had failed to 
produce PV (Figure 5.4). 
 
 
Figure 5.4 Comparison of Cell Lines for Production of Filovirus Pseudotyped Virus 
The titres of lentiviral EBOV/Mak GP PV produced after transfection of three cell lines, HEK 293T/17, 
HeLa05 and E-SIAT MDCK, were tested by infection of HEK 293T/17 cells. Infectious titres were recorded 
as relative light units per ml (RLU/ml). Error bars show SD (n = 2).  
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It had been reported that lowering the quantity of envelope GP plasmid DNA used in transfections 
to produce an Ebolavirus pseudotype could increase production, while high levels of envelope GP 
on the PV surface can impair infectivity (Mohan et al., 2015). Consequently, HEK 293T/17 cells 
were transfected in the 6-well format (Section 2.2.10) to produce lentiviral EBOV/May GP PV, 
varying the quantity of envelope plasmid DNA from the standard 0.6 μg to include three lower (0.3 
μg, 0.06 μg and 0.03 μg) and two higher (1.0 μg and 2.4 μg) quantities. An infection assay, titrating 
onto HEK 293T/17 cells, found that each of the lower quantities of envelope plasmid DNA caused 
a decrease in PV titre (Figure 5.5). The decrease was significant using 0.06 μg and 0.03 μg of 
envelope plasmid DNA (p < 0.0001; two-tailed t-test), which were in line with the quantities 
reported to give increased titres by Mohan et al. (2014). Interestingly, the highest quantity of 
envelope plasmid DNA used resulted in a significant, 1.5 fold, increase in PV titre (p = 0.0004; 
two-tailed t-test) (Figure 5.5). However, the quantity of envelope plasmid DNA used in 
transfections for this study was not altered due to the low magnitude of the increase and concerns 
over the comparatively large quantity of DNA in the transfection which can cause cytotoxicity, 
although none was observed. Further, the morphology of EBOV/May GP PV produced using this 
transfection method was as expected, with a good covering of envelope GP visible, when assessed 
via electron microscopy as part of a collaboration (Appendix III).  
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Figure 5.5 Production of Pseudotyped Virus after Transfecting with Different Quantities 
of Envelope Plasmid DNA 
Titres of EBOV/May GP PV, measured by infecting HEK 293T/17 cells, following transfection using 
different quantities of envelope GP plasmid DNA in comparison to the standard 0.6 μg normally used. Titres 
are measured in relative light units per ml (RLU/ml) (***p ≤ 0.0004; two-tailed t-test). Error bars show SD 
(n = 6). 
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5.2.2. Chimeric and Truncated Ebolavirus Envelope Glycoprotein 
Construction  
The lentiviral PV produced with an Ebolavirus GP was found to have titres lower than both 
Marburgvirus GP PV and the control CVS-11 G PV, thus requiring larger volumes be produced to 
perform downstream assays. As it had previously been proven that switching a RABV envelope G 
cytoplasmic domain to that of VSV could increase PV titres (Chapter 3), this approach was 
investigated for its application to the production of Ebolavirus GP PV. Chimeric envelope GP was 
generated for the SUDV, EBOV/May and EBOV/Mak isolates, covering two Ebolavirus species 
(Table 5.1). The cytoplasmic domain of the three isolate’s GP was replaced with that of the VSV G 
using SOE PCR (Section 2.2.4) and primers designed (C2.15 – 2.17; Table 2.4) based on mapping 
the Ebolavirus GP cytoplasmic domain to amino acids 672 – 677 (UniProt: Q05320), with the VSV 
G cytoplasmic domain mapped to amino acids 483 – 512. As the RAVV isolate of the 
Marburgvirus genus had pseudotyped efficiently in this study, chimeric envelope GP was also 
produced with a RAVV GP cytoplasmic domain using primers (C2.7 – 2.9; Table 2.4) designed for 
standard PCR (Section 2.2.3) owing to the short length of the Marburgvirus cytoplasmic domain 
which spans amino acids 674 – 682 (Mittler et al., 2013). Finally, as it had been reported that 
truncation of the envelope protein cytoplasmic domain could increase MeV PV titre (Frecha et al., 
2008), primers were designed (C2.10 – 2.12; Table 2.4) to remove the cytoplasmic domain of the 
envelope GP. The constructs produced are depicted in Figure 5.6 and were each cloned into the 
pCAGGS expression plasmid and sequencing verified (Section 2.2.8).  
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Figure 5.6 Schematic Representation of Chimeric and Truncated Ebolavirus Envelope 
Glycoprotein Constructs  
The chimeric envelope glycoprotein constructs produced by switching or removing the cytoplasmic domain 
are depicted. Numbers represent the amino acids of the respective full length glycoprotein for the Ebolavirus 
ecto-transmembrane domain and VSV or RAVV cytoplasmic domain. 
 
 
Lentiviral PV with a firefly luciferase reporter gene was produced comprising each of the chimeric 
and truncated GP constructs, alongside wildtype SUDV, EBOV/May and EBOV/Mak GP, by 
transfection of HEK 293T/17 cells (Section 2.2.10). To determine whether the chimeric or 
truncated GP had increased PV titre, an infection assay was set up (Section 2.2.11.1) titrating onto 
HEK 293T/17 cells. It was found that all chimeric and truncated GP, except the chimeric SUDV 
GP with a RAVV cytoplasmic domain (SUDVetmRAVVc), caused a substantial or complete loss 
in PV titre in comparison to their respective wildtype GP PV (Figure 5.7). The chimeric 
SUDVetmRAVVc GP PV gave a 28% (1.4 fold) increase in PV titre relative to wildtype SUDV 
GP PV, yet had a high level of variance (28.1 ± 36.2 %; mean ± SD). While there was instead a 
loss in PV titre, this high level of variance was shared by the chimeric EBOV GP isolates with a 
RAVV cytoplasmic domain (EBOV/May -52.4 ± 19.6 %; EBOV/Mak -33.0 ± 40.0 %). Overall, the 
use of a chimeric GP with a RAVV cytoplasmic domain did not prove to be an efficient method of 
increasing Ebolavirus PV titres. 
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Figure 5.7 Percentage Change in Ebolavirus Pseudotyped Virus Titre using a Chimeric 
or Truncated Envelope Glycoprotein 
Lentiviral PV with wildtype (SUDV, EBOV/May or EBOV/Mak) envelope GP was titrated onto HEK 
293T/17 cells in parallel to a corresponding PV with either a truncated GP or a chimeric VSV or RAVV 
cytoplasmic domain GP. Titres were measured in relative light units (RLU) and the percentage change 
relative to PV with wildtype GP calculated. Error bars show SD (n = 6). 
 
 
A further attempt to increase the titre of Ebolavirus PV using a chimeric envelope GP was made, 
using envelope fusion proteins of the same class. Two class I fusion proteins, an influenza virus 
haemagglutinin (HA) (A/Vietnam/1194/2004(H5N1); ABP51976) which had previously 
pseudotyped efficiently (Molesti et al., 2014b) and the human immunodeficiency virus (HIV) 
gp160 envelope protein (type 1 HXB2; K03455) were used. Chimeric SUDV and EBOV/Mak GP 
with a HA cytoplasmic domain was produced by standard PCR (Section 2.2.3) using primers 
designed (C2.13 – 2.14; Table 2.4) based on the HA cytoplasmic domain spanning amino acids 577 
– 569 (Scolari et al., 2016) (UniProt: P03459). The chimeric SUDV and EBOV/Mak GP with a 
HIV cytoplasmic domain was produced via SOE PCR (Section 2.2.4), with primers designed 
(C2.18 – 2.19; Table 2.4) mapping the cytoplasmic domain to amino acids 706 – 857 (UniProt: 
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P04578). The constructs are depicted in Figure 5.8 and as before were each cloned into the 
pCAGGS expression plasmid and sequencing verified (Section 2.2.8). 
 
 
 
Figure 5.8 Schematic Representation of Chimeric Ebolavirus Envelope Glycoprotein 
Constructs with a HA or HIV Cytoplasmic Domain 
The chimeric envelope glycoprotein constructs produced by switching or removing the cytoplasmic domain 
are depicted. Numbers represent the amino acids of the respective full length glycoprotein for the Ebolavirus 
ecto-transmembrane domain and HA or HIV cytoplasmic domain.  
 
 
As before, lentiviral PV with a firefly luciferase reporter gene was produced comprising each of the 
chimeric and truncated GP constructs, alongside wildtype SUDV and EBOV/Mak GP, by 
transfection (Section 2.2.10). Following an infection assay (Section 2.2.11.1), it was found that 
both chimeric envelope GP with a HA and HIV cytoplasmic domain failed to increased Ebolavirus 
PV titres (Figure 5.9). The use of a chimeric HIV cytoplasmic domain GP caused a complete loss 
in PV titre for both the SUDV and EBOV/Mak GP.  
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Figure 5.9 Percentage Change in Ebolavirus Pseudotyped Virus Titre using a Chimeric 
Envelope Glycoprotein with a HA or HIV Cytoplasmic Domain 
Lentiviral PV with wildtype (SUDV or EBOV/Mak) envelope GP was titrated onto HEK 293T/17 cells in 
parallel to a corresponding PV with a chimeric HA or HIV cytoplasmic domain GP. Titres were measured in 
relative light units (RLU) and the percentage change relative to PV with wildtype GP calculated. Error bars 
show SD (n = 6). 
 
 126 
 
5.2.3. Influence of Target Cell Line on Ebolavirus Pseudotyped Virus Serology 
Studies 
As attempts to increase the titre of the Ebolavirus PV were not successful and thus larger input 
volumes, compared to other virus families, would be required for serology studies; a PVNA was 
initially performed to assess the behaviour of lentiviral ∆envelope PV, continuing the analysis in 
Section 4.2.1 (Figure 5.3). The PVNA was set up (Section 2.2.13) to test the EBOV/May GP PV 
alongside ∆envelope PV using a potent mAb, EVB114 (Corti et al., 2016), over a 2-fold serial 
dilution with a starting concentration of 50 μg/mL and using HEK 293T/17 cells as the target cell 
line. An input of 12.5 μL of PV was used, equating to a 1:16 dilution. PV infection controls were 
included to measure infectivity in the absence of mAb. Results recorded as RLU following 
incubation showed that the EBOV/May GP PV titre decreased with an increasing concentration of 
the EVB114 mAb sample and was below that of the infection control (Figure 5.10). The ∆envelope 
PV titre did not share the same correlation and had a higher level of infectivity than the infection 
control at several points, including the two highest concentrations of EVB114 (Figure 5.10). This 
showed that ∆envelope PV was not neutralised and thus would not interfere with the serological 
assessment of samples via the PVNA. 
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Figure 5.10 Assessment of the Neutralisation of Lentiviral Pseudotyped Virus with and 
without Envelope Glycoprotein  
Neutralisation of lentiviral EBOV/May GP PV compared to that of a ∆envelope PV by the EVB114 mAb 
sample, titrating on HEK 293T/17 cells. EVB114 was tested at a starting concentration of 50 μg/ml. Values 
are reported as average relative light units per ml (RLU/ml) (n = 2). Data points for each PV infection control 
represent the average of four replicates of PV incubated without mAb.  
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To evaluate whether the target cell line influenced the collection of Ebolavirus PV neutralisation 
data, which could prove detrimental in the evaluation of antivirals and prophylaxis, a PVNA 
(Section 2.2.13) was performed using the three target cell lines found to be most permissive to 
infection (HEK 293T/17, CRFK and CHO-K1). Lentiviral EBOV/Mak GP PV was used, with an 
input of 50 TCID50 for each cell line determined via a titration assay (Section 2.2.11.2). Three mAb 
samples, KZ52 (Lee et al., 2008b), P6 (Dr A. Townsend, University of Oxford) and EVB114 (Corti 
et al., 2016), were tested in parallel for neutralisation of the EBOV/Mak PV on each of the cell 
lines over a 2-fold serial dilution, with a starting concentration of 20 μg/mL for P6 and 40 μg/mL 
for each of the other mAb samples. A mAb derived against RABV, RVB492 (De Benedictis et al., 
2016), was used as a negative control, with a starting concentration of 40 μg/mL. PV infection 
controls were included by titrating the EBOV/Mak GP PV onto each of the cell lines without the 
addition of mAb, and used to calculate percentage neutralisation. Results showed that neutralisation 
with the EVB114 mAb sample produced a similar dose-response pattern on each of the target cell 
lines (Figure 5.11). The neutralisation data for the KZ52 and P6 mAb samples did not produce a 
smooth dose-response on the CRFK cell line (Figure 5.11B). To aid the comparison, IC50 endpoint 
values were extrapolated via regression analysis, for which a value could not be determined for the 
KZ52 mAb on the CRFK cell line (Table 5.2). The dose-response pattern on both the HEK 
293T/17 and CHO-K1 cell lines allowed extrapolation of IC50 values (Table 5.2). However, as the 
data was cleanest on the CHO-K1 cell line (Figure 5.11C) this was considered the preferable target 
cell line to use for neutralisation assays. 
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Figure 5.11 Comparison of Ebolavirus Pseudotyped Virus Neutralisation by Monoclonal 
Antibody Samples on Three Target Cell Lines 
The percentage neutralisation of lentiviral EBOV/Mak GP PV by the monoclonal antibody samples KZ52, 
P6 and EVB114 was measured by comparison to a PV infection control on three target cell lines, HEK 
293T/17 (A), CRFK (B) and CHO-K1 (C). Non-linear regression analysis (Log10[inhibitor] vs. response) was 
performed, constraining the bottom value to be > 0%. Data points are plotted for the RVB492 negative 
control mAb sample. (n = 2) 
A 
B 
C 
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Table 5.2 Neutralisation IC50 Endpoint Titres of Monoclonal Antibody Samples 
Measured by Pseudotyped Virus Neutralisation Assay on Three Target Cell Lines 
The IC50 endpoint values (ng/mL) for neutralisation of EBOV/Mak GP PV via three monoclonal antibody 
samples, on three target cell lines, were calculated via extrapolation from non-linear regression analysis 
(Log10[inhibitor] vs. response). Where the IC50 endpoint could not be extrapolated, values are absent (-). 
 
 Monoclonal Antibody IC50 Endpoint Titre (ng/mL) 
Cell Line KZ52 P6 EVB114 
HEK 293T/17 2360.5 3288.5 306.9 
CRFK - 1905.5 443.6 
CHO-K1 632.4 1032.8 254.7 
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A further PVNA was performed using serum samples to assess whether the neutralisation pattern 
on each of the target cell lines corresponded with that found when testing the mAb samples. As 
before, lentiviral EBOV/Mak GP PV was used with an input of 50 TCID50 for each cell line. Three 
serum samples were tested, which included the human convalescent plasma sample (H79; WHO 
anti-EBOV reference reagent) and a transchromosomal bovine sample (B31), included in a 
collaborative study coordinated by NIBSC (Wilkinson et al., 2017), along with the 
transchromosomal ovine serum sample S4 (Dr T. Lambe, Jenner Institute). The samples were 
tested in parallel over a 2-fold serial dilution, from a starting dilution of 1:50 for the H79 and B31 
sample and a 1:20 dilution for the S4 sample. A negative control serum (N36), which was also 
included in the NIBSC collaborative study (Wilkinson et al., 2017), was used at a starting dilution 
of 1:50. PV infection controls were again used to calculate percentage neutralisation at each 
dilution of the serum samples. Due to the lower potency of the serum samples in comparison to the 
mAb preparations, the neutralisation data was generally less clear (Figure 5.12). A low level of 
neutralisation was observed for the negative serum sample N36, following the findings of the 
collaborative study (Wilkinson et al., 2017). Overall, the position of the data points and dose 
response pattern was similar on the HEK 293T/17 and CRFK cell lines (Figure 5.12A and B). Low 
levels of neutralisation (< 50%) for some samples on these cell lines meant IC50 values could only 
be extrapolated via regression analysis for a single serum sample on each, S4 and H79 respectively 
(Table 5.3). In comparison, the serum neutralisation data on the CHO-K1 cell line (Figure 5.12C) 
allowed IC50 values to be extrapolated for each serum sample (Table 5.3), which further suggested 
this cell line may be more appropriate for use in the ebolavirus PVNA. 
 
 132 
 
 
Figure 5.12 Comparison of Ebolavirus Pseudotyped Virus Neutralisation by Serum 
Samples on Three Target Cell Lines 
The percentage neutralisation of lentiviral EBOV/Mak GP PV by the serum samples H79, B31 and S4 was 
measured by comparison to a control without the addition of sera on three target cell lines, HEK 293T/17 
(A), CRFK (B) and CHO-K1 (C). Non-linear regression analysis (Log10[inhibitor] vs. response) was 
performed, constraining the bottom value to be > 0%. Data points are plotted for the N36 negative control 
sera sample. (n = 2) 
A 
B 
C 
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Table 5.3 Neutralisation IC50 Endpoint Titres of Serum Samples Measured by 
Pseudotyped Virus Neutralisation Assay on Three Target Cell Lines 
The IC50 endpoint values (reciprocal serum dilution) for neutralisation of EBOV/Mak GP PV via three serum 
samples, on three target cell lines, were calculated via extrapolation from non-linear regression analysis 
(Log10[inhibitor] vs. response). Where the IC50 endpoint could not be extrapolated, values are absent (-). 
 
 Serum Sample IC50 Endpoint Titre (reciprocal serum dilution) 
Cell Line H79 B31 S4 
HEK 293T/17 - - 59.2 
CRFK 86.9 - - 
CHO-K1 182.2 1004.7 149.3 
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5.3. Discussion 
The ability to rapidly develop PV, enabling highly pathogenic viruses to be handled in low 
containment laboratories, makes them an excellent tool to respond to emerging virus outbreaks, 
particularly those which pose a significant public health threat such as the recent EVD outbreak. 
The three plasmid transfection protocol for PV production using a retroviral core is highly 
successful, having been used in the development of PV for many zoonotic virus families 
(Temperton et al., 2015b). Serology studies undertaken via a PVNA allow the inhibition of viral 
infectivity to be measured and are a valuable tool in the development of efficacious vaccines and 
antivirals. This study optimised the production of filovirus PV and its use in the PVNA, 
demonstrating how PV can rapidly be developed in response to an emerging virus outbreak, 
allowing their application to the development of efficacious vaccines and antivirals along with 
being applicable in the resource-limited countries where the filovirus species responsible for 
causing EVD circulate.  
 
The target cell line chosen for infection assays can greatly influence the titre of PV due to a 
difference in the density of cell surface receptors required for transduction. Previous studies 
utilizing a filovirus PV have shown that while lymphoid cells are resistant to filovirus infection, 
they otherwise have a broad host range; infecting cells derived from different species and tissues 
(Chan et al., 2000; Ito et al., 2001; Takada, 2012; Wool-Lewis & Bates, 1998). Like many 
enveloped viruses, filoviruses require endocytosis to infect cells, however it is thought to occur 
primarily via macropinocytosis, with initial uptake occurring after a relatively non-specific 
interaction between host cell receptors for viral membrane phosphatidylserine and a viral GP-
dependent interaction with host cell lectin receptors, expressed on a range of cell types (Moller-
Tank & Maury, 2015; Nanbo et al., 2010; Pöhlmann, 2013; Saeed et al., 2010). Crucially, filovirus 
exit from the late endosome is triggered by the GP receptor binding domain, exposed following 
proteolytic processing by endosomal cathepsin proteases, interacting with the ubiquitously 
expressed fusion receptor Niemann-Pick C1 (NPC1) (Côté et al., 2011; Kuroda et al., 2015; Miller 
et al., 2012; Moller-Tank & Maury, 2015). This distinct and relatively non-specific pathway is 
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thought to account for the wide host cell range. In this study, the highest titres of lentiviral core 
Ebolavirus PV were achieved using HEK 239T/17 cells, which were previously reported to be 
highly permissive to filovirus infection and had been used as target cells in pseudotyping assays 
(Simmons et al., 2003b; Wool-Lewis & Bates, 1998). While the Vero-E6 primate cell line is 
commonly used to propagate wildtype filovirus due to its high permissibility (Ito et al., 2001; 
Takada, 2012), it is not permissive to infection with lentiviral PV owing to having an intrinsic 
restriction factor, TRIM5α, which inhibits un-coating of the genome and targets the HIV-based 
core for degradation (Stremlau et al., 2004). Using a gammaretroviral core to overcome this was 
not successful. While commonly used for pseudotyping it can only infect proliferating cells, unlike 
lentivirus, which is detrimental to the level of transduction of target cells (Maetzig et al., 2011; 
Temperton et al., 2015b).  
 
The infectious titres observed with ∆envelope PV preparations are a common artifact and not cause 
for concern. It is thought the mechanism behind this apparent non-specific infection is accounted 
for by a combination of passive transfer of reporter protein trapped within the ∆envelope PV 
particles (Nash & Lever, 2004), which can bind in an envelope-independent manner to the surface 
proteins and carbohydrate of target cells (Pizzato et al., 1999; Sharma et al., 2000), as well as being 
internalized via endocytosis (Voelkel et al., 2012). Due to the high sensitivity and enzymatic nature 
of the luciferase assay, a small quantity of passively transferred luciferase protein is likely capable 
of producing the relatively high luminescence signals seen within this study. Using an alternative 
reporter gene with lower sensitivity, such as GFP or the lacZ gene, may give lower ∆envelope PV 
titres. In this study it was shown that decreasing the input volume of PV into an assay caused 
∆envelope PV titres to diminish, indicating an advantage to the production of high titre PV stocks. 
It is also likely that a lower amount of ∆envelope PV is produced when an envelope protein is 
included in transfections. Further, the ∆envelope PV was not neutralised in the PVNA, ultimately 
mitigating concerns. 
 
 136 
 
Generation of PV by transient transfection of HEK 293T/17 cells is widely used and highly 
efficient. However, using the same cell line for both production and infection studies should be 
avoided if possible. As retroviral-based PV bud from the producer cell, their plasma membrane 
forms the outer viral membrane and incorporates membrane proteins. This could lead to an increase 
in non-specific binding and uptake as discussed above for ∆envelope PV, or alter sensitivity to 
human serum from the combination of human complement receptors on the viral surface (Magre et 
al., 2004; Takeuchi et al., 1996). The use of alternative transfection cells, such as found using 
HeLa cells within this study, is unlikely to lead to higher PV production titres. Both HEK 293T/17 
and HeLa cells are very well studied and thought to be good transfection hosts due to the inability 
to sense intracellular DNA and mount an antiviral response via the cGAS-STING and RIG-I 
pathways, owing to interfering viral oncogenes of human adenovirus 5 (hAd5) and human 
papilloma virus 18 (HPV18), which were introduced during the immortalisation of each of these 
cell lines respectively (Lau et al., 2015). However it is often found that HEK 293T/17 cells are 
most readily transfectable and generate high protein yields (Baldi et al., 2007; Thomas & Smart, 
2005) and transfection of other cell lines requires further protocol optimisation. Additionally, use 
of the E-SIAT MDCK cell line stably expressing the EBOV/Mak GP failed to produce infectious 
PV. The cell line was originally adapted for use in cell culture studies to better assess human 
influenza virus sensitivity to neuraminidase inhibitors, transducing MDCK cells with the gene of 
human SIAT-1 (2,6 - sialyltransferase) so that they stably express a higher proportion of the α-2,6 
sialic acid receptor required for human influenza transduction (Matrosovich et al., 2003). Thus this 
further adapted E-SIAT MDCK cell line may be better suited to anti-EBOV antibody screening and 
biochemical studies. 
 
While the Marburgvirus envelope GP is encoded within a single open reading frame, the 
expression of Ebolavirus envelope GP is mediated via an RNA-editing mechanism with the GP 
gene encoded in two overlapping reading frames (Sanchez et al., 1996; Volchkov et al., 1995). 
Unedited mRNA is translated to secreted GP (sGP) which accounts for around 80% of transcripts, 
while the introduction of an extra adenosine within the editing site via slippage of the viral 
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polymerase leads to the transcription of structural envelope GP. Additionally, transcriptional 
editing to insert two extra adenosines in the editing site produces a low level of small, truncated, 
sGP (ssGP). The more recently described Cuevavirus species also express GP in two open reading 
frames (Negredo et al., 2011). While sGP has been implicated in curtailing the immune response 
(Ito et al., 2001; Mohan et al., 2012), it has also been proposed that the production of sGP acts to 
control expression of structural GP, which can be cytotoxic, to optimize production and infectivity 
of virus (Mohan et al., 2015; Volchkov, 2001). Given the use of an edited mRNA transcript in this 
study meant that sGP was not produced, and the implication of higher expression levels of 
structural GP causing cytotoxicity as well as limiting infection, the infective titre of PV produce via 
transfection with various quantities of envelope GP DNA was investigated. Interestingly, using 
four times the standard quantity of envelope GP DNA gave the highest infective PV titre. This did 
not correlate with the results of a study by Mohan et al. (2015), which reported that infectivity of 
ebolavirus PV was maximized with a reduced input of envelope GP DNA. The same study reports 
that for the production of ebolavirus-like particles expression of the matrix protein VP40 is reduced 
when high levels of envelope GP are expressed, impairing production. Consequently, the higher 
quantity of envelope GP DNA was not used for transfections due to remaining concerns over 
production and increased cytotoxicity, as well as an increased surface density of envelope GP 
having the potential to impair infectivity or neutralisation. As the role of sGP is not fully 
understood, it could be a factor in the higher infective titres achieved for PV with envelope GP 
from the Marburgvirus species, in comparison to those using Ebolavirus and Cuevavirus envelope 
GP. This could otherwise be related to slight structural differences reported between the envelope 
GP (Feldmann et al., 2001), such as the position of the cleavage site and cysteine residues.  
 
In the previous study (Chapter 3) it was found that the use of a chimeric, VSV cytoplasmic domain, 
envelope G successfully increased the infectious titre of RABV PV, without altering the 
neutralisation profile. However, the mechanism responsible for this increase in titre has not been 
fully elucidated. Applying this approach to the Ebolavirus GP used within this study, while also 
creating chimeric GP with a Marburgvirus cytoplasmic domain or removing it entirely, proved 
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unsuccessful. Marburgvirus PV has a higher titre than Ebolavirus PV and a GP cytoplasmic 
domain three amino acids longer than the five amino acids of Ebolavirus GP. A direct or indirect 
interaction between the envelope GP cytoplasmic domain and the lentiviral matrix protein is known 
to be important for viral assembly (Cosson, 1996; Freed, 1998; Sandrin et al., 2004; Yu et al., 
1992). Additionally, short or truncated cytoplasmic domains have been suggested to reduce steric 
hindrance or allow incorporation into lentiviral particles independent of matrix protein interaction 
for MeV (Frecha et al., 2008; Freed & Martin, 1995). However, following this approach by 
truncating the Ebolavirus GP cytoplasmic domain within this study resulted in a failure to produce 
infectious PV. This can be explained by a study looking at the assembly of the Marburgvirus 
envelope GP using a recombinant virus system. It found that while truncation of the GP 
cytoplasmic domain did not alter incorporation into progeny virions, they were less infectious and 
it was demonstrated that removal of the cytoplasmic domain had caused conformational changes to 
the GP ectodomain (Mittler et al., 2011, 2013). It was also reported that the GP transmembrane 
domain, rather than the cytoplasmic domain, interacted with the matrix protein VP40. Attempts to 
follow the previously successful method of using a chimeric VSV cytoplasmic domain, which 
indicated a favourable interaction with the lentiviral core (Chapter 3), also failed to increase the 
titre of Ebolavirus PV.  
 
As filoviruses and rhabdoviruses have a different class of fusion protein, I and III respectively, and 
trafficking motifs are located within the cytoplasmic domain (Cosset & Lavillette, 2011), it was 
thought likely that correct GP folding and trafficking was abolished by switching the cytoplasmic 
domain between different classes of fusion protein. However, chimeric Ebolavirus GP PV 
produced with the cytoplasmic domain of the influenza HA and HIV Env (gp160) envelope 
proteins, which are both class I fusion proteins, caused a reduction in PV titres. High titre lentivirus 
PV had previously been produced using the HA envelope protein (Molesti et al., 2014a) and the 
HIV gp160 envelope protein has a very long cytoplasmic domain which has been shown to interact 
with its matrix protein MA (Freed & Martin, 1995). Yet it is thought likely that each of these 
alternate cytoplasmic domains prevented correct folding of the ecto- and transmembrane domains 
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of the Ebolavirus GP, similar to that previously reported for the Marburgvirus GP (Mittler et al., 
2013). While structurally similar, there is still a high degree of variability between the mode of 
fusion within the class I proteins. Uniquely, the filovirus GP does not require proteolytic cleavage 
during maturation to become infectious (Ito et al., 2001; Neumann et al., 2002). The complex 
series of conformation rearrangements in the late endosome, leading to fusion and entry, involves 
triggering by low pH dependent cathepsin proteolysis to expose the GP receptor binding domain 
which interacts with NPC1 (Moller-Tank & Maury, 2015; Pöhlmann, 2013). These priming events 
can differ between the class I fusion proteins, indeed fusion by the HA and HIV gp160 envelope 
proteins is triggered solely by a low pH and receptor binding respectively (Cosset & Lavillette, 
2011; White et al., 2008). Additionally, the GP has a heavily glycosylated mucin like domain 
which plays a role in cell entry and an acylation site at the boundary between the transmembrane 
and cytoplasmic domain, which is thought to help anchor GP within the envelope (Mittler et al., 
2013; Takada, 2012). Each of these factors highlights the complexity of altering envelope protein 
domains and the potential to negatively impact both structure and function. 
 
Assessment of the neutralization pattern of EBOV/Mak GP PV on the three cell lines most 
permissive to infection via a PVNA, revealed the CHO-K1 cell line, although less permissive to 
infection than HEK 293T/17 and CRFK cells, provides clearer neutralisation data and therefore 
may be more appropriate for use in serology studies. As mentioned above, this is further favourable 
as it prevents using the same cell line for PV production and infection. The limited and valuable 
supply of prophylactic samples at the time of this study restricted the assessment of the 
neutralisation pattern of PV for each filovirus species, yet the data collected on the CHO-K1 cell 
line is most likely attributable to the cell line rather than GP specific. The variability in 
neutralisation observed between the cell lines highlights the importance of including standards or 
reference material with a known activity or potency when assessing prophylaxis undergoing 
development, allowing calibration of results (Temperton & Page, 2015). Of particular importance, 
this will allow comparisons on the immunogenicity of vaccines undergoing development and the 
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correlation of protective titres (Gilbert, 2015). The correlates of protection for the Filoviridae are 
currently unknown.  
 
Generating a library of PVs for filoviruses, and other emerging viruses, is highly effective for prior 
outbreak preparedness and should be prioritised in response to an emerging virus outbreak 
(Temperton & Page, 2015). PV can be utilized to undertake serosurveillance, antiviral screening, 
assess vaccine efficacy and investigate viral tropism or aspects of cell biology. More recently, they 
were used as a standard themselves for Ebola virus diagnostic nucleic acid tests, circumventing the 
need for inactivated virus, which is typically used for standardisation (Mattiuzzo et al., 2015). The 
filovirus PVNA developed within this study was rapidly applied to a range of projects, including a 
phase one clinical trial testing the immunogenicity of an adenovirus vaccine encoding the Zaire 
ebolavirus GP (ChAd3 EBOZ) in a prime-boost vaccination regime, by detecting vaccine induced 
antibody in volunteer’s sera (Ewer et al., 2016). The study also correlated data collected via the 
PVNA with that of a live Ebolavirus neutralisation assay, showing a promising level of 
concordance between the two assays. In further studies, the PVNA was applied as part of a 
collaborative study coordinated by NIBSC to rapidly evaluate and develop the first anti-EBOV 
antibody WHO International Reference Reagent (Wilkinson et al., 2017), as well as to screen 
repurposed drugs for their ability to block filovirus entry (Long et al., 2015) and in the 
development of novel antibody therapeutics (Corti et al., 2016). This acts to highlight the 
applicability of the PV platform and its value in responding to future emerging virus outbreaks. 
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Chapter 6. Pseudotyped Virus Quantification and 
Reporter Gene Characterisation 
 
6.1. Introduction 
When generating lentiviral PV to study properties related to viral entry, a reporter gene is packaged 
as an RNA dimer by retroviral core proteins that is encapsulated by a lipid membrane bearing 
envelope proteins from the virus of interest (Section 1.4.3). Upon transduction of a susceptible cell 
line, the reporter gene is reverse transcribed and integrated into the cell genome, leading to its 
expression. Thus, reporter gene expression correlates with transduced cells and can be used to infer 
interactions between the viral envelope protein and cellular receptor or neutralising antibody 
function. The incorporation of multiple reporter genes within the pseudotype platform, which have 
a range of methods to measure gene expression, with various cost and time requirements, is 
fundamental to expanding the flexibility and applicability of PV assays to meet various resource 
requirements within different laboratory settings. Given PV technology is primarily used to 
circumvent the need for high containment facilities, thereby reducing risk and costs, reporters with 
economical readout assays which retain the sensitivity and specificity of the current repertoire are 
highly attractive targets. 
 
Bioluminescent, luciferase, reporters which act to catalyse the oxidation of a light emitting luciferin 
substrate, have proven popular for use in the study of a wide variety of biological processes due to 
their good sensitivity and high-throughput capabilities (Ghim et al., 2010; Kaskova et al., 2016). 
The firefly luciferase gene, of beetle (Photinus pyralis) origin was first expressed in mammalian 
cells in 1987 (De Wet et al., 1987) and is now one of the most commonly used along with renilla 
luciferase of sea pansy (Renilla reniformis) origin (Alam & Cook, 2003; Lorenz et al., 1996). In 
keeping with this, the firefly luciferase reporter is the most popular of the current portfolio of 
reporter genes which have been incorporated within the pseudotype platform, with renilla 
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luciferase being another that has been incorporated (Temperton et al., 2015a; Wright et al., 2010). 
Output is quantified as relative light units (RLU) following the lysis of transduced cells, to release 
firefly or renilla luciferase, in the presence of beetle luciferin or coelenterazine substrate 
respectively and emission of luminescence detected using a luminometer. While the requirement 
for specialised equipment and high cost of the substrate limits use of luciferase reporter PV to well-
resourced laboratories, its high-throughput and sensitivity coupled with the relative ease of data 
analysis is attractive in a research setting. Many alternative luciferases have been discovered or 
engineered, such as isolation of the secreted cypridina luciferase from the ostracod (Cypridina 
noctiluca) (Nakajima et al., 2004). As well as the ability to measure activity without disrupting 
cells, it is one of the most stable luciferases and emits a high level of luminescence (Kaskova et al., 
2016). Alternatively, NanoLuc luciferase (Hall et al., 2012) is engineered from the deep sea shrimp 
(Oplophorus gracilirostris) to offer a 150-fold increase in luminescence intensity compared to the 
firefly and renilla luciferases and improved stability, while being a fraction of the size. The 
properties of each of these luminescent reporters are attractive towards expansion of the 
pseudotype system and their suitability for inclusion requires investigation. 
 
Fluorescent proteins are an equally popular choice of reporter in the study of biological processes, 
and like luciferases, occur naturally. They are excited by light of an appropriate wavelength, 
emitting a longer wavelength in response, with emission profiles of current fluorescent protein 
variants covering almost the entire visible light spectrum (Shaner et al., 2005). The most well-
known is green fluorescent protein (GFP), which was first isolated from the Aequoria victoria 
jellyfish in the 1960’s but not cloned and expressed until three decades later (Chalfie et al., 1994). 
It has undergone several modifications to improve fluorescent intensity, folding and expression 
within mammalian cells (Alam & Cook, 2003; Shaner et al., 2005) and one such variant with 
improved sensitivity, enhanced GFP (referred to herein as GFP) (Zhang et al., 1996), is 
incorporated within the pseudotype platform (Temperton et al., 2015a). Further, the brighter 
emerald GFP (emGFP) (Cubitt et al., 1998) variant was used in Chapter 3. Output is quantified as 
infectious units (IFU) by counting transduced cells via either fluorescent microscopy or flow 
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cytometry. As quantification of a fluorescent protein reporter does not require lysis of transduced 
cells, qualitative data can simultaneously be collected via fluorescent microscopy. As fluorescence 
occurs throughout the nucleus and cytoplasm of transduced cells, differentiating adjacent cells by 
fluorescent microscopy can be challenging. However, this could be improved through the use of 
localisation signals which target fluorescent proteins to cellular compartments, such as the nucleus, 
and are widely used for cellular trafficking and gene expression imaging studies (Alam & Cook, 
2003; Wu et al., 2011). Further, the incorporation of a fluorescent protein from a different spectral 
class, such as the red fluorescent proteins derived from Discosoma species which have undergone 
extensive optimisation to have functional utility comparable to those within the green spectrum 
(Shaner et al., 2004), would be beneficial in expanding the utility of the current reporter gene 
repertoire. 
 
Finally, colourimetric reporter readouts can make use of low cost reagents and do not require 
specialised equipment, thus they are favourable to resource-limited laboratory environments. This 
covers the final reporter incorporated within the pseudotype platform; the lacZ reporter gene which 
encodes β-galactosidase. This bacterial enzyme, first expressed in mammalian cells in the early 
1980’s (An et al., 1982), acts to hydrolyse various synthetic substrates containing galactose  which 
includes the chromogens X-gal (5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside), ONPG (o-
nitrophenyl-β-D-ga-lactopyranoside) and CPRG (chlorophenol red-β-D-galac-topyranoside) that 
have previously been used to quantify transduction of cells by PV with a lacZ reporter (Wright et 
al., 2009). X-gal is most commonly used, producing a blue precipitate at the nuclei of transduced 
cells, which is quantified as IFU by light microscopy. Alternatively, using the ONPG or CPRG 
substrates causes a colour change which can be assessed on a microplate reader at 405nm and 
550nm respectively, or by eye (Wright et al., 2009). An alternative colourimetric reporter which 
should be assessed for incorporation into the pseudotype platform is secreted alkaline phosphatase 
(SEAP) (Berger et al., 1988; Yang et al., 1997). The quantification of SEAP expression in the 
media of transfected cells can be performed via a high-throughput colourimetirc assay and would 
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offer a low cost and accessible alternative to the secreted cypridina luciferase simultaneously being 
investigated for inclusion.  
 
While it is possible to compare data collected when using PV with a fluorescent and some 
colourimetric reporters, due to both using IFU as a measure of transduction, the data cannot easily 
be compared to that measured as RLU for PV with a luminescent reporter gene. To be able to 
correlate the disparate readout units of IFU and RLU, a luminescent reporter requires packaging 
within the genome of PV in combination with either a fluorescent or colourimetric reporter. An 
adaption to the currently used (pCS[reporter]W) reporter gene expression plasmid to generate 
pDUAL has been described by Escors, et al., (2008). This introduced an additional promoter, 
ubiquitin (UBIQ), and cloning site (Site II) to allow incorporation and expression of a second gene 
downstream of the spleen focus forming virus (SFFV) promoter and cloning site (Site I) in the 
original reporter plasmid (Figure 6.1). This alternative reporter expression plasmid may be used for 
the packaging of two reporters within PV and thus correlation of readouts by their sequential 
quantification from transduced cells. 
 
  
 
1
4
5
 
 
Figure 6.1 Schematic Representation of the pCS[reporter]W and pDUAL Reporter Gene Expression Plasmids 
(A) The pCS[reporter]W expression plasmid includes a cloning site (Site I) flanked by BamHI/NotI restriction enzyme sites with expression driven by a spleen focus forming 
virus (SFFV) promoter and enhanced by the woodchuck hepatitis virus posttranscriptional regulatory element (WPRE) (B) The pDUAL is adapted to include a ubiquitin 
(UBIQ) promoter which confers expression of genes within a second cloning site (Site II) flanked by KpnI/XhoI restriction sites. Other structural elements include: LTR, long 
terminal repeat; , packaging signal; gag, structural proteins; RRE, Rev response element; cPPT, central polypurine tract. A deletion in the downstream LTR U3 promoter 
region (∆U3) creates a self-inactivating vector. 
 
A 
B 
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The quantification of PV preparations via the measurement of reporter gene expression levels in 
transduced target cells is used to assign a biological titre, inferring the number of functional PV 
particles in the preparation. Yet in addition to the relatively new technology of nanoparticle 
tracking analysis, which enables quantification of the total number of particles within PV 
preparations (Filipe et al., 2010; Heider & Metzner, 2014), other methods have been described to 
quantify different PV components in a non-functional manner. The RNA genome of PV can be 
quantified via an RT-qPCR reaction using primers targeting the HIV-1 long terminal repeats (LTR; 
Figure 6.1) (Lizée et al., 2003; Mattiuzzo et al., 2015) Further, the core component can separately 
be quantified via an RT-qPCR assay which has been adapted to measure the reverse transcriptase 
(RT) activity associated with the core component (Pizzato et al., 2009; Vermeire et al., 2012). This 
SYBR Green product-enhanced RT (SG-PERT) assay has been developed as a sensitive, cost 
effective, alternative to the use of an enzyme-linked immunosorbent assay (ELISA), which detects 
the HIV-1 p24 core protein and has historically been used to quantify HIV-1 virions. While it is 
widely reported that use of these non-functional quantification methods over-estimate, and thus 
cannot predict, biological titres (Geraerts et al., 2006; Heider & Metzner, 2014; Lizée et al., 2003; 
Sastry et al., 2002; Scherr et al., 2001), it is thought they can help evaluate the quality and 
composition of PV preparations and be utilised in their standardisation.  
 
This study aimed to investigate the suitability of new reporters for incorporation into the 
pseudotype platform, expanding the current repertoire to improve the range of outputs available 
and increase its applicability to meet various laboratory resource requirements. It further aimed to 
determine the ratio between the disparate readout units of IFU and RLU and review alternative 
methods of quantifying PV, in addition to biological titre which is currently used, that could be 
used for standardisation and quality control. 
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6.2. Results 
6.2.1. Incorporating New Reporters into the Pseudotyped Virus Platform 
A set of six new reporter protein genes, covering the luminescent, colourimetric and fluorescent 
readout methods (Table 6.1) were cloned within the pCS[reporter]W expression plasmid (Section 
2.1.3). Each of the reporter gene sequences were amplified via standard cDNA PCR (Section 
2.2.3), introducing restriction enzyme sites for sub-cloning into pCS[reporter]W (Section 2.2.5), 
and all newly cloned reporter gene constructs were sequencing verified (Section 2.2.8). To assess 
the suitability of each of the new reporter genes, evaluating output and functionality in comparison 
to the existing repertoire, lentiviral PV comprising a CVS-11 G was produced incorporating each 
of the new reporters by transfecting HEK 293T/17 cells (Section 2.2.10). 
 
Table 6.1 Primers for Cloning New Reporter Genes 
Index of primers and source of reporter genes cloned into the pCS[reporter]W expression plasmid. 
Readout Reporter Gene Construct 
Primers
1
 
Source Plasmid/Accession 
Number
2
 
Luminescent Cypridina Luciferase C3.1 pCMV-CLuc 2  
(NEB) 
 NanoLuc Luciferase C3.2 pNL1.1[Nluc] 
JQ437370 (Promega) 
Colourimetric Secreted Alkaline Phosphatase 
(SEAP) 
C3.3 pSEAP-Basic 
U09660 (Clonetech) 
 Secreted Alkaline Phosphatase 
(version 2) (SEAP2) 
C3.4 pSEAP2-Basic 
U89937 (Clonetech) 
Fluorescent Dual-Nuclear Localised GFP 
(dNG) 
C3.5 pCMS28-NLS-GFP-
SAMHD1-CtD  
(Schwefel et al., 2014) 
 Dual-Nuclear Localised 
tdTomato (dNT) 
C3.6 ptdTomato-Nuc  
(Kind gift from Colin Crump, 
University of Cambridge) 
1Refers to Chapter 2, Table 2.5 
2Further details and sequence in Appendix I 
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To assess the suitability of each of the new luminescent readout reporter genes, cypridina and 
NanoLuc luciferase, they were compared to PV comprising either the currently used firefly 
luciferase or renilla luciferase reporter genes. An infection assay was set up, titrating each PV in 
parallel across a 2-fold serial dilution from a starting dilution of 1:2 onto the BHK-21 target cell 
line, in duplicate (Section 2.2.11.1). The level of infection at each PV dilution was recorded in 
RLU via the appropriate assay system (Section 2.2.12.1). Titration of PV comprising a firefly or 
renilla luciferase reporter positively correlated with RLU values and the level of infection was 
above background levels recorded for the PV supernatant and uninfected cells (Figure 6.2A & B). 
Results of titrating PV comprising the newly incorporated cypridina luciferase reporter, which 
unlike the currently used luciferase reporters is secreted from infected cells, showed this did not 
positively correlate with RLU values, instead increasing up to a PV dilution of 1:128 before 
decreasing beyond this point (Figure 6.2C). Background RLU values were high for both the PV 
supernatant, which recorded an RLU (7.6 x 10
4
) higher than that for infection with 1:2 diluted PV, 
and the uninfected cells (9.7 x 10
3
 RLU; Figure 6.2C). This corroborated with the level of 
background between 10
2
 – 104 RLU reported by the BioLux® cypridina luciferase assay (NEB) 
manufacturer for assays performed with media supplemented with 10% FBS. The titration of PV 
with the NanoLuc luciferase reporter similarly gave a negative correlation with RLU values at low 
dilutions of PV, before positively correlating at PV dilutions greater than 1:16 (Figure 6.2D). While 
the background RLU value for the uninfected cells read via the NanoLuc luciferase assay was in 
line with that for the firefly and renilla luciferase reporters, the RLU recorded for the PV 
supernatant was high (6.5 x 10
7
 RLU; Figure 6.2D). This indicated a high level of passive transfer 
of the protein in the transfection supernatant. Consequently, neither the cypridina nor NanoLuc 
luciferase reporters were appropriate for incorporation into the PV platform. 
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Figure 6.2 Comparative Titration of Pseudotyped Virus Incorporating Existing and New 
Luciferase Reporter Genes 
Lentiviral PV produced with a CVS-11 G and incorporating either the existing firefly luciferase (A) and 
renilla luciferase (B) reporter genes or the newly incorporated cypridina luciferase (C) and NanoLuc 
luciferase (D) reporter genes were titrated onto the BHK-21 cell line, along with controls of PV supernatant 
alone and uninfected cells. Titres were measured as relative light units (RLU) and mean values are plotted for 
each dilution of PV. Error bars show SD (n = 2). 
A B 
C D 
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Two versions of the colourimetric secreted alkaline phosphatase reporter gene, SEAP and an 
updated version SEAP2, which had been modified to include a 39 nucleotide C-terminal extension 
(Appendix I), were compared. Initially, an infection assay was set up titrating PV with each of the 
reporter genes across a 2-fold serial dilution onto the BHK-21 target cell line, in duplicate (Section 
2.2.11.1). The level of infection was recorded via measuring absorbance at 405 nm (A405) following 
an alkaline phosphatase enzymatic assay (Section 2.2.12.2). It was found that each version of the 
reporter gene offered approximately the same level of absorbance, which positively correlated with 
PV dilution (Figure 6.3A). However, undiluted PV supernatant controls gave high absorbance 
readings which matched the level obtained for infection with 1:2 diluted PV (Figure 6.3A). To 
further investigate the absorbance signal from the PV supernatant control, a repeat assay was 
performed titrating the PV supernatant in parallel to the infection with PV incorporating the SEAP2 
reporter gene. Results of the titration showed that the absorbance signal from the PV supernatant 
was greater than that from the infection, measuring 3.9 and 2.4 respectively at a PV dilution of 1:4, 
and decreased at a similar rate (Figure 6.3B). This indicated the absorbance signal read from the 
infection could be a result of the passive transfer of alkaline phosphatase produced during 
transfection.  
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Figure 6.3 Titration of Pseudotyped Virus Incorporating a Secreted Alkaline 
Phosphatase Reporter Gene 
(A) Lentiviral PV produced with a CVS-11 envelope G and incorporating either the SEAP or SEAP2 version 
of the alkaline phosphatase reporter gene titrated onto the BHK-21 target cell line with controls of PV 
supernatant alone, uninfected cells and media alone included to measure background absorbance levels. (B) 
CVS-11 envelope G PV incorporating an SEAP2 reporter gene titrated onto the BHK-21 target cell line along 
with a parallel titration of the PV supernatant and controls of uninfected cells and media alone. All titres were 
measured after 48 hours incubation at an absorbance of 405 nm and average values plotted for each dilution 
of PV. Error bars show SD (n = 2). 
B 
A 
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To further evaluate whether the signal was solely from the passively transferred alkaline 
phosphatase, an infection assay was performed as before, titrating PV with each SEAP reporter 
onto target cells in parallel to the PV supernatant as a control, however following 3 hours 
incubation the media was removed for incubation in a separate culture plate and replaced with fresh 
media. Results showed that changing the media on the transduced cells resulted in A405 readings in 
the range of 0.085 – 0.104 which were in line with those of the background measured from cell and 
media controls of 0.086 and 0.085 respectively (Figure 6.4A). Absorbance readings taken from the 
media incubated following removal after 3 hours remained above background, decreasing from 3.5 
and 2.8 for 1:4 diluted PV comprising the SEAP and SEAP2 reporter gene respectively (Figure 
6.4B). To ensure 3 hours incubation was long enough for PV entry to occur, an infection assay was 
set up, titrating CVS-11 envelope G PV incorporating a firefly luciferase reporter gene onto the 
BHK-21 target cell line and changing the media after 3 hours, alongside a control infection where 
the media was not changed. Results recorded as RLU showed that while the control infection had 
RLU readings on average 5-fold higher than those recorded for infection with PV where the media 
had been changed, 3 hours was sufficient for a significant level of infection to occur and the RLU 
readings from the media removed were low or level with the background recorded on the cell and 
media controls (Figure 6.4C). Thus, secreted alkaline phosphatase is not produced by infection of 
target cells with PV comprising the SEAP or SEAP2 reporter genes, but passively transferred after 
being produced during transfection and as a result not suitable for use as a reporter gene in the PV 
platform.  
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Figure 6.4 Titres of Pseudotyped Virus Incorporating a Secreted Alkaline Phosphatase 
or Firefly Luciferase Reporter Gene after Changing the Media during Incubation 
Lentiviral CVS-11 G PV incorporating an SEAP or SEAP2 reporter gene was titrated onto the BHK-21 cell 
line alongside a PV supernatant control. (A) After 3-hours incubation media was changed and 45-hours later 
titres were read via the absorbance at 405 nm. (B) The media removed was incubated separately and the 
absorbance read. (C) Lentiviral CVS-11 G PV incorporating a firefly luciferase (FLuc) reporter gene was 
titrated onto the BHK-21 cell line and the media changed after 3-hours, alongside an infection control where 
the media was not changed, measuring titres as relative light units (RLU) after a total of 48-hours incubation. 
In each case controls of uninfected cells and media alone were included. Error bars show SD (n = 2). 
A 
B 
C 
 154 
 
 
An improvement to the currently used enhanced GFP reporter gene was investigated by 
comparison with dual-nuclear localised versions of GFP (dNG) and tdtomato fluorescent protein 
(dNT). To assess each reporter gene visually, an infection assay was set up titrating PV with each 
of the fluorescent reporter genes over a 2-fold dilution series onto the BHK-21 target cell line and, 
following incubation, infected cells were fixed and visualised using the appropriate fluorescent 
microscope filter (Section 2.2.12.3). Visualisation of cells infected with PV incorporating a GFP 
reporter gene showed much of the cell monolayer emitting bright fluorescence, with a low level of 
definition between individually infected cells and a high level of background auto-fluorescence 
(Figure 6.5A). The level of definition between adjacently infected cells was greatly improved when 
infected with PV incorporating a dNG reporter gene, owing to the nuclear localisation signal, 
however fluorescence intensity was reduced and background auto-fluorescence remained high 
(Figure 6.5B). Infecting cells with PV incorporating the dNT reporter gene reduced background 
auto-fluorescence and produced an intense fluorescence signal from the nucleus of infected cells, 
yet a reduced number of cells appeared to be infected (Figure 6.5C).  
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Figure 6.5 Cell Infection by Pseudotyped Virus Incorporating New Fluorescent Reporter Protein Genes in Comparison to Standard GFP 
Fluorescent microscopy images showing BHK-21 cells infected by 1:4 diluted CVS-11 G PV incorporating (A) a standard GFP reporter gene, in comparison to (B) a dual-
NLS GFP (dNG) reporter gene and (C) dual-NLS TFP (dNT) reporter gene. Images were captured using the x10 objective. Cells were at 100% confluence. 
 
A B C 
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To quantify the level of infection for PV incorporating each of the fluorescent reporter genes, GFP, 
dNG and dNT, infection assays were set up to measure titres via flow cytometry and fluorescent 
microscopy (Section 2.2.12.3). Flow cytometry data was collected using the FITC protocol for a 
GFP or dNG reporter gene and the PE-Texas Red protocol for the dNT reporter gene (Section 
2.2.12.3). Analysis of the data was undertaken by applying gates to the cell population, to remove 
cell debris, along with gates applied to count cells emitting a fluorescence signal above the 
background level, where the background was set to the end of the first log-decade (Figure 6.6A-D). 
Data was collected via fluorescent microscopy by counting cells emitting fluorescence as positive 
for infection. The level of infection quantified by each method was reported as infectious units per 
ml (IFU/ml). Comparison of the infective titres measured via flow cytometry showed that for PV 
incorporating a GFP or dNG reporter, the titre was significantly higher than PV with a dNT 
reporter by 25.5 and 29.7 fold respectively (p < 0.0001; Figure 6.7). However, infective titres for 
each of the reporters measured via fluorescent microscopy were not significantly different (Figure 
6.7). When comparing the two methods of quantification, titres recorded via flow cytometry were 
4.5 fold higher than via fluorescent microscopy when quantifying the dNG reporter (p = 0.001), yet 
conversely the dNT reporter titres were 4.5 fold higher when quantified via fluorescent microscopy 
(p < 0.0001; Figure 6.7). Overall, the infective titre of PV incorporating a dNT reporter was lower 
than with a GFP or dNG reporter.  
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Figure 6.6 Gating of Cells for Flow Cytometry Analysis via the FITC or PE-Texas Red 
Channel 
Example of gates set for analysis of BHK-21 cells infected with GFP or dNG reporter gene PV via the FITC 
channel, with (A) the gate R1 placed over the main cell population and (B) a second gate, R2, applied to 
count cells emitting fluorescence above background, from the end of the first log-decade. To analyse BHK-
21 cells infected with dNT reporter gene PV via the PE-Texas red channel, (C) the gate R1 was placed over 
the main cell population and (D) a second gate, R2, applied as per the FITC channel, to count cells emitting 
fluorescence above background.   
A B 
C D 
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Figure 6.7 Comparison of Infective Titres Measured for Pseudotyped Virus 
Incorporating New and Existing Fluorescent Reporter Genes 
Infective titres of CVS-11 G PV incorporating a GFP, dNG or dNT reporter gene and titrated onto BHK-21 
target cells were measured via flow cytometry analysis or counted via fluorescent microscopy and reported as 
infectious units per ml (IFU/ml). (**p = 0.001 and ***p < 0.0001; two-tailed t-test) Error bars show SD (via 
flow cytometry n = 4 and via fluorescent microscopy n = 2).  
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6.2.2. Comparison and Correlation of the Disparate Readout Units of 
Pseudotyped Virus Reporters 
To compare the disparate readout units of luminescent reporters, measured as RLU, with those of 
fluorescent or colourimetric reporters, measured as IFU, the ability to incorporate two reporter 
genes within the PV core and their equal expression from transduced cells was investigated. Using 
the pDUAL expression plasmid (Figure 6.1B) the reporter genes firefly luciferase (FLuc), GFP and 
LacZ which cover the luminescent, fluorescent and colourimetric readout methods respectively, 
were paired and incorporated within the pDUAL cloning sites (Site I & II) in each orientation, 
producing six constructs (Figure 6.8). For cloning into Site I the reporter genes were digested and 
subsequently ligated (Section 2.2.5) using BamHI/NotI restriction enzyme sites previously 
introduced for cloning into pCS[reporter]W. To insert each reporter gene into Site II, the sequences 
were amplified via standard cDNA PCR (Section 2.2.3) using primers for constructs C4.1 – 4.3 
(Table 2.6, Section 2.1.3) to introduce KpnI/XhoI restriction enzyme sites for sub-cloning. All 
pDUAL reporter constructs were verified by sequencing (Section 2.2.8).  
 
Figure 6.8 Schematic Representation of the Orientation of Reporter Genes Incorporated 
within the pDUAL Expression Plasmid 
Reporter constructs produced by pairing the reporter genes, firefly luciferase (FLuc), green fluorescent 
protein (GFP) and LacZ and inserting them into cloning site I and site II of the pDUAL expression plasmid in 
each orientation. Expression of genes in site I is driven by the spleen focus forming virus (SFFV) and 
enhanced by the woodchuck hepatitis virus posttranscriptional regulatory element (WPRE), while a ubiquitin 
(UBIQ) promoter confers expression of genes within site II.   
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To evaluate the functionality of each of the pDUAL reporter constructs (Figure 6.8B), they were 
incorporated within CVS-11 G PV produced via the transfection of HEK 293T/17 cells (Section 
2.2.10). As a control, CVS-11 G PV was also produced incorporating an FLuc, GFP or LacZ 
reporter gene separately by transfection within the pCS[reporter]W expression plasmid. Infection 
assays were performed, titrating each PV over a 2-fold dilution series, in duplicate, onto the BHK-
21 target cell line (Section 2.2.11.1), to allow evaluation of each reporter gene incorporated within 
the PV core via the pDUAL expression plasmid. The infective titres were quantified as RLU/ml 
when detecting the FLuc reporter via luminescence (Section 2.2.12.1) and as IFU/ml when 
detecting the GFP or LacZ reporters via fluorescent microscopy (Section 2.2.12.3) or the β-
galactosidase assay (Section 2.2.12.2) respectively. Results showed that for each of the paired 
reporters, the infective titre measured for the reporter when it was in Site I of the pDUAL 
expression plasmid was higher than when it was in Site II (Figure 6.9A-C). An exception was 
observed for the detection of fluorescence from GFP when paired with LacZ, which gave a higher 
infective titre when in Site II (Figure 6.9C); however this was not the case when GFP was paired 
with FLuc (Figure 6.9A). Interestingly, no signal was detected via the colourimetric assay for LacZ 
when it was in Site II when paired with both FLuc and GFP (Figure 6.9B&C). Together, this data 
showed that there were not equal levels of expression of reporter genes in Site I and II of the 
pDUAL expression plasmid and as a result infective titres from the two reporter genes incorporated 
could not be correlated.  
 
 161 
 
 
Figure 6.9 Infective Titres to Evaluate Incorporating Two Reporter Genes within the 
Pseudotyped Virus Core via a pDUAL Expression Plasmid 
Titres from BHK-21 cells infected with CVS-11 G PV incorporating two reporter genes (A) FLuc and GFP, 
(B) FLuc and LacZ and (C) LacZ and GFP which had been paired and cloned into the pDUAL expression 
plasmid Site I and Site II and were tested in both orientations (Site I – Site II). Titres were measured 
individually via luminescence for FLuc, fluorescence for GFP and a colorimetric assay for LacZ, which were 
within Site I of the control (C) pCS[reporter]W expression plasmid. Luminescence results are reported as 
relative light units per ml (RLU/ml) while fluorescence and colourimetric assay results are in infectious units 
per ml (IFU/ml). Controls represent titres from BHK-21 cells infected with CVS-11 G PV incorporating a 
single reporter FLuc, GFP or LacZ corresponding to the readout assay. Error bars show SD (n = 2). 
A 
B 
C 
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Therefore, to explore an alternative system of incorporating and expressing two reporter genes 
from a single PV, the use of a 2A peptide which mediates protein cleavage from a single open 
reading frame via a ribosomal skip mechanism was investigated. The mechanism works by 
preventing a normal peptide bond forming between a 2A glycine and 2B proline residue without 
affecting the downstream translation of the 2B peptide and thus allows concordant expression of 
genes placed either side (Donnelly et al., 2001; Szymczak et al., 2004). Of several 2A peptide 
sequences identified, the well-studied and comparatively short T2A sequence 
(EGRGSLLTCGDVEENPG*P) from the insect Thosea asigna virus (TaV) was selected and used 
to generate an adapted pCS[reporter]W expression plasmid which incorporated cloning sites for 
two genes separated by the T2A peptide with expression driven by the SFFV promoter (pCS-T2A-
W, Figure 6.10A). The construct was designed to include a flexible Gly-Ser-Gly (GSG) linker 
upstream of the T2A peptide sequence due to a reported enhancement of cleavage efficiency to 
near 100% (Szymczak-Workman et al., 2012) and for this reason a shorter Ser-Gly (SG) linker was 
also included downstream of the T2A peptide (Figure 6.10A). Restriction enzyme sites were 
incorporated either side for simplicity of cloning of future genes into Site I and II by BamHI/PacI 
and SmiI/NotI digestion respectively. Importantly, all sequences were kept in frame with the T2A 
peptide sequence, with stop codons omitted from the 3’ end of genes in Site I and start codons not 
included at the 5’ end of genes in Site II. The pCS-T2A-W expression plasmid was produced to 
include the FLuc and GFP reporter genes in each orientation (Figure 6.10B) by the use of SOE 
PCR amplification (Figure 2.1B, Section 2.2.4) and primers for the constructs C3.7 and C3.8 
(Table 2.5, Section 2.1.3) to produce FLuc-T2A-GFP and GFP-T2A-FLuc respectively, which 
were then cloned into the pCS[reporter]W vector using the flanking BamHI/NotI restriction sites. 
Each construct was sequencing verified (Section 2.2.8) using pCS[reporter]W primers and the 
appropriate pCSFLuc-T2A-W or pCS-T2A-FLucW primer dependant on the position of the FLuc 
gene (Table 2.7, Section 2.1.3).  
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Figure 6.10 Schematic Representation of the T2A Peptide Sequence and Orientation of Reporter Genes Incorporated within the pCS-T2A-W 
Expression Plasmid 
(A) The incorporated T2A peptide sequence is shown boxed with the point of cleavage (*) and flanking flexible linker sequences indicated. PacI and SmiI restriction enzyme 
sites were included to produce cloning sites (Site I and Site II) either side of the T2A peptide, with additional ‘C’ nucleotides to keep the sequence in-frame. The position of 
hypothetical genes is shown by ‘X’ which would omit a stop codon at the 3’ end of the gene within Site I and a start codon at the 5’ end of the gene within Site II. Expression 
of both genes is driven by the spleen focus forming virus (SFFV) promoter. Other structural elements include: LTR, long terminal repeat; , packaging signal; gag, structural 
proteins; RRE, Rev response element; cPPT, central polypurine tract; WPRE, woodchuck hepatitis virus posttranscriptional regulatory element. A deletion in the downstream 
LTR U3 promoter region (∆U3) creates a self-inactivating vector. (B) Position of the firefly luciferase (FLuc) and green fluorescent protein (GFP) reporter genes, 
incorporated in both orientations, in the pCS-T2A-W constructs produced. 
A 
B 
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Initially, CVS-11 envelope G PV incorporating each of the pCS-T2A-W constructs (Figure 6.10B) 
was produced and an infection assay undertaken to determine whether the reporter genes within 
each position were expressed. Following positive early results, in depth evaluation was undertaken 
through the production of a panel of PV comprising a VSV G, RABV (CVS-11) G and EBOV 
(Makona) GP envelope protein to cover high, medium and low titre PV respectively, incorporating 
each of the pCS-T2A-W constructs via transfection of HEK 293T/17 cells (Section 2.2.10). As 
before, controls were produced incorporating an FLuc or GFP reporter gene within the 
pCS[reporter]W expression plasmid. Infection assays were performed in triplicate on three 
occasions, titrating over a 2-fold dilution series onto either BHK-21 cells (VSV and RABV G PV) 
or HEK 293T/17 cells (EBOV GP PV) (Section 2.2.11.1). The assays were set up to first evaluate 
expression of the GFP reporter by fluorescent microscopy, cells were not fixed but washed and 
PBS added (Section 2.2.12.3), recording results as IFU/ml. Expression of the FLuc reporter was 
then evaluated by assaying for luminescence, transferring the supernatant to an opaque culture plate 
prior to reading (Section 2.2.12.1) and reporting results as RLU/ml. The results showed that there 
were near equal levels of expression of each of the reporters, GFP and FLuc, when cloned into Site 
I compared to Site II of the pCS-T2A-W expression plasmid (Figure 6.11A&B). Lower titres were 
consistently observed when using the adapted pCS-T2A-W expression plasmid in comparison to 
controls incorporating a single reporter gene into the PV core using the pCS[reporter]W expression 
plasmid, however this did not impact on the ability to correlate titres.  
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Figure 6.11 Infective Titres to Evaluate Incorporating Two Reporter Genes within the 
Core of Pseudotyped Virus with a VSV, RABV or EBOV Envelope Glycoprotein via the pCS-
T2A-W Expression Plasmid 
Titres from BHK-21 cells infected with VSV and RABV (CVS-11) G PV and HEK 293T/17 cells infected 
with EBOV (Makona) GP PV incorporating an FLuc and GFP reporter gene cloned in each orientation (Site I 
– Site II) within the pCS-T2A-W expression vector. PV controls were included for each comprising a single 
Fluc or GFP reporter. (A) First titres were measured as fluorescence to detect expression of the GFP reporter 
and recorded as infectious units per ml (IFU/ml). (B) Titres were then measured via luminescence to detect 
the FLuc reporter and results recorded at relative light units per ml (RLU/ml). Average titres are plotted and 
error bars show SD (n = 3). 
A 
B 
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To compare the disparate readout units of the two reporter genes the ratio between RLU and IFU 
titres (RLU:IFU) was determined by combining average values for the T2A peptide linked FLuc 
and GFP reporter genes in each orientation, after calculating ratios at single PV dilution points. For 
comparison, ratios were also calculated from matched dilutions of the separately titrated, single 
FLuc and GFP reporter, control PV. The average ratio of RLU to IFU for VSV G PV was 1417:1 
while for RABV G PV it was calculated to be 1101:1 and in each case this was significantly 
different to the ratio calculated using the control PV titration data (539:1, p = 0.0012 and 2016:1, p 
= 0.0355 respectively; Figure 6.12). Unexpectedly, the ratio for EBOV GP PV was significantly 
higher at 2601:1 (p < 0.0007) and not found to be significantly different to that calculated for the 
corresponding control PV (p = 0.3155; Figure 6.12). This result was considered to arise from a 
difference between the HEK 293T/17 cell line used to titrate EBOV GP PV compared to the BHK-
21 cell line used for both the VSV and RABV G PV titrations. Combining the calculated ratios for 
the VSV and RABV G PV arises at approximately 1259 RLU equating to 1 IFU on the BHK-21 
cell line. 
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Figure 6.12 Ratio between Luminescent (RLU) and Fluorescent (IFU) Readout Units 
Using Reporter Genes Linked by a T2A Peptide  
From infection assay data for VSV G, RABV G and EBOV GP PV incorporating both an FLuc and GFP 
reporter gene via the pCS-T2A-W expression plasmid, the ratio between RLU and IFU (RLU:IFU) was 
calculated from titres measured at single PV dilutions and averages for both orientations of FLuc and GFP 
combined. *p = 0.0355 and **p = 0.0012 when comparing samples with corresponding controls and ***p < 
0.0001 when comparing EBOV GP PV sample to both VSV and RABV G PV samples (two-tailed t-test). 
Error bars show SD (n = 6 for samples and n = 3 for controls).  
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6.2.3. Quantification of Pseudotyped Virus  
In order to evaluate four methods of quantifying PV preparations, and to account for any variance 
associated with the reporter gene or titre, a panel of lentiviral PVs were produced comprising a 
VSV G, RABV (CVS-11) G and EBOV (Makona) GP envelope protein and incorporating a firefly 
luciferase, GFP or LacZ reporter gene via the transfection of HEK 293T/17 cells (Section 2.2.10). 
Single use aliquots of the PV harvest were prepared for each quantification method and stored at -
80°C. The biological titre of the different preparations was assessed via an infection assay, titrating 
each PV over a 2-fold dilution series onto either BHK-21 cells (VSV and RABV G PV) or HEK 
293T/17 cells (EBOV GP PV) (Section 2.2.11.1) and measured as previously detailed (Section 
2.2.12). The number of particles that were approximately 100 nm in size, corresponding to the 
diameter of lentivirus, were counted via nanoparticle tracking analysis and recorded as particles/ml 
(Section 2.2.17). Quantification of the number of genome copies was undertaken via an RT-qPCR 
reaction, reported as genome copies/ml (Section 2.2.15), and the RT activity measured via an SG-
PERT assay and reported as pU/ml (Section 2.2.16) (Standard curves; Appendix IV).  
 
Analysis of the quantification of PV incorporating a firefly luciferase reporter showed that the 
pattern of highest to lowest biological titres for PV with different envelope proteins (VSV > RABV 
> EBOV; Figure 6.13A) was inversed when measuring the number of particles (EBOV > RABV > 
VSV; Figure 6.13B). However, the genome copies and RT activity of the PV preparations 
correlated with the biological titre rankings (Figure 6.13C&D). For PV incorporating a GFP 
reporter gene, the biological titre and particle counts mirrored those of PV with a firefly luciferase 
reporter gene, with an inverse relationship between biological titre and particle count (Figure 
6.14A&B); yet this was not the case for the genome copies and RT activity data. Preparations of 
PV comprising a RABV G or EBOV GP and incorporating a GFP reporter gene consisted of 
greater genome copies (8.7 x 10
8
 and 9.5 x 10
8
 genome copies/ml, respectively) and higher RT 
activity (9.0 x 10
10
 and 7.0 x 10
10
 pU/ml, respectively) than those with a VSVG (2.8 x 10
8
 genome 
copies/ml and 1.5 x 10
10
 pU/ml; Figure 6.14C&D). Finally, the quantification data collected for PV 
with a LacZ reporter showed the same inverse relationship between biological titre and the number 
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of particles (Figure 6.15A&B). Further, as seen with the firefly luciferase reporter, the quantity of 
genome copies and RT activity was found to correlate with biological titre (Figure 6.15C&D). In 
all instances, the number of particles, genome copies and RT activity was lowest when 
incorporating a LacZ reporter, with the biological titres also being lower in comparison to PV with 
a GFP reporter.  
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Figure 6.13 Quantification of Firefly Luciferase Reporter Gene Pseudotyped Virus 
Comprising a VSV, RABV or EBOV Envelope Glycoprotein 
For the quantification of PV comprising a VSV G, RABV (CVS-11) G or EBOV (Makona) GP and 
incorporating a firefly luciferase reporter gene (A) biological titres were measured via luminescence and 
reported as relative light units per ml (RLU/ml) from BHK-21 cells infected with VSV G and RABV G PV 
and HEK 293T/17 cells infected with EBOV GP PV (n = 2). (B) The number of particles measuring ~100 nm 
in size were counted via nanoparticle tracking analysis (n = 5). (C) Genome copies were quantified via an 
RT-qPCR reaction targeting the HIV-1 LTR region (n = 2) and (D) the RT activity was quantified via an SG-
PERT assay and reported as pU/ml (n = 2). In all cases error bars represent SD. 
 
A B 
C D 
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Figure 6.14 Quantification of Green Fluorescent Protein Reporter Gene Pseudotyped 
Virus Comprising a VSV, RABV or EBOV Envelope Glycoprotein 
For the quantification of PV comprising a VSV G, RABV (CVS-11) G or EBOV (Makona) GP and 
incorporating a GFP reporter gene (A) biological titres were measured via fluorescent microscopy and 
reported as infectious units per ml (IFU/ml) from BHK-21 cells infected with VSV G and RABV G PV and 
HEK 293T/17 cells infected with EBOV GP PV (n = 2). (B) The number of particles measuring ~100 nm in 
size were counted via nanoparticle tracking analysis (n = 5). (C) Genome copies were quantified via an RT-
qPCR reaction targeting the HIV-1 LTR region (n = 2) and (D) the RT activity was quantified via an SG-
PERT assay and reported as pU/ml (n = 2). In all cases error bars represent SD. 
 
A B 
C D 
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Figure 6.15 Quantification of LacZ Reporter Gene Pseudotyped Virus Comprising a VSV, 
RABV or EBOV Envelope Glycoprotein 
For the quantification of PV comprising a VSV G, RABV (CVS-11) G or EBOV (Makona) GP and 
incorporating a LacZ reporter gene (A) biological titres were measured via light microscopy and reported as 
infectious units per ml (IFU/ml) from BHK-21 cells infected with VSV G and RABV G PV and HEK 
293T/17 cells infected with EBOV GP PV (n = 2). (B) The number of particles measuring ~100 nm in size 
were counted via nanoparticle tracking analysis (n = 5). (C) Genome copies were quantified via an RT-qPCR 
reaction targeting the HIV-1 LTR region (n = 2) and (D) the RT activity was quantified via an SG-PERT 
assay and reported as pU/ml (n = 2). In all cases error bars represent SD. 
 
A B 
C D 
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To determine if there was a direct relationship between the quantification of PV particles and 
biological titre; the ratio of particles counted, genome copies and RT activity compared to the 
measured biological titre was calculated (Table 6.2). It can be seen that the ratios are subject to 
variation between the different titre (envelope protein) PV preparations and thus these non-
functional quantification methods cannot be used to predict the biological titre. The highest titre, 
VSV G PV, was found to have the lowest ratio in each instance, which demonstrates that the non-
functional quantification of PV can be used to indicate for the presence of unviable particles. 
Interestingly, there is a low level of ratio variance between PV with a GFP verses a LacZ reporter 
which further suggests the envelope protein to be the source of variance.  
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Table 6.2 Ratio of Pseudotyped Virus Quantified by Counting Particles, Genome Copies 
and RT Activity to Biological Titre  
Ratios are calculated for each method of quantification in comparison to the biological titre measured as 
either RLU/ml or IFU/ml. 
 
 
Reporter  
Envelope 
Glycoprotein 
Ratio of Quantification Data to Biological Titre 
(QD:BT) 
  Particles Genome Copies RT Activity 
Firefly Luciferase VSV 2.0 x 10
0
 1.0 x 10
-1 
8.1 x 10
0
 
 RABV 1.7 x 10
2
 2.5 x 10
0
 1.6 x 10
2
 
 EBOV 9.0 x 10
3 
1.5 x 10
1 
2.4 x 10
3 
     
GFP VSV 9.2 x 10
3 
2.0 x 10
2 
1.0 x 10
4 
 RABV 3.8 x 10
4 
2.3 x 10
3 
2.3 x 10
5
 
 EBOV 1.8 x 10
6
 6.2 x 10
4
 4.5 x 10
6
 
     
LacZ VSV 2.2 x 10
4
 1.6 x 10
2 
1.8 x 10
4
 
 RABV 9.0 x 10
5
 3.8 x 10
3
 2.3 x 10
5
 
 EBOV 3.0 x 10
7
 4.5 x 10
4
 4.0 x 10
6
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6.3. Discussion 
The pseudotype platform requires the incorporation of reporters which can be easily detected and 
measured quantitatively when expressed in transduced cells. The current range of reporters offers 
the choice of three outputs; luminescence, fluorescence and colourimetric as well as having 
different cost and resource requirements. Yet the assessment of new reporter genes, which could 
offer an improvement to the existing portfolio or alternative readout methods, is important to 
enhance the flexibility of the system. With an increasing uptake in pseudotype technology further 
characterisation for instance, by determining the correlation between disparate readout units of the 
different reporter outputs, will enhance their utility. Further, the evaluation of alternative methods 
to quantify the composition of PV preparations, to provide information on their quality, is highly 
valuable for the future implementation of standardisation and quality control. This study looked to 
address each of these aspects; investigating the suitability of new bioluminescent, fluorescent and 
colourimetric reporters for their incorporation within the pseudotype platform, developing a system 
to allow correlation of the disparate readout units of reporters and evaluating alternative methods of 
PV quantification towards future standardisation. 
 
Assessment of the two bioluminescent reporter genes, secreted cypridina luciferase and NanoLuc 
luciferase, demonstrated they were not suitable for incorporation into the pseudotype platform. The 
BioLux® cypridina luciferase assay (NEB) was found to have background luminescence activity 
with just cell culture media that was approximately 100-fold higher than that for currently used 
assays for the firefly and renilla luciferase reporter gene. This reduces the lower limit of detection 
and useable dynamic range of the assay. Further, there was not a linear relationship between the 
volume of PV and cypridina luciferase activity, with an initial negative correlation before turning 
positive once PV input volumes became lower. While not fully understood, this could be due to 
contaminants in the PV harvest impairing cell transduction or cytotoxicity that was not detected 
due to using opaque culture plates, which was overcome by dilution at lower volumes of the PV 
supernatant. However due to the unfavourably high background luminescence levels this was not 
investigated further. While the background luminescence from cell media via the Nano-Glo® assay 
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(Promega) for NanoLuc luciferase was in line with that seen for firefly and renilla luciferase, there 
was a considerably high level of luminescence from the supernatant containing harvested PV. This 
was in line with that produced from transduced cells and thus rendered the NanoLuc luciferase 
unsuitable for the pseudotype platform. The luminescence intensity of NanoLuc is described to be 
approximately 150-fold more than that of firefly and renilla luciferase, which correlated with the 
luminescence measured in this study, as well as having a higher physical stability and being only 
19 kDa in size compared to the 61 kDa and 36 kDa of firefly and renilla luciferase respectively 
(Hall et al., 2012). The phenomenon of passively transferred reporter protein was previously 
discussed (Chapter 4), with some reporter protein thought to be incorporated into PV during their 
formation (Nash & Lever, 2004). It is suspected the small size of NanoLuc luciferase could favour 
a higher level of passive incorporation into PV, with the additional factors of its stability and 
luminescence intensity each contributing to the high level of luminescence observed from the PV 
supernatant. 
 
Results generated from the incorporation of the colourimentric SEAP into the pseudotype platform, 
which like cypridina luciferase is secreted, proved it too was not appropriate for use in the PV 
system. When assaying the culture media of target cells for the presence of SEAP, it was 
determined the secreted reporter was not being produced yet high levels were detected within the 
PV supernatant. During transient transfection for PV production, reporter protein expression will be 
detected as a result of translation and also from transduction of cells by newly generated PV. In 
fact, the advantage of not requiring disruption of producer cells to detect a secreted reporter protein 
means SEAP is cited for use to monitor successful transfection (Berger et al., 1988; Cullen & 
Malim, 1992; Yang et al., 1997). However, secreted SEAP has previously been described as a PV 
reporter using alternative pseudotyping systems, initially via a transfection method for the 
intracellular production of papilloma viral vectors (Pastrana et al., 2004) and more recently to 
produce VSV pseudotyped with Nipah virus F and G proteins (Kaku et al., 2012). The former 
involves multiple lysis and centrifugation steps to purify the intracellularly produced viral vectors 
which would eliminate secreted SEAP, while for the latter SEAP is supplied as a replacement to 
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the VSV glycoprotein within a plasmid encoding the cDNA for the VSV genome (VSV∆G-SEAP) 
which could dampen its expression during transfection. The apparent complete lack of SEAP 
secretion from transduced cells in this study suggests the efficient packaging of SEAP as an RNA 
dimer within the PV core or budding of PV from the producer cell membrane during formation 
could be confounded by its secretion. Alternatively, it is not known whether the presence of 
secreted SEAP within the PV supernatant may interfere with PV transduction of target cells. It has 
previously been shown that a secreted proteoglycan acts to inhibit cell infection, with proposed 
mechanisms of either binding to the envelope protein or cellular receptors to block entry (Le Doux 
et al., 1996). The use of secreted SEAP was not further explored in this study as additional 
requirements, such as a purification step, would eliminate its beneficial properties of being a high 
throughput and resource-sparing PV reporter. However, these results act to highlight potential 
issues with incorporating secreted reporters into the pseudotype platform.   
 
Each of the fluorescent reporter proteins, dNG and dNT, were successfully incorporated into the 
pseudotype platform and offered improved visual differentiation of transduced target cells through 
the nuclear localisation of the fluorescent protein. However, the dNG reporter had a lower 
fluorescent intensity and both caused an apparent reduction in PV titre. Auto-fluorescence when 
using a fluorescent protein which emits light in the green spectrum is a common artefact impairing 
visual clarity, and the result of cellular components absorbing light at wavelengths close to this 
spectrum (Brogan et al., 2012). The photostability of fluorescent proteins, which bleach upon 
extended excitation, is a further aspect which determines clarity when imaging and varies greatly 
amongst the fluorescent proteins (Shaner et al., 2005). While the high fluorescent intensity of 
enhanced GFP generally minimises the interference of background auto-fluorescence and it also 
has good photostability, it was found that the dNG reporter had a lower intensity, which impaired 
differentiation of transduced cells from background auto-fluorescence, and poor photostability. On 
the other hand, the dNT reporter displayed greater fluorescence intensity and photostability than the 
currently used GFP. It could be that the reduced PV titre using each of these reporters may arise 
from their higher molecular weight, due to two copies of the fluorescent protein gene being 
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included within these dual reporters along with their post-translational trafficking to the nucleus. 
Further, the reduced number of dNT transduced cells counted via flow cytometry may arise from 
being unable to use the optimum excitation laser. The tdtomato fluorescent protein has an 
excitation peak at 554 nm (Shaner et al., 2004), however a 488 nm excitation laser was used within 
this study. Despite a reduction in PV titre, the dNT reporter is a good addition to the range of 
reporters incorporated within the PV platform. 
 
In order to correlate the disparate readout units of IFU and RLU, a pDUAL expression plasmid was 
initially used in an attempt to package and co-express two reporter genes from a single PV. While 
coincident expression of two fluorescent reporter genes was reported by Escors, et al., (2008), in 
this study it was found that each of the promoters within the pDUAL expression plasmid, SFFV 
and UBIQ, did not provide equal levels of reporter gene expression. There were lower, or in the 
case of the LacZ reporter gene, no detectable levels when expression was driven by the UBIQ 
promoter. The functionality of promoters can be cell type specific due to variations in cell 
transcription machinery and regulatory factors. However, the UBIQ promoter has previously been 
shown to offer good gene expression levels in both haematopoietic and mesenchymal cells (Byun 
et al., 2005), which covers the cell type used in the initial pDUAL study and this study 
respectively. The choice of promoter is important in the design of reporter plasmids for PV 
production. It has previously been reported how the transduction efficiency of lentiviral vectors can 
be underestimated if using a suboptimal promoter and can differ between cell lines originating from 
different species (Ikeda et al., 2002). In fact, the SFFV promoter was introduced into the currently 
used pCS[reporter]W expression plasmid to replace a cytomegalovirus (CMV) promoter due to 
enhanced transgene expression in haematopoietic cells (Demaison et al., 2002). Further, the 
woodchuck hepatitis virus post-transcriptional regulatory element (WPRE), which was originally 
found to increase expression of transgenes under the CMV promoter (Zufferey et al., 1999), and 
subsequently also acted to increase expression when the promoter was changed to SFFV in both 
cell types (Clements et al., 2006; Demaison et al., 2002), likely contributes to the unbalanced 
expression between the two promoters.  
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However, by placing a 2A peptide sequence between two reporter gene sequences, it was possible 
to achieve equal levels of expression under the single SFFV promoter. The use of 2A peptide 
sequences has emerged as an improvement to internal ribosomal entry sites (IRES) which are 
widely employed to express multiple genes from a single vector but have several disadvantages, 
including their large size and a reported variable or unbalanced level of expression which can differ 
between cell types (Szymczak & Vignali, 2005). The 2A peptide cleavage mechanism operates via 
preventing a normal bond formation between a glycine and proline residue of a conserved peptide 
sequence via a ribosomal skip event during translation. It was initially identified in the foot and 
mouth disease virus and has since been described in other picornaviruses, insect and rotaviruses 
(Donnelly et al., 2001; Ryan et al., 1991; Szymczak & Vignali, 2005). The peptide sequences are 
short and have previously demonstrated equal levels of reporter gene expression, as well as the 
ability to efficiently express multiple genes (Ibrahimi et al., 2009; Szymczak et al., 2004). Through 
incorporating both a firefly luciferase and GFP reporter gene into PV, which were expressed in 
transduced cells via this mechanism, it was possible to correlate the disparate readout units of RLU 
and IFU. While the combination of data collected from the BHK-21 cell line transduced with a 
VSV G or RABV G PV indicates 1259 RLU equates to 1 IFU, the ratio was higher from the 
analysis of data collected from HEK 293T/17 cells transduced with an EBOV GP PV. This may be 
the result of differences in the efficiency of GFP post-translational modifications or folding 
between the two cell lines, which may result in reduced sensitivity of the reporter in the HEK 
293T/17 cell lines. Further analysis of RLU and IFU ratios in additional cell lines, together with the 
inclusion of alternative reporters, such as LacZ, with the pCS-T2A-W expression plasmid 
constructed within this study are required to address this finding.  
 
Results from several methods, other than biological titre, to quantify and standardise PV 
preparations based on targeting the core, RNA genome or evaluating the total number of particles 
have been shown. Within this study a full assessment of the utility of each method was assessed for 
PV of varying biological titres and incorporating different reporters. It was shown that when 
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counting total particles via nanoparticle tracking analysis, a higher particle count did not translate 
to a higher biological titre. The lowest titre PV preparation consisted of the highest number of 
particles. As this was not the case for the quantification of genome copies or RT activity which, 
except for with a GFP reporter, correlated with biological titres, it would suggest a higher 
proportion of extracellular vesicles are being produced, which shed from the membrane of healthy 
and virally infected cells and can contain viral protein or RNA, as well as being similar in size to 
lentiviral PV (Heider & Metzner, 2014; Meckes & Raab-Traub, 2011; Raposo & Stoorvogel, 
2013). Therefore a limitation of quantification via nanoparticle tracking analysis is that it cannot 
differentiate between PV particles and extracellular vesicles. The fact low and mid-titre PV 
preparations incorporating a GFP reporter had a higher number of genome copies and RT activity, 
not following the pattern observed for those with a firefly luciferase or LacZ reporters, may reflect 
the packaging efficiency of the smaller GFP reporter gene within the lentiviral core, which could 
shed within extracellular vesicles. The use of nanoparticle tracking analysis is not a reliable 
indicator to determine the quantity of PV particles. 
 
While previous studies have used individual assays to assess PV preparations this is the first report 
where the same PV preparations have been assessed by each assay simultaneously. It has 
previously been demonstrated that the non-functional quantification of the genome and core 
components overestimates the level of functional PV, capable of transducing target cells. 
Quantification of the RNA genome has been reported to give a 10 – 10,000 fold overestimate of the 
biological titre (Geraerts et al., 2006; Ikeda et al., 2002; Lizée et al., 2003; Sastry et al., 2002) and 
that of the core component via the SG-PERT assay by approximately 1500 fold (Vermeire et al., 
2012). These results are built on here, and can be explained by a multitude of factors, which 
includes the presence of defective interfering particles (Higashikawa & Chang, 2001; Lizée et al., 
2003), such as from PV produced incorporating a mutant genome (Kirkwood & Bangham, 1994) or 
the stability of the envelope protein which, if unstable, sheds from the PV particle and is less able 
to withstand freeze-thaw (Davis et al., 1997). The secretion of transduction inhibitors from 
producer cells during PV generation has also been described, identifying the secretion of 
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proteoglycans as a major inhibitor (Le Doux et al., 1996). Additionally, it has been shown that 
reporter gene integration into the genome of a transduced cell may not always result in a detectable 
level of the reporter being expressed (Lizée et al., 2003; Martin-Rendon et al., 2002; Sastry et al., 
2002). It should also be remembered that lentiviral cores are produced, with or without the 
inclusion of a reporter gene during transfection, as well as in the absence of envelope protein 
(Geraerts et al., 2006). 
 
While a relatively low level of variance in the non-functional quantification of separate 
preparations of a single lentiviral vector had been reported (Logan et al., 2004; Vermeire et al., 
2012), this study was able to show that between PV preparations incorporating different envelope 
proteins there was a high level of variation. This is likely linked to the factors stated above 
associated with the envelope protein, with a difference in stability and level of extracellular vesicle 
secretion. Calculating the ratio between the non-functional quantification and biological titre was 
found to be a useful indicator of the quality of PV preparations, with a lower ratio indicating less 
non-functional particles and associated with a higher biological titre. Therefore, while 
quantification of genome copies or RT-activity cannot be used to standardise across PV 
incorporating different envelope proteins, it offers utility in the standardisation of single PV 
preparations and provides valuable information on their quality.  
 
In conclusion, the current range of reporters incorporated within the pseudotype platform was 
expanded through the inclusion of a red fluorescent protein reporter, which is nuclear localised and 
enhances the detection and ability to distinguish transduced cells. Attempts to incorporate secreted 
reporters into the platform highlighted limitations in their use, owing to the need to purify PV to 
remove reporter secreted during production. The ability to correlate the disparate readout units of 
RLU collected using a luminescent reporter and IFU using a fluorescent reporter was achieved 
through joining two reporter genes with a 2A peptide sequence, for packaging with PV core and 
subsequent equal expression levels under a single promoter. Initial data suggests approximately 
1260 RLU equates to 1 IFU when transducing the BHK-21 cell line, yet future work is required to 
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assess how this fluctuates between cell lines. Finally, assessment of non-functional quantification 
methods of multiple PV preparations showed quantifying the genome and core components 
provides information on the quality of preparations. However, non-functional quantification cannot 
be used to standardise virus input for downstream assays between PV incorporating different 
envelope proteins. 
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Chapter 7. Conclusions and Future Work 
 
Emerging zoonotic viruses pose a major threat to human and animal health, with significant 
economic implications. Often, there is a lack or shortfall of effective prophylaxis and diagnostic 
capabilities. Research towards their development, together with surveillance activities for early 
detection and an improved understanding of their persistence within host populations, are 
recognised as high priority activities towards preparedness and the mitigation of outbreak threats. 
Studies of emerging viruses are commonly limited to high BSL 3 or 4 laboratories, yet this can be 
circumvented by the use of PV which can be handled at low containment levels, acting as a 
surrogate for pathogenic viruses. The use of PV in the serological study of emerging viruses is 
becoming increasingly prominent and it has been reported to be as a safe, robust and flexible tool 
(Mather et al., 2013; Steffen & Simmons, 2016; Temperton et al., 2015b). This study aimed to 
exploit novelties in the flexibility of the pseudotype system, quantifying NAb responses raised 
against the envelope protein of emerging zoonotic viruses using a PVNA and determining the 
importance of antigenic sites. The study also looked at technical aspects towards PV production, 
aimed at expanding the repertoire of reporter genes and identifying alternative methods of 
quantification to assist the standardisation of PV assay input.  
 
The flexibility to manipulate envelope proteins for incorporation within PV offers unique 
opportunities. Within Chapter 3, it was shown that the low titre of PV bearing the envelope protein 
of AL RABV could be increased when chimeric envelope proteins incorporating the cytoplasmic 
domain of VSV, which pseudotypes highly efficiently, were used. This did not alter the 
neutralisation profile, so permitted serological assessment to confirm the efficacy of existing rabies 
vaccines and post-exposure prophylaxis against the AL RABV lineage. Given the near 100% case 
fatality rate associated with rabies and the circulation of AL RABV across rabies endemic Middle 
East and Asian regions, with India alone reporting more than 20,000 fatalities annually (Kuzmin et 
al., 2008; Sudarshan et al., 2007), it was important to understand the threat it posed. Indeed, this 
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work further demonstrates the applicability of the pseudotype system to contribute towards 
serosurveillance of emerging viruses. Efforts towards rabies control require a comprehensive, high 
quality, analysis of circulating RABVs (Fooks et al., 2014; Matsumoto et al., 2013). An additional 
outcome of successfully increasing the titre of AL RABV PV was their inclusion in the study by 
De Benedictis et al., (2016), screening mAb for broadly neutralising activity against all lyssavirus 
phylogroups.   
 
Although using a chimeric envelope protein lead to an increase in the titre of the AL RABV PV, 
the mechanism responsible for this increase remains to be elucidated. As such, attempts within 
Chapter 5 to replicate this previous success and increase the titre of Ebolavirus PV were 
unsuccessful. This included accounting for structural differences related to alternative classes of 
fusion protein. The use of a truncated cytoplasmic domain was also investigated, which had been 
suggested in other studies to either reduce steric hindrance of the cytoplasmic domain, or eliminate 
an unfavourable interaction with the matrix protein (Frecha et al., 2008; Freed & Martin, 1995). 
However Ebolavirus PV titres were reduced within this study. These results act to highlight the 
complexities in altering the domains of envelope proteins. Cytoplasmic domains may include 
trafficking motifs and have direct effects on fusion, while the transmembrane domain is important 
for correct folding and structural changes during fusion (Cosset & Lavillette, 2011; White et al., 
2008). Future work to better understand the reason for the sometimes varying efficiency of PV 
production with envelope proteins of closely related viral species, which demonstrate relatively 
high sequence homology, is required. It is thought differences in structural features of the envelope 
protein, such as glycosylation patterns, may be important factors. Both the lyssavirus and filovirus 
envelope proteins are glycosylated, with that of filoviruses having a heavily glycosylated mucin-
like domain which has a high level of sequence variability between species (Pöhlmann, 2013; 
Takada, 2012). 
 
Identifying the importance and structural location of neutralising epitopes has been an important 
part of mAb development. PV has been utilised in studies characterising rabies mAb for this 
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purpose, with the flexibility to mutate the defined antigenic sites of the rabies envelope protein (De 
Benedictis et al., 2016; Both et al., 2013b). Work initiated by Evans et al., (2013) looked to use 
this flexibility to switch antigenic sites between a phylogroup I and II lyssavirus and investigate the 
effect on neutralisation by polyclonal sera from vaccine recipients. Work undertaken within 
Chapter 4 expands upon this investigation by including the envelope protein of WCBV, a 
phylogroup III lyssavirus. Assessment of polyclonal sera samples by a PVNA showed antigenic 
site III and I were immunologically dominant for the phylogroup I and III lyssaviruses respectively. 
The neutralisation data also supported the theory that other epitopes may be involved in 
neutralisation by polyclonal sera than those that have been defined by mAb screening. Future 
inclusion of other divergent lyssaviruses will help define important immunogens which could be 
combined to develop a more broadly neutralising vaccine. This work demonstrates how the PVNA 
platform can be used to perform important serological assessment of the antigenic hierarchy of 
neutralising epitopes on viral envelope proteins. Combining data collected via the PVNA with 
antigenic cartography, which constructs a biological map by combining neutralisation and sequence 
data, will help enhance the quantification of immunological divergence. This would enable low 
containment assessment of emerging virus variants to help assess vaccine escape, with the use of 
PV also being applicable to a high throughput approach.  
 
As the production of PV for newly emerging viruses only requires access to the nucleotide 
sequence of the envelope protein, they are amenable to rapid development. This was exemplified 
by the work undertaken within Chapter 5 in response to the recent Ebola virus outbreak. Following 
a PHEIC being declared, there was an urgent call by the WHO for the priority development of 
efficacious vaccines, antivirals and improved diagnostics. Given members of the Filoviridae are 
BSL 4 pathogens, developing a PVNA was valuable towards the serological assessment of 
candidate prophylaxis. A library of filovirus PVs was quickly developed, which included the Zaire 
ebolavirus Makona isolate responsible for the outbreak. Following steps to optimise production and 
performance of the PVNA it was applied to a range of projects, including the assessment of a 
vaccine undergoing a phase I clinical trial (Ewer et al., 2016). It is proposed that generating and 
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maintaining a library of PVs for other emerging viruses offers a highly effective outbreak 
preparedness tool (Temperton & Page, 2015). This would involve optimising PV production for 
important emerging viruses, such as those listed on the WHO blueprint of priority diseases (Figure 
1.1). In future work to optimise production, it would be advisable to consider evaluating the use of 
alternative pseudotyping cores for improved efficiency and indeed such work has already begun 
(O’Keefe et al., 2017). It is reported a VSV core can offer a higher incorporation efficiency for 
certain envelope proteins (King et al., 2016; Whitt, 2010) and thus it would be worth evaluating 
this system, albeit being more complex to produce PV.  
 
As part of the development of a PV library, and in light of the increasing prominence in the use of 
PV assays to assess vaccine and antiviral activity, it is recognised that efforts towards their 
standardisation are required. The work undertaken within Chapter 6 looked to evaluate alternative 
methods to quantify the composition of PV preparations, in addition to biological titre which is 
primarily used. It was found that non-functional, molecular, methods to quantify the genome and 
core components of PV could be used to provide information on the quality of preparations and 
have potential to be used to standardise input. While it was shown non-functional standardisation 
cannot be applied between PV incorporating different envelope proteins, it is considered to have 
utility to be applied as a quality control for repeat production. Additional work was undertaken in 
Chapter 6 towards an enhanced characterisation of outputs of the PV platform, expanding its 
functionality. This included incorporating an additional, red fluorescent, reporter gene which offers 
output in a different spectrum to current fluorescent reporters and has greater clarity for data 
collection owing to a nuclear localisation signal. Finally, a new construct was produced to integrate 
and equally express two reporters from cells transduced with PV. For the first time, this allowed a 
common question on the correlation between the disparate readout units of IFU and RLU to be 
addressed. Initial data suggest approximately 1260 RLU equates to 1 IFU. Future work to 
understand how this may fluctuate between target cell lines is required. Both the range of reporters 
available, which offer different cost and time constraints, combined with an increasing level of 
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standardisation, make the use of pseudotypes suitable to a range of sectors, with various resource 
and output requirements.  
 
In summary, the projects undertaken as part of this thesis have exploited many novelties in the 
flexibility of the pseudotype platform to undertake emerging virus research. This has included 
manipulating the envelope protein to improve PV production and serologically determine the 
efficacy of existing prophylaxis, contributing towards emerging virus serosurveillance efforts. It 
was further exploited to determine the immunological importance of antigenic sites on the envelope 
protein, informing the development of broadly neutralising prophylaxis. Work to respond to an 
important emerging virus outbreak, rapidly developing a PVNA which was used in a range of 
studies, demonstrating the value of the pseudotype platform for both outbreak response and future 
preparedness. In contributing to technical aspects of PV production, adding to the range of reporter 
genes, offering a novel way to correlate disparate readout units and identifying the value of other 
methods of quantification, their functionality and future standardisation are strengthened. These 
findings have already contributed to continuing studies using PV for emerging virus research and 
will continue to inform development and the implementation of standardisation to enhance quality 
controls. Ultimately, the work presented in this thesis supports the notion that the pseudotype 
platform offers a safe, robust and flexible tool to undertake emerging virus research. 
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Appendix I  
I.1. Virus Envelope Protein  
 
Genus | Species | Isolate | Abbreviation | Accession Number | Length (bp) | Obtained from | 
Construct ID
1 
1
Where applicable refers to amplification primers detailed in Chapter 2 (Table 2.3 – 2.4)  
 
Lyssavirus | Rabies lyssavirus | Challenge virus standard 11 | CVS-11 | EU352767 | 1575 | 
APHA | C1.1 
ATGGTTCCTCAGGTTCTTTTGTTTGTACCCCTTCTGGGTTTTTCGTTGTGTTTCGGGAAGTTCCCCATTTACACGATACCAGACGAACTTGGTCCCT
GGAGCCCTATTGACATACACCATCTCAGCTGTCCAAATAACCTGGTTGTGGAGGATGAAGGATGTACCAACCTGTCCGAGTTCTCCTACATGGAACT
CAAAGTGGGATACATCTCAGCCATCAAAGTGAACGGGTTCACTTGCACAGGTGTTGTGACAGAGGCAGAGACCTACACCAACTTTGTTGGTTATGTC
ACAACCACATTCAAGAGAAAGCATTTCCGCCCCACCCCAGACGCATGTAGAGCCGCGTATAACTGGAAGATGGCCGGTGACCCCAGATATGAAGAGT
CCCTACACAATCCATACCCCGACTACCACTGGCTTCGAACTGTAAGAACCACCAAAGAGTCCCTCATTATCATATCCCCAAGTGTGACAGATTTGGA
CCCATATGACAAATCCCTTCACTCAAGGGTCTTCCCTGGCGGAAAGTGCTCAGGAATAACGGTGTCCTCTACCTACTGCTCAACTAACCATGATTAC
ACCATTTGGATGCCCGAGGATCCGAGACCAAGGACACCTTGTAACATTTTTACCAATAGCAGAGGGAAGAGAGCATCCAAAGGGAACAAGACTTGCG
GCTTTGTGGATGAAAGAGGCCTGTATAAGTCTCTAAAAGGAGCATGCAGGCTCAAGTTATGTGGAGTTCTTGGACTTAGACTTATGGATGGAACATG
GGTCGCGATGCAAACATCAGATGAGACCAAATGGTGCCCTCCAGATCAGTTGGTGAATTTGCACGACTTTCACTCAGACGAGATTGAGCATCTCGTT
GTGGAGGAGTTAGTCAAGAAAAGAGAGGAATGTCTGGATGCATTAGAGTCCATCATGACCACCAAGTCAGTAAGTTTCAGACGTCTCAGTCACCTGA
GAAAACTTGTCCCAGGGTTTGGAAAAGCATATACCATATTCAACAAAACCTTGATGGAGGCTGATGCTCACTACAAGTCAGTCCGGACCTGGAATGA
GATCATCCCCTCAAAAGGGTGTTTGAAAGTTGGAGGAAGGTGCCATCCTCATGTGAACGGGGTGTTTTTCAATGGTATAATATTAGGGCCTGACGGC
CATGTCCTAATCCCAGAGATGCAATCATCCCTCCTCCAGCAACATATGGAGTTGTTGAAATCTTCAGTTATCCCCCTGATGCACCCCCTGGCAGACC
CTTCTACAGTTTTCAAAGAAGGTGATGAGGCTGAGGATTTTGTTGAAGTTCACCTCCCCGATGTGTACAAACGGATCTCAGGGGTTGACCTGGGTCT
CCCGAACTGGGGAAAGTATGTATTGATGACTGCAGGGGCCATGATTGGCCTGGTGTTGATATTTTCCCTAATGACATGGTGCAGAAGAGCCAATCGA
CCAGAATCGAAACAACGCAGTTTTGGAGGGACAGGGAGGAATGTGTCAGTCACTTCCCAAAGCGGAAAAGTCATACCTTCATGGGAATCATATAAGA
GTGGAGGTGAGATCAGACTGTAA 
 
  
 189 
 
Lyssavirus | Rabies lyssavirus | India.human.87.RV61 | RV61 | KU534939 | 1575 | APHA | C1.2 
ATGGTTCCTCAAGTTCTTTTGTTTGTACCCCTTCTGGTTTTCTCAATGTGTTTCGGGAAATTTCCTATCTATACGATACCAGACAAACTTGGTCCCT
GGAGCCCGATTGACATACATCATCTCAGCTGTCCAAACAACCTGGTTGTGGAAGATGAAGGATGCACTAACTTGTCGGGTTTCTCCTACATGGAACT
TAAGGTGGGATACATCTCGGCCATAAAAGTAAACGGGTTCACGTGCACAGGTGTGGTAACAGAGGCAGAGACTTACACTAACTTTGTCGGTTATGTT
ACCACCACGTTCAAAAGAAAGCATTTCCGCCCAACACCAGATGCATGTCGAGCTGCTTACAACTGGAAGATGGCAGGTGACCCCAGATATGAAGAAT
CGCTGCACAATCCGTACCCTGACTACCACTGGCTTCGAACCGTTAAAACCACAAAGGAGTCCCTCGTCATCATATCCCCAAGTGTAGCGGACCTGGA
CCCATACGACAAATCCCTTCATTCGAGGGTCTTTCCTAGCGGGAAGTGCTCGGGAATAACAATATCATCTACTTACTGCTCTACTAACCATGATTAC
ACAATCTGGATGCCTGAGAATCCGAGACTGGGGACATCTTGTGACATCTTTACCAACAGTAGAGGGAAGAGAGCATCCAAAGGGGGCAAAACTTGCG
GATTTGTTGATGAAAGAGGCTTGTATAAGTCTTTGAAAGGGGCATGCAAACTCAAGTTGTGTGGAGTTCTCGGCCTTAGACTTATGGATGGAACGTG
GGTTGCGATGCAAACATCGGACGAAACCAAGTGGTGTCCTCCTGATCAGTTGGTAAATCTACACGACTTTCGCTCGGACGAGATCGAACATCTTGTT
GTAGAGGAGTTGGTCAAGAAAAGAGAGGAGTGTCTGGATGCACTAGAGTCCATCATGACTACCAAGTCGGTGAGTTTCAGACGTCTCAGCCACTTGA
GGAAACTTGTCCCTGGGTTCGGAAAAGCATACACCATATTCAACAAAACCTTGATGGAAGCAGATGCCCATTACAAGTCAGTCCGAACCTGGAATGA
AATCATCCCCTCCAAAGGGTGTTTGAGAGTTGGAGGGAGGTGTCATCCTCACGTGAAGGGGGTGTTTTTTAACGGTATAATACTGGGTCCTGACGGC
CATGTTCTAATCCCAGAAATGCAATCGTCCCTCCTTCAGCAGCATATGGAGTTGTTGGAATCCTCAGTTATTCCCCTGATGCACCCTTTGGCAGACC
CGTCTACAGTTTTCAAGGACGGTGATGAAGCAGAGGATTTTGTTGAGGTTCACCTTCCCGACGTGCACAAACAAATTTCAGGTGTTGACCTGGGTCT
CCCCAGCTGGGGAAGGTATGTTTTGGTGAGTGCAGGGGTCTTGGTTGTCCTGATGTTGACAATTTTCATAATAACATGTTGCGGAAGAGTCCATCGA
CCCAAATCTACACAACACGGTCTCGGGGGGACAGGGAGGAAGGTGTCGGTCACTTCCCAAAGCGGGAAGGTCATATCTTCATGGGAGTCATATAAGA
GTGGGGGTGAGACCAGACTGTGA 
 
 
Lyssavirus | Rabies lyssavirus | Pakistan.dog.89.RV193 | RV193 | KU534940 | 1575 | APHA | 
C1.3 
ATGGTTCCTCAGGTTCTTTTGTTTGTACCCCTTCTGGTTTTCTCAATGTGTTTCGGGAAATTTCCTATCTATACGATACCAGACAAACTTGGTCCCT
GGAGCCCGATTGACATTCATCATCTCAGCTGTCCAAACAACCTGGTTGTGGAAGATGAAGGATGCACTAACTTGTCGGGTTTCTCCTACATGGAACT
TAAGGTGGGATACATCTCGGCCATAAAAGTAAACGGGTTCACGTGCACAGGTGTGGTGACAGAGGCAGAGACTTACACTAACTTTGTCGGTTATGTT
ACCACCACGTTCAAAAGAAAGCATTTCCGCCCAACACCAGATGCATGTCGAGCTGCTTACAACTGGAAGATGGCCGGTGACCCCAGATATGAAGAAT
CGCTGCACAATCCGTACCCTGACTACCACTGGCTTCGAACCGTTAAAACCACAAAGGAGTCCCTCGTCATCATATCCCCAAGTGTAGCGGACCTGGA
CCCATACGACAAATCCCTTCATTCGAGGGTCTTTCCTAGCGGGAAGTGCTCGGGAATAACAATATCATCTACTTACTGCTCTACTAACCATGATTAC
ACAATCTGGATGCCCGAGAATCCGAGACTGGGGACATCTTGTGACATCTTTACCAACAGTAGAGGGAAGAGAGCATCCAAAGGGGGCAAAACTTGCG
GGTTTGTTGATGAAAGAGGCTTGTATAAGTCTTTGAAAGGGGCATGCAAACTCAAGTTGTGTGGAGTTCTTGGCCTTAGACTTATGGATGGAACGTG
GGTTGCGATGCAAACATCGGACGAAACCAAGTGGTGTCCTCCTGATCAGTTGGTAAATCTACACGACTTTCGCTCGGACGAAATCGAACATCTTGTT
GTGGAGGAGTTGGTCAAGAAAAGAGAGGAGTGTCTGGATGCCCTAGAGTCCATCATGACTACCAAGTCGGTGAGTTTCAGACGTCTCAGCCACTTGA
GAAAACTTGTCCCTGGGTTCGGAAAAGCATATACCATATTCAACAAAACCTTGATGGAAGCAGATGCCCATTACAAGTCAGTCCGAACCTGGAATGA
AATCATCCCATCCAAAGGGTGTTTGAGAGTTGGAGGGAGGTGTCATCCTCACGTGAAGGGGGTGTTTTTTAACGGTATAATACTGGGTCCTGACGGC
CATGTTCTAATCCCAGAGATGCAATCATCCCTCCTTCAGCAGCATATGGAGTTGTTGGAATCCTCAGTTATCCCCCTGATGCACCCTTTAGCAGATC
CGTCTACAGTTTTCAAGGACGGTGATGAAGCAGAGGATTTTGTTGAGGTTCACCTTCCCGACGTGCACAAACAAATTTCAGGTGTTGACCTGGGTCT
CCCCAGCTGGGGAAAGTATGTTTTGGCGAGTGCAGGGGTCTTGGTTGTCCTGATGTTGACAATTTTCATAATAACATGTTGCGGAAGAGTCCATCGA
CCCAAGTCTACACAACACGGTCTCGGGGGGACAGGGAGGAAGGTGTCAGTCACTTCCCAAAGCGGGAAGGTCATATCTTCATGGGAGTCATATAAGA
GTGGAGGTGAGACCAGACTGTGA 
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Lyssavirus | Rabies lyssavirus | Russia.squirrel.RV250 | RV250 | KU534941 | 1575 | APHA | 
C1.4 
ATGGTTCCTCAAGCTCTTTTGTTTGTGCCCCTTCTGGCTTTTCCAATGTGTTTCGGGAAATTCCCCATCTACACAATACCAGACAAACTTGGTCCCT
GGAGCCCGATTGACATACATCATCTCAGCTGTCCAAATAACTTGGTTGTGGAAGACGAAGGATGCACCAACTTGTCGGGTTTCTCCTACATGGAACT
TAAAGTGGGATACATTTCGGCCATAAAAGTGAACGGGTTCACGTGCACAGGTGTGGTTACAGAGGCTGAGACTTACACTAACTTTGTCGGTTATGTT
ACCACCACGTTCAAGAGAAAGCATTTCCGCCCAACACCAGATGCATGTCGAGCTGCTTACAACTGGAAAATGGCCGGTGACCCCAGATATGAAGAAT
CTCTTCATAATCCGTACCCTGACTACCATTGGCTTCGAACCGTGAAAACCACGAAGGAGTCTCTCATCATCATATCCCCAAGTGTAGCAGACCTAGA
CCCATATGACAAATCCCTTCACTCGAGGGTCTTTCCTAGCGGGAAGTGCTTGGGAATAACAATATCATCTACCTACTGCTCGACTAACCATGATTAC
ACCATCTGGATGCCCGAGAATCTGAGATTAGGGACATCTTGTGACATCTTTACCAATAGTAGAGGGAAGAGAGCATCCAAAGGGAGCAAGACTTGCG
GATTTGTTGACGAAAGAGGCTTGTATAAGTCTTTGAAGGGGGCATGCAAGCTCAAATTATGTGGGGTTCTGGGACTTAGACTTATGGACGGAACGTG
GGTCGCGATGCAAACATCGGATGAGACCAAGTGGTGTCCCCCTGATCAGTTGGTAAATCTACACGACTTTCGCTCGGACGAGATCGAACATCTTGTC
GTGGAGGAGTTGGTCAAGAAAAGAGAGGAGTGTCTGGATGCCCTAGAGTCCATCATGACTACCAAGTCGGTGAGTTTTAGACGTCTCAGCCACTTGA
GAAAACTTGTCCCTGGGTTCGGAAAAGCATACACCATATTCAACAAAACCCTGATGGAAGCTGATGCTCACTACAAGTCAGTCAGGACCTGGAACGA
GATCATCCCCTCCAAGGGGTGTCTGAGAGTTGGAGGGAGGTGTCATCCCCATGTAAACGGAGTGTTTTTTAACGGCATAATACTGGGCCCTGACGGC
CATGTTTTGATCCCAGAGATGCAATCATCCCTCCTTCAGCAACATATGGAGTTGTTGGAATCATCAGTTATCCCTCTGATGCATCCTTTAGCAGACC
CGTCTACAGTTTTCAAGGACGGTGATGAAGCAGAGGATTTTGTTGAGGTTCACCTTCCCGATGTGCACAAACAAATCTCAGGGGTTGACCTGGGTCT
CCCTAACTGGGGAAAGTATGTCTTAATAATTGCAGGGGTATTGATTGCCATGATATTGACAATCTTCTTAATGACATGTTGTGGAAGAGGTAATCGA
CCCAAGTCCACACAACACAGTCTTGGAGGGATAGGGAGGAAGGTGTCAGCCACTTCCCAAAGCGGGAAGGTCATATCCTCGTGGGAGTCATATAAAA
GCGGGGGTGAGACCAGACTGTGA 
 
 
Lyssavirus | Rabies lyssavirus | Pakistan.goat.RV277 | RV277 | KU534942 | 1575 | APHA | C1.5 
ATGGTTCCTCAGGTTCTTTTGTTTGTACCCCTTCTTGTTTTCTCAATGTGTTTCGGGAAATTCCCTATCTATACAATACCAGACAAACTTGGTCCCT
GGAGCCCGATCGATATACATCATCTCAGCTGTCCAAACAATCTGGTTGTGGAAGATGAAGGATGTACCAACTTGTCGGGTTTCTCCTACATGGAACT
TAAGGTGGGATACATCTCGGCCATAAAAGTAAACGGATTCACGTGCACAGGTGTGGTGACAGAGGCAGAGACTTACACTAACTTTGTCGGTTATGTC
ACCACCACGTTCAAAAGAAAGCATTTCCGCCCAACACCAGATGCATGTCGAGCTGCTTACAACTGGAAGCTGGCCGGTGACCCCAGATATGAAGAAT
CTCTGCACAATCCGTACCCTGACTACCACTGGCTTCGAACCGTCAAAACCACAAAGGAGTCCCTCGTCATCATATCCCCAAGTGTAGCGGACCTGGA
CCCATACGACAAATCCCTTCATTCGAGGGTCTTTCCTAGCGGGAAGTGCTTGGGAATAACAATATCATCTACTTACTGCTCTACTAACCATGATTAC
ACAATCTGGATGCCCGAGAATCCGAGACTGGGGACATCTTGTGACATCTTTACCAACAGTAGAGGGAAGAGAGCATCCAAAGGGAGCAAAACTTGCG
GATTTGTTGATGAAAGAGGCTTGTATAAGTCTTTGAAAGGGGCATGCAAACTCAAGTTATGTGGAGTTCTTGGCCTTAGACTTATGGATGGAACGTG
GGTTGCGATGCAAACATCGGACGAAACCAAGTGGTGTCCTCCTGATCAGTTGGTAAATCTACACGACTTTCGCTCGGACGAGATTGAACATCTTGTT
GTGGAGGAGTTGGTCAAGAAAAGAGAGGAGTGTCTGGATGCACTAGAGTCCATCATGACTACCAAGTCGGTGAGTTTCAGACGTCTCAGCCATCTAA
GAAAACTTGTCCCTGGGTTCGGAAAAGCATATACCATATTCAACAAAACCTTGATGGAAGCAGATGCTCATTACAAGTCAGTCCGAACCTGGAATGA
GATCATCCCCTCCAAAGGGTGTTTGAGAGTGGGAGGGAGGTGTCATCCTCACGTGAATGGGGTGTTTTTTAACGGTATAATACTGGGTCCTGACGGC
CATGTTCTAATCCCAGAGATGCAATCATCCCTCCTTCAGCAGCATATGGAGTTGTTGGAATCCTCAGTTATCCCCCTGATGCACCCTTTAGCAGACC
CATCTACAGTTTTTAAGGACGGTGATGAAGCAGAGGATTTTGTTGAGGTTCACCTTCCCGACGTGCACAAACAAATTTCAGGTGTTGACCTGGGTCT
CCCCAGCTGGGGAAAGTATGTTTTGGTGAGTGCAGGGGTCTTGGTTGTCCTGATGTTGACAATTTTCATAATGACATGTTGCGGAAGAGTCCATCGA
CCCAAGTCTACGCAACACAGTCTCGGAGGGACCGGGAGGAAGGTGTCGGTCACTTCCCAAAGCGGGAAGGTCATATCTTCATGGGAGTCATATAAGA
GCGGGGGTGAGACCAGACTGTGA 
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Lyssavirus | West Caucasian bat lyssavirus | Russia.Bat.02.WCBV | WCBV | EF614258 | 1578 | 
GenScript | C1.6 
ATGGCTTCCTACTTTGCGTTGGTCTTGAACGGGATCTCTATGGTTTTCAGTCAAGGTCTTTTCCCCCTTTACACTATCCCTGACCATCTGGGACCAT
GGACCCCCATAGATCTAAGTCACCTTCACTGCCCGAACAATCTTTATACTGATGCCTCTTATTGTACAACTGAACAAAGCATAACCTACACAGAGTT
GAAGGTCGGATCATCTGTGTCACAAAAAATCCCCGGATTTACATGTACGGGGGTAAGAACTGAATCTGTAACATATACCAACTTTGTTGGCTATGTG
ACTACCACGTTCAAGAAAAAACACTTTCCTCCTAAATCCAGGGACTGTAGAGAGGCGTATGAGAGGAAGAAAGCAGGAGATCCTAGATATGAAGAGT
CTTTAGCCCACCCATATCCTGACAACAGTTGGCTGAGAACAGTGACTACAACAAAGGATTCCTGGGTGATCATCGAGCCCAGTGTAGTGGAGTTAGA
TATATACACAAGTGCCTTGTATTCACCTCTTTTCAAGGATGGAACATGTTCAAAATCTAGAACATATTCCCCCTACTGTCCAACCAATCATGACTTC
ACCATTTGGATGCCAGAGAGTGAAAACATAAGATCTGCCTGTAATCTGTTTTCCACAAGTAGAGGGAAACTAGTCAGGAACCGCACATCCACCTGCG
GGATTATCGATGAGAGAGGGCTGTTCAGATCAGTTAAAGGAGCATGCAAAATATCAATATGCGGTAGGCAGGGAATCCGTTTAGTGGATGGAACTTG
GATGTCTTTTAGATACTCAGAGTACTTACCTGTGTGTTCTCCATCACAGCTGATCAACACGCACGACATCAAGGTCGATGAGCTGGAGAATGCTATA
GTTTTAGACTTGATTAGGAGGAGAGAAGAATGTCTTGACACCCTAGAAACAATTTTGATGTCAGGATCTGTGAGTCACAGGAGGCTGAGTCATTTCA
GAAAGCTGGTTCCAGGATCTGGGAAGGCTTACTCTTATATAAACGGCACCTTAATGGAATCAGATGCTCACTACATCAAGGTAGAGAATTGGTCAGA
GGTCATCCCACACAAAGGATGTCTCATGGTCGGGGGCAAATGCTATGAGCCAGTCAATGATGTGTATTTCAACGGGATCATTCGGGATTCAAATAAT
CAGATCTTGATACCTGAGATGCAGTCCAGTCTTCTCAGAGAACATGTTGACCTGTTGAAGGCTAATATAGTTCCGTTCAGGCATCCAATGTTACTTA
GGTCCTTCACATCTGACACTGAAGAAGATATCGTCGAGTTTGTCAACCCTCATCTCCAAGATACCCAGAAGTTGGTGTCAGATATGGATCTCGGGTT
ATCAGACTGGAAGAGATATCTACTAATTGGATCTTTGGCCGTAGGAGGAGTGGTAGCAATCTTATTCATCGGAACATGTTGTCTGAGATGTAGAGCA
GGGAGAAACAGAAGAACAATCCGATCCAATCATAGGTCATTGTCCCATGACGTGGTGTTCCATAAAGATAAGGATAAAGTGATTACTTCTTGGGAAT
CTTACAAGGGACAAACTGCCCAATAA 
 
 
Vesiculovirus | Indiana vesiculovirus | Vesicular stomatitis Indiana virus (San Juan 56-NM-B) 
| VSV | M35219| 1536 | Addgene #12259 | - 
ATGAAGTGCCTTTTGTACTTAGCCTTTTTATTCATTGGGGTGAATTGCAAGTTCACCATAGTTTTTCCACACAACCAAAAAGGAAACTGGAAAAATG
TTCCTTCTAATTACCATTATTGCCCGTCAAGCTCAGATTTAAATTGGCATAATGACTTAATAGGCACAGCCATACAAGTCAAAATGCCCAAGAGTCA
CAAGGCTATTCAAGCAGACGGTTGGATGTGTCATGCTTCCAAATGGGTCACTACTTGTGATTTCCGCTGGTATGGACCGAAGTATATAACACAGTCC
ATCCGATCCTTCACTCCATCTGTAGAACAATGCAAGGAAAGCATTGAACAAACGAAACAAGGAACTTGGCTGAATCCAGGCTTCCCTCCTCAAAGTT
GTGGATATGCAACTGTGACGGATGCCGAAGCAGTGATTGTCCAGGTGACTCCTCACCATGTGCTGGTTGATGAATACACAGGAGAATGGGTTGATTC
ACAGTTCATCAACGGAAAATGCAGCAATTACATATGCCCCACTGTCCATAACTCTACAACCTGGCATTCTGACTATAAGGTCAAAGGGCTATGTGAT
TCTAACCTCATTTCCATGGACATCACCTTCTTCTCAGAGGACGGAGAGCTATCATCCCTGGGAAAGGAGGGCACAGGGTTCAGAAGTAACTACTTTG
CTTATGAAACTGGAGGCAAGGCCTGCAAAATGCAATACTGCAAGCATTGGGGAGTCAGACTCCCATCAGGTGTCTGGTTCGAGATGGCTGATAAGGA
TCTCTTTGCTGCAGCCAGATTCCCTGAATGCCCAGAAGGGTCAAGTATCTCTGCTCCATCTCAGACCTCAGTGGATGTAAGTCTAATTCAGGACGTT
GAGAGGATCTTGGATTATTCCCTCTGCCAAGAAACCTGGAGCAAAATCAGAGCGGGTCTTCCAATCTCTCCAGTGGATCTCAGCTATCTTGCTCCTA
AAAACCCAGGAACCGGTCCTGCTTTCACCATAATCAATGGTACCCTAAAATACTTTGAGACCAGATACATCAGAGTCGATATTGCTGCTCCAATCCT
CTCAAGAATGGTCGGAATGATCAGTGGAACTACCACAGAAAGGGAACTGTGGGATGACTGGGCACCATATGAAGACGTGGAAATTGGACCCAATGGA
GTTCTGAGGACCAGTTCAGGATATAAGTTTCCTTTATACATGATTGGACATGGTATGTTGGACTCCGATCTTCATCTTAGCTCAAAGGCTCAGGTGT
TCGAACATCCTCACATTCAAGACGCTGCTTCGCAACTTCCTGATGATGAGAGTTTATTTTTTGGTGATACTGGGCTATCCAAAAATCCAATCGAGCT
TGTAGAAGGTTGGTTCAGTAGTTGGAAAAGCTCTATTGCCTCTTTTTTCTTTATCATAGGGTTAATCATTGGACTATTCTTGGTTCTCCGAGTTGGT
ATCCATCTTTGCATTAAATTAAAGCACACCAAGAAAAGACAGATTTATACAGACATAGAGATGAACCGACTTGGAAAGTAA 
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Ebolavirus | Zaire ebolavirus | EBOV/Mayinga/COD/1976 | EBOV/May | EU224440 | 2031 | 
Graham Simmons, Bloodsystems USA | C2.1 
ATGGGCGTTACAGGAATATTGCAGTTACCTCGTGATCGATTCAAGAGGACATCATTCTTTCTTTGGGTAATTATCCTTTTCCAAAGAACATTTTCCA
TCCCACTTGGAGTCATCCACAATAGCACATTACAGGTTAGTGATGTCGACAAACTAGTTTGTCGTGACAAACTGTCATCCACAAATCAATTGAGATC
AGTTGGACTGAATCTCGAAGGGAATGGAGTGGCAACTGACGTGCCATCTGCAACTAAAAGATGGGGCTTCAGGTCCGGTGTCCCACCAAAGGTGGTC
AATTATGAAGCTGGTGAATGGGCTGAAAACTGCTACAATCTTGAAATCAAAAAACCTGACGGGAGTGAGTGTCTACCAGCAGCGCCAGACGGGATTC
GGGGCTTCCCCCGGTGCCGGTATGTGCACAAAGTATCAGGAACGGGACCGTGTGCCGGAGACTTTGCCTTCCATAAAGAGGGTGCTTTCTTCCTGTA
TGATCGACTTGCTTCCACAGTTATCTACCGAGGAACGACTTTCGCTGAAGGTGTCGTTGCATTTCTGATACTGCCCCAAGCTAAGAAGGACTTCTTC
AGCTCACACCCCTTGAGAGAGCCGGTCAATGCAACGGAGGACCCGTCTAGTGGCTACTATTCTACCACAATTAGATATCAGGCTACCGGTTTTGGAA
CCAATGAGACAGAGTACTTGTTCGAGGTTGACAATTTGACCTACGTCCAACTTGAATCAAGATTCACACCACAGTTTCTGCTCCAGCTGAATGAGAC
AATATATACAAGTGGGAAAAGGAGCAATACCACGGGAAAACTAATTTGGAAGGTCAACCCCGAAATTGATACAACAATCGGGGAGTGGGCCTTCTGG
GAAACTAAAAAAAACCTCACTAGAAAAATTCGCAGTGAAGAGTTGTCTTTCACAGTTGTATCAAACGGAGCCAAAAACATCAGTGGTCAGAGTCCGG
CGCGAACTTCTTCCGACCCAGGGACCAACACAACAACTGAAGACCACAAAATCATGGCTTCAGAAAATTCCTCTGCAATGGTTCAAGTGCACAGTCA
AGGAAGGGAAGCTGCAGTGTCGCATCTAACAACCCTTGCCACAATCTCCACGAGTCCCCAATCCCTCACAACCAAACCAGGTCCGGACAACAGCACC
CATAATACACCCGTGTATAAACTTGACATCTCTGAGGCAACTCAAGTTGAACAACATCACCGCAGAACAGACAACGACAGCACAGCCTCCGACACTC
CCTCTGCCACGACCGCAGCCGGACCCCCAAAAGCAGAGAACACCAACACGAGCAAGAGCACTGACTTCCTGGACCCCGCCACCACAACAAGTCCCCA
AAACCACAGCGAGACCGCTGGCAACAACAACACTCATCACCAAGATACCGGAGAAGAGAGTGCCAGCAGCGGGAAGCTAGGCTTAATTACCAATACT
ATTGCTGGAGTCGCAGGACTGATCACAGGCGGGAGAAGAACTCGAAGAGAAGCAATTGTCAATGCTCAACCCAAATGCAACCCTAATTTACATTACT
GGACTACTCAGGATGAAGGTGCTGCAATCGGACTGGCCTGGATACCATATTTCGGGCCAGCAGCCGAGGGAATTTACATAGAGGGGCTAATGCACAA
TCAAGATGGTTTAATCTGTGGGTTGAGACAGCTGGCCAACGAGACGACTCAAGCTCTTCAACTGTTCCTGAGAGCCACAACTGAGCTACGCACCTTT
TCAATCCTCAACCGTAAGGCAATTGATTTCTTGCTGCAGCGATGGGGCGGCACATGCCACATTCTGGGACCGGACTGCTGTATCGAACCACATGATT
GGACCAAGAACATAACAGACAAAATTGATCAGATTATTCATGATTTTGTTGATAAAACCCTTCCGGACCAGGGGGACAATGACAATTGGTGGACAGG
ATGGAGACAATGGATACCGGCAGGTATTGGAGTTACAGGCGTTGTAATTGCAGTTATCGCTTTATTCTGTATATGCAAATTTGTCTTTTAG 
 
 
Ebolavirus | Zaire ebolavirus | EBOV/Makona/GIN/2014/Kissidougou-C15 | EBOV/Mak | 
KJ660346 | 2031 | Alain Townsend, University of Oxford | C2.2 
ATGGGCGTGACCGGAATCCTGCAGCTGCCCAGAGACAGGTTCAAGCGGACCAGCTTCTTCCTGTGGGTGATCATCCTGTTCCAGCGGACCTTCAGCA
TCCCTCTGGGCGTGATCCACAACAGCACCCTGCAGGTCTCCGACGTGGACAAGCTCGTGTGCCGGGACAAGCTGAGCAGCACCAACCAGCTGCGGAG
CGTGGGCCTGAACCTGGAAGGCAACGGCGTGGCCACCGATGTGCCCAGCGCCACCAAGAGATGGGGCTTCAGATCCGGCGTGCCACCCAAGGTGGTG
AACTACGAAGCCGGCGAGTGGGCCGAGAACTGCTACAACCTGGAAATCAAGAAGCCCGACGGCAGCGAGTGCCTGCCTGCCGCTCCTGATGGCATCC
GGGGCTTCCCCAGATGCAGATACGTGCACAAGGTGTCCGGCACCGGCCCCTGTGCTGGCGACTTCGCCTTTCACAAAGAGGGCGCCTTTTTCCTGTA
CGACCGGCTCGCCAGCACCGTGATCTACCGGGGCACCACCTTTGCCGAGGGCGTGGTGGCCTTCCTGATCCTGCCCCAGGCCAAGAAGGACTTCTTC
AGCAGCCACCCTCTGCGCGAGCCCGTGAACGCCACAGAAGATCCCAGCAGCGGCTACTACAGCACCACCATCAGATACCAGGCCACCGGCTTCGGCA
CCAACGAGACAGAGTACCTGTTCGAGGTGGACAACCTGACCTACGTGCAGCTGGAAAGCCGGTTCACCCCTCAGTTTCTGCTGCAGCTGAACGAGAC
AATCTACGCCAGCGGCAAGCGGAGCAACACCACCGGCAAGCTGATCTGGAAAGTGAACCCCGAGATCGACACCACAATCGGAGAGTGGGCCTTCTGG
GAGACAAAGAAGAACCTGACCCGGAAGATCAGAAGCGAGGAACTGAGCTTCACCGCCGTGTCCAACGGCCCCAAGAACATCAGCGGCCAGAGCCCCG
CCAGAACCAGCAGCGACCCCGAGACAAACACCACCAACGAGGACCACAAGATCATGGCCAGCGAGAACAGCAGCGCCATGGTGCAGGTCCACAGCCA
GGGCAGAAAGGCCGCCGTGTCTCACCTGACCACCCTCGCCACCATCAGCACCAGCCCTCAGAGCCTGACCACCAAGCCTGGCCCCGACAACTCCACC
CACAACACCCCTGTGTACAAGCTGGACATCAGCGAGGCCACCCAAGTGGGACAGCACCACAGACGGGCCGACAACGACAGCACCGCCAGCGATACCC
CTCCAGCCACAACAGCCGCCGGACCCCTGAAGGCCGAGAACACCAACACCAGCAAGAGCGCCGACAGCCTGGATCTGGCCACCACAACCAGTCCTCA
GAACTACTCCGAGACAGCCGGCAACAACAACACCCACCACCAGGACACCGGCGAGGAAAGCGCCAGCTCTGGCAAGCTGGGCCTGATCACCAACACA
ATCGCCGGCGTGGCCGGACTGATCACCGGAGGCAGACGGACCAGACGGGAAGTGATCGTGAACGCCCAGCCCAAGTGCAACCCCAACCTGCACTACT
GGACCACCCAGGACGAGGGCGCTGCTATCGGCCTGGCCTGGATTCCTTACTTCGGCCCTGCCGCCGAGGGCATCTACACCGAGGGCCTGATGCACAA
CCAGGACGGCCTGATCTGCGGCCTGCGGCAGCTGGCCAATGAGACAACCCAGGCCCTGCAGCTGTTCCTGCGGGCCACCACCGAGCTGCGGACCTTC
TCCATCCTGAACAGAAAGGCCATCGACTTTCTGCTGCAGCGCTGGGGAGGCACCTGTCACATCCTGGGCCCCGACTGCTGCATCGAGCCCCACGACT
GGACCAAGAATATCACCGACAAGATCGACCAGATCATCCACGACTTCGTGGACAAGACCCTGCCCGACCAGGGCGACAACGATAACTGGTGGACCGG
CTGGCGGCAGTGGATTCCAGCCGGAATCGGAGTGACCGGCGTGATCATTGCCGTGATCGCCCTGTTCTGCATCTGCAAGTTCGTGTTCTGA 
  
 193 
 
Ebolavirus | Bundibugyo ebolavirus | BDBV/UGA/2007 | BDBV | FJ217161 | 2031 | 
Synthesised, BioBasic | C2.3 
ATGGTTACATCAGGAATTCTACAATTGCCCCGTGAACGCTTCAGAAAAACATCATTTTTTGTTTGGGTAATAATCCTATTTCACAAAGTTTTCCCTA
TCCCATTGGGCGTAGTTCACAACAACACTCTCCAGGTAAGTGATATAGATAAATTGGTGTGCCGGGATAAACTTTCCTCCACAAGTCAGCTGAAATC
GGTCGGGCTTAATCTAGAAGGTAATGGAGTTGCCACAGATGTACCAACAGCAACGAAGAGATGGGGATTCCGAGCTGGTGTTCCACCCAAAGTGGTG
AACTACGAAGCTGGGGAGTGGGCTGAAAACTGCTACAACCTGGACATCAAGAAAGCAGATGGTAGCGAATGCCTACCTGAAGCCCCTGAGGGTGTAA
GAGGCTTCCCTCGCTGCCGTTATGTGCACAAGGTTTCTGGAACAGGGCCGTGCCCTGAAGGTTACGCTTTCCACAAAGAAGGCGCTTTCTTCCTGTA
TGATCGACTGGCATCAACAATCATCTATCGAAGCACCACGTTTTCAGAAGGTGTTGTGGCTTTCTTGATCCTCCCCGAAACTAAAAAGGACTTTTTC
CAATCGCCACCACTACATGAACCGGCCAATATGACAACAGACCCATCCAGCTACTACCACACAGTCACACTTAATTATGTGGCTGACAATTTTGGGA
CCAATATGACTAACTTTCTGTTTCAAGTGGATCATCTAACTTATGTGCAACTTGAACCAAGATTCACACCACAATTTCTTGTCCAACTCAATGAGAC
CATTTATACTAATGGGCGTCGCAGCAACACCACAGGAACACTAATTTGGAAAGTAAATCCTACTGTTGACACCGGCGTAGGTGAATGGGCCTTCTGG
GAAAATAAAAAAAACTTCACAAAAACCCTTTCAAGTGAAGAGCTGTCTGTCATATTTGTACCAAGAGCCCAGGATCCAGGCAGCAACCAGAAGACGA
AGGTCACTCCCACCAGCTTCGCCAACAACCAAACCTCCAAGAACCACGAAGACTTGGTTCCAGAGGATCCCGCTTCAGTGGTTCAAGTGCGAGACCT
CCAGAGGGAAAACACAGTGCCGACCCCACCCCCAGACACAGTCCCCACAACTCTGATCCCCGACACAATGGAGGAACAAACCACCAGCCACTACGAA
CCACCAAACATTTCCAGAAACCATCAAGAGAGGAACAACACCGCACACCCCGAAACTCTCGCCAACAATCCCCCAGACAACACAACCCCGTCGACAC
CACCTCAAGACGGTGAGCGGACAAGTTCCCACACAACACCCTCCCCCCGCCCAGTCCCAACCAGCACAATCCATCCCACCACACGAGAGACTCACAT
TCCCACCACAATGACAACAAGCCATGACACCGACAGCAATCGACCCAACCCAATTGACATCAGCGAGTCTACAGAGCCAGGACCACTCACCAACACC
ACAAGAGGGGCTGCAAATCTGCTGACAGGCTCAAGAAGAACCCGAAGGGAAATCACCCTGAGAACACAAGCCAAATGCAACCCAAACCTACACTATT
GGACAACCCAAGATGAAGGGGCTGCCATTGGTTTAGCCTGGATACCTTACTTCGGGCCCGCAGCAGAGGGAATTTATACGGAAGGGATAATGCACAA
TCAAAATGGGCTAATTTGCGGGTTGAGGCAGCTAGCAAATGAGACGACTCAAGCCCTACAGTTATTCTTGCGTGCTACCACGGAATTGCGCACTTTC
TCTATATTGAATCGAAAAGCCATCGACTTTTTACTCCAAAGATGGGGAGGAACGTGCCACATCTTAGGCCCAGATTGCTGTATTGAGCCCCATGATT
GGACTAAGAACATTACTGACAAAATAGATCAAATCATTCATGATTTCATTGATAAACCTCTACCAGATCAAACAGATAATGACAATTGGTGGACAGG
GTGGAGGCAATGGGTTCCTGCCGGGATCGGGATCACGGGGGTAATAATCGCAGTTATAGCACTGCTGTGTATTTGCAAATTTCTACTCTAA 
 
 
Ebolavirus | Tai Forest ebolavirus | TAFV/CIV/1994 | TAFV | FJ217162 | 2031 | Graham 
Simmons, Bloodsystems USA | C2.4 
ATGGGAGCGTCAGGGATTCTGCAATTGCCCCGTGAGCGCTTCAGGAAAACATCTTTCTTTGTTTGGGTAATAATCCTATTCCATAAAGTCTTTTCAA
TCCCGTTGGGGGTTGTACACAACAATACCCTACAAGTGAGTGATATTGACAAGTTTGTGTGCCGAGACAAACTCTCTTCAACTAGCCAATTGAAGTC
AGTCGGGTTGAACTTGGAGGGCAATGGAGTAGCAACTGATGTACCAACGGCAACCAAAAGATGGGGTTTTCGAGCTGGTGTTCCACCAAAGGTGGTA
AATTGCGAAGCTGGAGAATGGGCTGAGAACTGTTATAACCTGGCTATAAAGAAAGTTGATGGTAGTGAGTGCCTACCAGAAGCCCCTGAGGGAGTGA
GGGATTTTCCCCGTTGCCGCTATGTACACAAAGTCTCAGGAACTGGACCATGCCCAGGAGGACTCGCCTTTCACAAAGAAGGAGCCTTCTTCCTGTA
TGACCGACTCGCATCAACAATCATTTATCGGGGTACAACCTTTGCCGAAGGAGTTATTGCATTTCTGATCTTGCCTAAGGCGCGAAAGGATTTTTTC
CAGTCTCCTCCATTGCATGAGCCTGCCAACATGACCACGGATCCCTCCAGTTACTATCACACGACAACAATAAACTACGTGGTTGATAATTTTGGAA
CCAACACCACAGAGTTTCTGTTCCAAGTCGATCATTTGACGTATGTGCAGCTCGAGGCAAGATTCACACCACAATTCCTTGTCCTCCTAAATGAAAC
CATCTACTCTGATAACCGCAGAAGTAACACAACAGGAAAACTAATCTGGAAAATAAATCCCACTGTTGATACCAGCATGGGTGAGTGGGCTTTCTGG
GAAAATAAAAAAAACTTCACAAAAACCCTTTCAAGTGAAGAGTTGTCTTTCGTACCTGTACCAGAAACCCAGAACCAGGTCCTTGACACGACAGCGA
CGGTCTCTCCTCCCATCTCCGCCCACAACCACGCAGCCGAAGACCACAAAGAATTGGTTTCAGAGGATTCCACTCCAGTGGTTCAGATGCAAAACAT
CAAGGGAAAGGACACAATGCCAACCACAGTGACGGGTGTACCAACAACCACACCCTCTCCATTTCCAATCAATGCTCGCAACACTGATCATACCAAA
TCATTTATCGGCCTGGAGGGGCCCCAAGAAGACCACAGCACCACACAGCCTGCCAAGACCACCAGCCAACCAACCAACAGCACAGAATCGACGACAC
TAAACCCAACATCAGAGCCCTCCAGTAGAGGCACGGGACCATCCAGCCCCACGGTCCCCAACACCACAGAAAGCCACGCCGAACTTGGCAAGACAAC
CCCAACCACACTCCCAGAACAGCACACTGCCGCCAGTGCCATTCCAAGAGCCGTGCACCCCGACGAACTCAGTGGACCTGGCTTCCTGACGAACACA
ATACGGGGGGTTACAAATCTCCTGACAGGATCCAGAAGAAAGCGAAGGGATGTCACTCCCAATACACAACCCAAATGCAACCCAAACCTGCACTATT
GGACAGCCTTGGATGAGGGTGCTGCCATAGGTTTAGCCTGGATACCATACTTCGGGCCAGCAGCTGAGGGAATTTACACTGAAGGCATAATGGAGAA
TCAAAATGGATTGATCTGTGGATTGAGGCAGCTGGCCAACGAAACGACACAAGCTCTTCAATTGTTCTTAAGGGCAACTACTGAGTTGCGTACATTC
TCTATACTAAATCGGAAAGCAATAGACTTCTTGCTCCAAAGATGGGGAGGAACATGTCACATTCTAGGGCCTGATTGTTGCATTGAACCCCAAGATT
GGACCAAAAATATCACTGATAAAATTGATCAAATAATCCATGACTTTGTCGATAATAATCTTCCAAATCAGAATGATGGCAGCAACTGGTGGACTGG
ATGGAAACAATGGGTTCCTGCTGGAATAGGAATCACAGGAGTAATCATTGCTATTATTGCTTTGCTGTGCATTTGCAAATTCATGCTTTGA 
  
 194 
 
Ebolavirus | Sudan ebolavirus | SUDV/Boniface/SUD/1976 | SUDV | FJ968794 | 2031 | Graham 
Simmons, Bloodsystems USA | C2.5 
ATGGAGGGTCTTAGCCTACTCCAATTGCCCAGAGATAAATTTCGAAAAAGCTCTTTCTTTGTTTGGGTCATCATCTTATTTCAAAAGGCCTTTTCCA
TGCCTTTGGGTGTTGTGACCAACAGCACTTTAGAAGTAACAGAGATTGACCAGCTAGTCTGCAAGGATCATCTTGCATCCACTGACCAGCTGAAATC
AGTTGGTCTCAACCTCGAGGGGAGCGGAGTATCTACTGATATCCCATCTGCGACAAAGCGTTGGGGCTTCAGATCTGGTGTGCCTCCCAAGGTGGTC
AGCTATGAAGCAGGAGAATGGGCTGAAAATTGCTACAATCTTGAAATAAAGAAGCCGGACGGGAGCGAATGCTTACCCCCACCGCCGGATGGTGTCA
GAGGCTTTCCAAGGTGCCGCTATGTTCACAAAGCCCAAGGAACCGGGCCCTGCCCGGGTGACTATGCCTTTCACAAGGATGGAGCTTTCTTCCTCTA
TGACAGGCTGGCTTCAACTGTAATTTACAGAGGAGTCAATTTTGCTGAGGGGGTAATTGCATTCTTGATATTGGCTAAACCAAAGGAAACGTTCCTT
CAATCACCCCCCATTCGAGAGGCAGTAAACTACACTGAAAATACATCAAGTTACTATGCCACATCCTACTTGGAGTACGAAATCGAAAATTTTGGTG
CTCAACACTCCACGACCCTTTTCAAAATTAACAATAATACTTTTGTTCTTCTGGACAGGCCCCACACGCCTCAGTTCCTTTTCCAGCTGAATGATAC
CATTCACCTTCACCAACAGTTGAGCAACACAACTGGGAAACTAATTTGGACACTAGATGCTAATATCAATGCTGATATTGGTGAATGGGCTTTTTGG
GAAAATAAAAAAAATCTCTCCGAACAACTACGTGGAGAAGAGCTGTCTTTCGAAACTTTATCGCTCAACGAGACAGAAGACGATGATGCGACATCGT
CGAGAACTACAAAGGGAAGAATCTCCGACCGGGCCACCAGGAAGTATTCGGACCTGGTTCCAAAGGATTCCCCTGGGATGGTTTCATTGCACGTACC
AGAAGGGGAAACAACATTGCCGTCTCAGAATTCGACAGAAGGTCGAAGAGTAGATGTGAATACTCAGGAAACTATCACAGAGACAACTGCAACAATC
ATAGGCACTAACGGTAACAACATGCAGATCTCCACCATCGGGACAGGACTGAGCTCCAGCCAAATCCTGAGTTCCTCACCGACCATGGCACCAAGCC
CTGAGACTCAGACCTCCACAACCTACACACCAAAACTACCAGTGATGACCACCGAGGAATCAACAACACCACCGAGAAACTCTCCTGGCTCAACAAC
AGAAGCACCCACTCTCACCACCCCAGAGAATATAACAACAGCGGTTAAAACTGTTTTGCCACAAGAGTCCACAAGCAACGGTCTAATAACTTCAACA
GTAACAGGGATTCTTGGGAGCCTTGGACTTCGAAAACGCAGCAGAAGACAAGTTAACACCAGGGCCACGGGTAAATGCAATCCCAACTTACACTACT
GGACTGCACAAGAACAACATAATGCTGCTGGGATTGCCTGGATCCCGTACTTTGGACCGGGTGCAGAAGGCATATACACTGAAGGCCTTATGCACAA
CCAAAATGCCTTAGTCTGTGGACTCAGACAACTTGCAAATGAAACAACTCAAGCTCTGCAGCTTTTCTTAAGGGCCACGACGGAGCTGCGGACATAT
ACCATACTCAATAGGAAGGCCATAGATTTCCTTCTGCGACGATGGGGCGGGACATGTAGGATCCTGGGACCAGATTGTTGCATTGAGCCACATGATT
GGACCAAAAACATCACTGATAAAATCAACCAAATCATCCATGATTTCATCGACAACCCTTTACCCAATCAGGATAATGATGATAATTGGTGGACGGG
CTGGAGACAGTGGATCCCTGCAGGAATAGGCATTACTGGAATTATTATTGCAATCATTGCTCTTCTTTGCGTCTGCAAGCTGCTTTGTTGA 
 
 
Ebolavirus | Reston ebolavirus | RESTV/Pennsylvania/USA/1989 | RESTV | AY769362 | 2034 | 
Graham Simmons, Bloodsystems USA | C2.6 
ATGGGGTCAGGATATCAACTTCTCCAATTGCCTCGGGAACGTTTTCGTAAAACTTCGTTCTTAGTATGGGTAATCATCCTCTTCCAGCGAGCAATCT
CCATGCCGCTTGGTATAGTGACAAATAGCACTCTCAAAGCAACAGAAATTGATCAATTGGTTTGTCGGGACAAACTGTCATCAACCAGTCAGCTCAA
GTCTGTGGGGCTGAATCTGGAAGGAAATGGAATTGCAACCGATGTCCCATCAGCAACAAAACGCTGGGGATTTCGTTCAGGTGTGCCTCCCAAGGTG
GTCAGCTATGAAGCCGGAGAATGGGCAGAAAATTGCTACAATCTGGAGATCAAAAAGTCAGACGGAAGTGAATGCCTCCCTCTCCCTCCCGACGGTG
TACGAGGATTCCCTAGATGTCGCTATGTCCACAAAGTTCAAGGAACAGGTCCTTGTCCCGGTGACTTAGCTTTCCATAAAAATGGGGCTTTTTTCTT
GTATGATAGATTGGCCTCAACTGTCATCTACCGAGGGACAACTTTTGCTGAAGGTGTCGTAGCTTTTTTAATTCTGTCAGAGCCCAAGAAGCATTTT
TGGAAGGCTACACCAGCTCATGAACCGGTGAACACAACAGATGATTCCACAAGCTACTACATGACCCTGACACTCAGCTACGAGATGTCAAATTTTG
GGGGCAATGAAAGTAACACCCTTTTTAAGGTAGACAACCACACATATGTGCAACTAGATCGTCCACACACTCCGCAGTTCCTTGTTCAGCTCAATGA
AACACTTCGAAGAAATAATCGCCTTAGCAACAGTACAGGGAGATTGACTTGGACATTGGATCCTAAAATTGAACCAGATGTTGGTGAGTGGGCCTTC
TGGGAAACTAAAAAAAACTTTTCCCAACAACTTCATGGAGAAAACTTGCATTTCCAAATTCTATCAACCCACACCAACAACTCCTCAGATCAGAGCC
CGGCGGGAACTGTCCAAGGAAAAATTAGCTACCACCCACCCGCCAACAACTCCGAGCTGGTTCCAACGGATTCCCCTCCAGTGGTTTCAGTGCTCAC
TGCAGGACGGACAGAGGAAATGTCGACCCAAGGTCTAACCAACGGAGAGACAATCACAGGTTTCACCGCGAACCCAATGACAACCACCATTGCCCCA
AGTCCAACCATGACAAGCGAGGTTGATAACAATGTACCAAGTGAACAACCGAACAACACAGCATCCATTGAAGACTCCCCCCCATCGGCAAGCAACG
AGACAATTTACCACTCCGAGATGGATCCGATCCAAGGCTCGAACAACTCCGCCCAGAGCCCACAGACCAAGACCACGCCAGCACCCACAACATCCCC
GATGACCCAGGACCCGCAAGAGACGGCCAACAGCAGCAAACCAGGAACCAGCCCAGGAAGCGCAGCCGGACCAAGTCAGCCCGGACTCACTATAAAT
ACAGTAAGTAAGGTAGCTGATTCACTGAGTCCCACCAGGAAACAAAGGCGATCGGTTCGACAAAACACCGCTAATAAATGTAACCCAGATCTTTACT
ATTGGACAGCTGTTGATGAGGGGGCAGCAGTAGGATTGGCATGGATTCCATATTTCGGACCTGCAGCAGAAGGCATCTACATTGAGGGTGTAATGCA
TAATCAGAATGGGCTTATTTGCGGGCTACGTCAGCTAGCCAATGAAACTACCCAGGCTCTTCAATTATTTCTGCGGGCCACAACAGAACTGAGGACT
TACTCACTTCTTAACAGAAAAGCTATTGATTTTCTTCTTCAACGATGGGGAGGTACCTGTCGAATCCTAGGACCATCTTGTTGCATTGAGCCACATG
ATTGGACAAAAAATATTACTGATGAAATTAACCAAATTAAACATGACTTTATTGACAATCCCCTACCAGACCACGGAGATGATCTTAATCTATGGAC
AGGTTGGAGACAATGGATCCCGGCTGGAATTGGGATTATTGGAGTTATAATTGCTATAATAGCCCTACTTTGTATATGTAAGATTTTGTGT 
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Cuevavirus | Lloviu cuevavirus | LLOV/ESP/2003 | LLOV | JF828358 | 2154 | Ayato Takada | - 
ATGGTGCCCACCTACCCGTACAGCAGCCTATTAGATTGGAGACCACCACCAAACACCCTACCATGGATCCTCAACCTTGTGGTCTTTTATACCATAG
CCTGGCTGCCCGGGGGAGTCTCAGGAATTCCACTCGGTTTGTTGGGAAACAACAGCATCACCCAAACTGTCGTGGACAATGTAGTGTGCAAGGAACA
CCTTGCCACAACAGATCAGCTACAGGCTATTGGATTGGGACTAGAGGGGCTTGGTGAACATGCTGACCTCCCGACTGCCACCAAGCGATGGGGTTTT
CGATCTGATGTCATCCCAAAAATCGTGGGATACACCGCTGGGGAATGGGTGGAAAACTGCTACAATCTTGAAATCACCAAGAAAGATGGTCATCCTT
GCCTCCCCAGCCCGCCAACTGGCTTACTTGGCTATCCCCGATGCCGCTATGTCCACAGAGCCAAAGGAGCAGGCCCTTGCCCAGGTGGGAATGCTTT
CCACAAACATGGTTCTTTCTTTCTGTACCACGGTATGGCTTCTACAGTAATTTATCATGGTGTAACCTTTACGGAAGGCACAATTGCTTTCCTAATT
GTCCCGAAGGATGCACCCCGTCTCAAGGCAGGGCTTGGAACAGGATTCAGTCATCAAGCAGAGAACCAAAACCCAAACAACCAATTTCGAACAACAA
CTTTAGATTATGATGTAATGAGTCCTTGGATGGACAATGCTACCTTCTTCTTTCGAGCGAGGGAAGACACATCAATGCTAATCCAAACAAGGTACCC
TCCAGCAAATCTAGAGCTTGTTCAAGAAAGATTGGCTAATCTTACCGGAGATCAAGCTGATCCATCAAAGATGGAAGAGATTGTCGCTGAGGTTTTG
ACATTGGAGCTCGGTGATTGGTCCGGTTGGACAACTAAAAAAAACCGCAGTACAAACCATACGGCTAAGAAACCCTTCACCAGCATCTGGTTCAACC
AAGGACAAGACTGGCCAGAAGCCCATGACGGATCATCAGGAGTTCATCCTCCAACCTCATTCTGCTGTTGGACAACCCTGCCTCTGGAACATTCTTC
GAACTCCGGGGCGGAACCCTGCACGAAGGCACCGGCGGGAAACACCACCAACAATGTCCATCACTGCTGCTCCTGGGTCAGGATACAAGCCGTACAT
CCAGGCAATACCTCTGGTGAAATTTCGATGCCATTGGGAGGGTCTTCGGCATGTGTGTCGTCGATACCCCTCCTGGGTTCAGTGAGCAACAATAGTT
CAATACAGGAGCTTGAGACTTCATCTAAAAGTGCAACAGAATTGACAACTCCCATCAATCACTCCCAATCACTACAGCTCGCATCCGTCACAAACAC
CCCCACACCGACAACACAGTCCAAGTCCTGGACAGTTGACTACAACAACACAACGCCAACCATGGATCCCACAACAATACTGACGACACCCGACACC
GCAACCATTCCCCCTAACAACTCATCTGATCACAACGCCACAACAACAAGCAAAACAAGACGAAGGAGACAGGTCAACCCAGTGCCCCCAACGATCA
CCCAACAAACCTCTACAAGCATCAATACCTCCCACCACCCCAATATGACAACACAGTTAGCAAGACATCCGAGTGTGCAAACAAGGATGCAAAACCC
CAGCTGTAATCCCAACCTTAGATACTGGACAAGCCGGGAGATGAGTAATGCTGGGGGGCTTGCATGGATTCCATGGATTGGACCAGGGATTGAGGGA
GGGATCACAGACGGGATAATGGAGCATCAGAACACAATTGTCTGTCAGTTACGGGAGCTCGCGAACACCACTACTAAAGCCCTACAGCTTTTCCTCC
GGGCTACCACTGAGCTCCGAACCTACTCTATCCTCAACCGCCATGCGATTGACTTTCTACTACAGCGTTGGGGTGGTACCTGCAGAATCCTTGGCCC
AAACTGCTGTATCGAACCTCATGATTGGTCTGCCAACATTACGGCTGAGATAAATCATATTAGAGAAGATATCCTGAACCATCATGAGATCCAACCT
TCTCAAGACCCCTCCTTTTGGACTGGATGGCAACAGTGGATCCCAACAGGAGCCAGTGCTCTCGGAATCATCCTGGCAATATTAGCCTTGATTTGTC
TGTGCAGAATAACACGATGA 
 
Marburgvirus | Marburg marburgvirus | RAVV/KEN/1987/KitumCave | RAVV | DQ447649 | 
2046 | Graham Simmons, Bloodsystems USA | - 
ATGAAGACCATATATTTTCTGATTAGTCTCATTTTAATCCAAAGTATAAAAACTCTCCCTGTTTTAGAAATTGCTAGTAACAGCCAACCTCAAGATG
TAGATTCAGTGTGCTCCGGAACCCTCCAAAAGACAGAAGATGTTCATCTGATGGGATTTACACTGAGTGGGCAAAAAGTTGCTGATTCCCCTTTGGA
AGCATCTAAACGATGGGCTTTCAGGACAGGTGTTCCTCCCAAGAACGTTGAGTATACGGAAGGAGAAGAAGCCAAAACATGTTACAATATAAGTGTA
ACAGACCCTTCTGGAAAATCCTTGCTGCTGGATCCTCCCAGTAATATCCGCGATTACCCTAAATGTAAAACTGTTCATCATATTCAAGGTCAAAACC
CTCATGCACAGGGGATTGCCCTCCATTTGTGGGGGGCATTTTTCTTGTATGATCGCGTTGCCTCTACAACAATGTACCGAGGCAAGGTCTTCACTGA
AGGAAATATAGCAGCTATGATTGTTAATAAGACAGTTCACAGAATGATTTTTTCTAGGCAAGGACAAGGTTATCGTCACATGAACTTGACCTCCACC
AATAAATATTGGACAAGCAGCAATGAAACGCAGAGAAATGATACGGGATGTTTTGGCATCCTCCAAGAATACAACTCCACAAACAATCAAACATGCC
CTCCATCTCTTAAACCTCCATCCCTGCCCACAGTAACTCCGAGCATTCACTCTACAAATACTCAAATTAATACTGCTAAATCTGGAACTATGAACCC
AAGTAGCGACGATGAGGACCTTATGATTTCCGGCTCAGGATCTGGAGAACAGGGGCCCCACACAACTCTTAATGTAGTCACTGAACAGAAACAATCG
TCAACAATATTGTCCACTCCTTCACTACATCCAAGCACCTCACAACATGAGCAAAACAGTACGAATCCTTCCCGACATGCTGTAACTGAGCACAATG
GAACCGACCCAACAACACAACCAGCAACGCTCCTCAACAATACTAATACAACTCCCACCTATAACACTCTCAAGTACAACCTCAGTACTCCTTCCCC
TCCAACCCGCAACATCACCAATAATGATACACAACGTGAACTAGCAGAAAGCGAACAAACCAATGCTCAGTTGAACACAACTCTAGATCCAACAGAA
AATCCCACCACAGGACAAGACACCAACAGCACAACCAACATCATCATGACGACATCAGATATAACAAGCAAACACCCCACAAATTCTTCTCCGGATT
CTAGTCCGACAACCCGCCCTCCTATATACTTTAGAAAGAAACGAAGCATTTTCTGGAAAGAAGGTGATATATTCCCGTTTTTAGATGGGTTAATAAA
TACTGAAATTGATTTTGATCCAATCCCAAACACAGAAACAATCTTTGATGAATCTCCCAGCTTTAATACTTCAACTAATGAGGAACAACACACTCCC
CCGAATATCAGTTTAACTTTCTCTTATTTTCCTGATAAAAATGGAGATACTGCCTACTCTGGGGAAAACGAGAATGATTGTGATGCAGAGTTGAGGA
TTTGGAGTGTGCAGGAGGACGATTTGGCGGCAGGGCTTAGCTGGATACCATTTTTTGGCCCTGGAATCGAAGGACTCTATACTGCCGGTTTAATCAA
AAATCAGAACAATTTAGTTTGTAGGTTGAGGCGCTTAGCTAATCAAACTGCTAAATCCTTGGAGCTCTTGTTAAGGGTCACAACCGAGGAAAGGACA
TTTTCCTTAATCAATAGGCATGCAATTGACTTTTTGCTTACGAGGTGGGGCGGAACATGCAAGGTGCTAGGACCTGATTGTTGCATAGGAATAGAAG
ATCTATCTAAAAATATCTCAGAACAAATCGACAAAATCAGAAAGGATGAACAAAAGGAGGAAACTGGCTGGGGTCTAGGTGGCAAATGGTGGACATC
TGACTGGGGTGTTCTCACCAATTTGGGCATCCTGCTACTATTATCTATAGCTGTTCTGATTGCTCTGTCCTGTATCTGTCGTATCTTCACTAAATAC
ATTGGATGA  
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Influenzavirus A | Influenza A virus | A/Vietnam/1194/2004(H5N1) haemagglutinin | HA | 
ABP51976 | 1707 | Nigel Temperton, University of Kent | - 
ATGGAGAAAATAGTGCTTCTTTTTGCAATAGTCAGTCTTGTTAAAAGTGATCAGATTTGCATTGGTTACCATGCAAACAACTCGACAGAGCAGGTTG
ACACAATAATGGAAAAGAACGTTACTGTTACACATGCCCAAGACATACTGGAAAAGACACACAATGGGAAGCTCTGCGATCTAGATGGAGTGAAGCC
TCTAATTTTGAGAGATTGTAGTGTAGCTGGATGGCTCCTCGGAAACCCAATGTGTGACGAATTCATCAATGTGCCGGAATGGTCTTACATAGTGGAG
AAGGCCAATCCAGTCAATGACCTCTGTTACCCAGGGGATTTCAATGACTATGAAGAATTGAAACACCTATTGAGCAGAATAAACCATTTTGAGAAAA
TTCAGATCATCCCCAAAAGTTCTTGGTCCAGTCATGAAGCCTCATTGGGGGTGAGCTCAGCATGTCCATACCAGGGAAAGTCCTCCTTTTTCAGAAA
TGTGGTATGGCTTATCAAAAAGAACAGTACATACCCAACAATAAAGAGGAGCTACAATAATACCAACCAAGAAGATCTTTTGGTACTGTGGGGGATT
CACCATCCTAATGATGCGGCAGAGCAGACAAAGCTCTATCAAAACCCAACCACCTATATTTCCGTTGGGACATCTACACTAAACCAGAGATTGGTAC
CAAGAATAGCTACTAGATCCAAAGTAAACGGGCAAAGTGGAAGGATGGAGTTCTTCTGGACAATTTTAAAACCGAATGATGCAATCAACTTCGAGAG
TAATGGAAATTTCATTGCTCCAGAATATGCATACAAAATTGTCAAGAAAGGGGACTCAACAATTATGAAAAGTGAATTGGAATATGGTAACTGCAAC
ACCAAGTGTCAAACTCCAATGGGGGCGATAAACTCTAGCATGCCATTCCACAATATACACCCTCTCACCATCGGGGAATGCCCCAAATATGTGAAAT
CAAACAGATTAGTCCTTGCGACTGGGCTCAGAAATAGCCCTCAAAGAGAGAGAAGAAGAAAAAAGAGAGGATTATTTGGAGCTATAGCAGGTTTTAT
AGAGGGAGGATGGCAGGGAATGGTAGATGGTTGGTATGGGTACCACCATAGCAACGAGCAGGGGAGTGGGTACGCTGCAGACAAAGAATCCACTCAA
AAGGCAATAGATGGAGTCACCAATAAGGTCAACTCGATTATTGACAAAATGAACACTCAGTTTGAGGCCGTTGGAAGGGAATTTAACAACTTAGAAA
GGAGAATAGAGAATTTAAACAAGAAGATGGAAGACGGGTTCCTAGATGTCTGGACTTATAATGCTGAACTTCTAGTTCTCATGGAAAACGAGAGAAC
TCTAGACTTTCATGACTCAAATGTCAAGAACCTTTACGACAAGGTCCGACTACAGCTTAGGGATAATGCAAAGGAGCTGGGTAACGGTTGTTTCGAG
TTCTATCATAAATGTGATAATGAATGTATGGAAAGTGTAAGAAACGGAACGTATGACTACCCGCAGTATTCAGAAGAAGCAAGACTAAAAAGAGAGG
AAATAAGTGGAGTAAAATTGGAATCAATAGGAATTTACCAAATATTGTCAATTTATTCTACAGTGGCGAGCTCCCTAGCACTGGCAATCATGGTAGC
TGGTCTATCCTTATGGATGTGCTCCAATGGGTCGTTACAATGCAGAATTTGCATTTAA 
 
Lentivirus | Human Immunodeficiency Virus 1 | HXB2 gp160 | HIV | K03455 | 2571 | Greg 
Towers, UCL | - 
ATGAGAGTGAAGGAGAAATATCAGCACTTGTGGAGATGGGGGTGGAGATGGGGCACCATGCTCCTTGGGATGTTGATGATCTGTAGTGCTACAGAAA
AATTGTGGGTCACAGTCTATTATGGGGTACCTGTGTGGAAGGAAGCAACCACCACTCTATTTTGTGCATCAGATGCTAAAGCATATGATACAGAGGT
ACATAATGTTTGGGCCACACATGCCTGTGTACCCACAGACCCCAACCCACAAGAAGTAGTATTGGTAAATGTGACAGAAAATTTTAACATGTGGAAA
AATGACATGGTAGAACAGATGCATGAGGATATAATCAGTTTATGGGATCAAAGCCTAAAGCCATGTGTAAAATTAACCCCACTCTGTGTTAGTTTAA
AGTGCACTGATTTGAAGAATGATACTAATACCAATAGTAGTAGCGGGAGAATGATAATGGAGAAAGGAGAGATAAAAAACTGCTCTTTCAATATCAG
CACAAGCATAAGAGGTAAGGTGCAGAAAGAATATGCATTTTTTTATAAACTTGATATAATACCAATAGATAATGATACTACCAGCTATAAGTTGACA
AGTTGTAACACCTCAGTCATTACACAGGCCTGTCCAAAGGTATCCTTTGAGCCAATTCCCATACATTATTGTGCCCCGGCTGGTTTTGCGATTCTAA
AATGTAATAATAAGACGTTCAATGGAACAGGACCATGTACAAATGTCAGCACAGTACAATGTACACATGGAATTAGGCCAGTAGTATCAACTCAACT
GCTGTTAAATGGCAGTCTAGCAGAAGAAGAGGTAGTAATTAGATCTGTCAATTTCACGGACAATGCTAAAACCATAATAGTACAGCTGAACACATCT
GTAGAAATTAATTGTACAAGACCCAACAACAATACAAGAAAAAGAATCCGTATCCAGAGAGGACCAGGGAGAGCATTTGTTACAATAGGAAAAATAG
GAAATATGAGACAAGCACATTGTAACATTAGTAGAGCAAAATGGAATAACACTTTAAAACAGATAGCTAGCAAATTAAGAGAACAATTTGGAAATAA
TAAAACAATAATCTTTAAGCAATCCTCAGGAGGGGACCCAGAAATTGTAACGCACAGTTTTAATTGTGGAGGGGAATTTTTCTACTGTAATTCAACA
CAACTGTTTAATAGTACTTGGTTTAATAGTACTTGGAGTACTGAAGGGTCAAATAACACTGAAGGAAGTGACACAATCACCCTCCCATGCAGAATAA
AACAAATTATAAACATGTGGCAGAAAGTAGGAAAAGCAATGTATGCCCCTCCCATCAGTGGACAAATTAGATGTTCATCAAATATTACAGGGCTGCT
ATTAACAAGAGATGGTGGTAATAGCAACAATGAGTCCGAGATCTTCAGACCTGGAGGAGGAGATATGAGGGACAATTGGAGAAGTGAATTATATAAA
TATAAAGTAGTAAAAATTGAACCATTAGGAGTAGCACCCACCAAGGCAAAGAGAAGAGTGGTGCAGAGAGAAAAAAGAGCAGTGGGAATAGGAGCTT
TGTTCCTTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGCGCAGCCTCAATGACGCTGACGGTACAGGCCAGACAATTATTGTCTGGTATAGTGCA
GCAGCAGAACAATTTGCTGAGGGCTATTGAGGCGCAACAGCATCTGTTGCAACTCACAGTCTGGGGCATCAAGCAGCTCCAGGCAAGAATCCTGGCT
GTGGAAAGATACCTAAAGGATCAACAGCTCCTGGGGATTTGGGGTTGCTCTGGAAAACTCATTTGCACCACTGCTGTGCCTTGGAATGCTAGTTGGA
GTAATAAATCTCTGGAACAGATTTGGAATCACACGACCTGGATGGAGTGGGACAGAGAAATTAACAATTACACAAGCTTAATACACTCCTTAATTGA
AGAATCGCAAAACCAGCAAGAAAAGAATGAACAAGAATTATTGGAATTAGATAAATGGGCAAGTTTGTGGAATTGGTTTAACATAACAAATTGGCTG
TGGTATATAAAATTATTCATAATGATAGTAGGAGGCTTGGTAGGTTTAAGAATAGTTTTTGCTGTACTTTCTATAGTGAATAGAGTTAGGCAGGGAT
ATTCACCATTATCGTTTCAGACCCACCTCCCAACCCCGAGGGGACCCGACAGGCCCGAAGGAATAGAAGAAGAAGGTGGAGAGAGAGACAGAGACAG
ATCCATTCGATTAGTGAACGGATCCTTGGCACTTATCTGGGACGATCTGCGGAGCCTGTGCCTCTTCAGCTACCACCGCTTGAGAGACTTACTCTTG
ATTGTAACGAGGATTGTGGAACTTCTGGGACGCAGGGGGTGGGAAGCCCTCAAATATTGGTGGAATCTCCTACAGTATTGGAGTCAGGAACTAAAGA
ATAGTGCTGTTAGCTTGCTCAATGCCACAGCCATAGCAGTAGCTGAGGGGACAGATAGGGTTATAGAAGTAGTACAAGGAGCTTGTAGAGCTATTCG
CCACATACCTAGAAGAATAAGACAGGGCTTGGAAAGGATTTTGCTATAA 
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I.2. Reporter Protein Sequences 
 
Reporter Gene | Length (bp) | Accession Number | Plasmid Source (Supplier) | Construct ID
1 
1
Refers to amplification primers detailed in Chapter 2 (Table 2.5 – 2.6) 
 
Cypridina Luciferase | 1662 | - | pCMV-CLuc 2 (New England BioLabs) | C3.1 
ATGAAGACCTTAATTCTTGCCGTTGCATTAGTCTACTGCGCCACTGTTCATTGCCAGGACTGTCCTTACGAACCTGATCCACCAAACACAGTTCCAA
CTTCCTGTGAAGCTAAAGAAGGAGAATGTATTGATAGCAGCTGTGGCACCTGCACGAGAGACATACTATCAGATGGACTGTGTGAAAATAAACCAGG
AAAAACATGTTGCCGAATGTGTCAGTATGTAATTGAATGCAGAGTAGAGGCCGCAGGATGGTTTAGAACATTCTATGGAAAGAGATTCCAGTTCCAG
GAACCTGGTACATACGTGTTGGGTCAAGGAACCAAGGGCGGCGACTGGAAGGTGTCCATCACCCTGGAGAACCTGGATGGAACCAAGGGGGCTGTGC
TGACCAAGACAAGACTGGAAGTGGCTGGAGACATCATTGACATCGCTCAAGCTACTGAGAATCCCATCACTGTAAACGGTGGAGCTGACCCTATCAT
CGCCAACCCGTACACCATCGGCGAGGTCACCATCGCTGTTGTTGAGATGCCAGGCTTCAACATCACCGTCATTGAGTTCTTCAAACTGATCGTGATC
GACATCCTCGGAGGAAGATCTGTAAGAATCGCCCCAGACACAGCAAACAAAGGAATGATCTCTGGCCTCTGTGGAGATCTTAAAATGATGGAAGATA
CAGACTTCACTTCAGATCCAGAACAACTCGCTATTCAGCCTAAGATCAACCAGGAGTTTGACGGTTGTCCACTCTATGGAAATCCTGATGACGTTGC
ATACTGCAAAGGTCTTCTGGAGCCGTACAAGGACAGCTGCCGCAACCCCATCAACTTCTACTACTACACCATCTCCTGCGCCTTCGCCCGCTGTATG
GGTGGAGACGAGCGAGCCTCACACGTGCTGCTTGACTACAGGGAGACGTGCGCTGCTCCCGAAACTAGAGGAACCTGCGTTTTGTCTGGACATACTT
TCTACGATACATTTGACAAAGCAAGATACCAATTCCAGGGTCCCTGCAAGGAGATTCTTATGGCCGCCGACTGTTTCTGGAACACTTGGGATGTGAA
GGTTTCACACAGGAATGTTGACTCTTACACTGAAGTAGAGAAAGTACGAATCAGGAAACAATCGACTGTAGTAGAACTCATTGTTGATGGAAAACAG
ATTCTGGTTGGAGGAGAAGCCGTGTCCGTCCCGTACAGCTCTCAGAACACTTCCATCTACTGGCAAGATGGTGACATACTGACTACAGCCATCCTAC
CTGAAGCTCTGGTGGTCAAGTTCAACTTCAAGCAACTGCTCGTCGTACATATTAGAGATCCATTCGATGGTAAGACTTGCGGTATTTGCGGTAACTA
CAACCAGGATTTCAGTGATGATTCTTTTGATGCTGAAGGAGCCTGTGATCTGACCCCCAACCCACCGGGATGCACCGAAGAACAGAAACCTGAAGCT
GAACGACTCTGCAATAGTCTCTTCGCCGGTCAAAGTGATCTTGATCAGAAATGTAACGTGTGCCACAAGCCTGACCGTGTCGAACGATGCATGTACG
AGTATTGCCTGAGGGGACAACAGGGTTTCTGTGACCACGCATGGGAGTTCAAGAAAGAATGCTACATAAAGCATGGAGACACCCTAGAAGTACCAGA
TGAATGCAAATAG 
 
 
NanoLuc Luciferase | 516 | JQ437370 | pNL1.1[Nluc] (Promega) | C3.2 
ATGGTCTTCACACTCGAAGATTTCGTTGGGGACTGGCGACAGACAGCCGGCTACAACCTGGACCAAGTCCTTGAACAGGGAGGTGTGTCCAGTTTGT
TTCAGAATCTCGGGGTGTCCGTAACTCCGATCCAAAGGATTGTCCTGAGCGGTGAAAATGGGCTGAAGATCGACATCCATGTCATCATCCCGTATGA
AGGTCTGAGCGGCGACCAAATGGGCCAGATCGAAAAAATTTTTAAGGTGGTGTACCCTGTGGATGATCATCACTTTAAGGTGATCCTGCACTATGGC
ACACTGGTAATCGACGGGGTTACGCCGAACATGATCGACTATTTCGGACGGCCGTATGAAGGCATCGCCGTGTTCGACGGCAAAAAGATCACTGTAA
CAGGGACCCTGTGGAACGGCAACAAAATTATCGACGAGCGCCTGATCAACCCCGACGGCTCCCTGCTGTTCCGAGTAACCATCAACGGAGTGACCGG
CTGGCGGCTGTGCGAACGCATTCTGGCGTAA 
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Secreted Alkaline Phosphatase (SEAP) | 1521 | U09660 | pSEAP-Basic (Clontech) | C3.3 
ATGCTGCTGCTGCTGCTGCTGCTGGGCCTGAGGCTACAGCTCTCCCTGGGCATCATCCCAGTTGAGGAGGAGAACCCGGACTTCTGGAACCGCGAGG
CAGCCGAGGCCCTGGGTGCCGCCAAGAAGCTGCAGCCTGCACAGACAGCCGCCAAGAACCTCATCATCTTCCTGGGCGATGGGATGGGGGTGTCTAC
GGTGACAGCTGCCAGAATCCTAAAAGGGCAGAAGAAGGACAAACTGGGGCCTGAGATACCCCTGGCCATGGACCGCTTCCCATATGTGGCTCTGTCC
AAGACATACAATGTAGACAAACATGTGCCAGACAGTGGAGCCACAGCCACGGCCTACCTGTGCGGGGTCAAGGGCAACTTCCAGACCATTGGCTTGA
GTGCAGCCGCCCGCTTTAACCAGTGCAACACGACACGCGGCAACGAGGTCATCTCCGTGATGAATCGGGCCAAGAAAGCAGGGAAGTCAGTGGGAGT
GGTAACCACCACACGAGTGCAGCACGCCTCGCCAGCCGGCACCTACGCCCACACGGTGAACCGCAACTGGTACTCGGACGCCGACGTGCCTGCCTCG
GCCCGCCAGGAGGGGTGCCAGGACATCGCTACGCAGCTCATCTCCAACATGGACATTGACGTGATCCTAGGTGGAGGCCGAAAGTACATGTTTCGCA
TGGGAACCCCAGACCCTGAGTACCCAGATGACTACAGCCAAGGTGGGACCAGGCTGGACGGGAAGAATCTGGTGCAGGAATGGCTGGCGAAGCGCCA
GGGTGCCCGGTATGTGTGGAACCGCACTGAGCTCATGCAGGCTTCCCTGGACCCGTCTGTGACCCATCTCATGGGTCTCTTTGAGCCTGGAGACATG
AAATACGAGATCCACCGAGACTCCACACTGGACCCCTCCCTGATGGAGATGACAGAGGCTGCCCTGCGCCTGCTGAGCAGGAACCCCCGCGGCTTCT
TCCTCTTCGTGGAGGGTGGTCGCATCGACCATGGTCATCATGAAAGCAGGGCTTACCGGGCACTGACTGAGACGATCATGTTCGACGACGCCATTGA
GAGGGCGGGCCAGCTCACCAGCGAGGAGGACACGCTGAGCCTCGTCACTGCCGACCACTCCCACGTCTTCTCCTTCGGAGGCTACCCCCTGCGAGGG
AGCTCCATCTTCGGGCTGGCCCCTGGCAAGGCCCGGGACAGGAAGGCCTACACGGTCCTCCTATACGGAAACGGTCCAGGCTATGTGCTCAAGGACG
GCGCCCGGCCGGATGTTACCGAGAGCGAGAGCGGGAGCCCCGAGTATCGGCAGCAGTCAGCAGTGCCCCTGGACGAAGAGACCCACGCAGGCGAGGA
CGTGGCGGTGTTCGCGCGCGGCCCGCAGGCGCACCTGGTTCACGGCGTGCAGGAGCAGACCTTCATAGCGCACGTCATGGCCTTCGCCGCCTGCCTG
GAGCCCTACACCGCCTGCGACCTGGCGCCCCCCGCCGGCACCACCGACGCCGCGCACCCGGGTTAA 
 
 
Secreted Alkaline Phosphatase (version 2) (SEAP2) | 1560 | U89937 | pSEAP2-Basic 
(Clontech) | C3.4 
ATGCTGCTGCTGCTGCTGCTGCTGGGCCTGAGGCTACAGCTCTCCCTGGGCATCATCCCAGTTGAGGAGGAGAACCCGGACTTCTGGAACCGCGAGG
CAGCCGAGGCCCTGGGTGCCGCCAAGAAGCTGCAGCCTGCACAGACAGCCGCCAAGAACCTCATCATCTTCCTGGGCGATGGGATGGGGGTGTCTAC
GGTGACAGCTGCCAGAATCCTAAAAGGGCAGAAGAAGGACAAACTGGGGCCTGAGATACCCCTGGCCATGGACCGCTTCCCATATGTGGCTCTGTCC
AAGACATACAATGTAGACAAACATGTGCCAGACAGTGGAGCCACAGCCACGGCCTACCTGTGCGGGGTCAAGGGCAACTTCCAGACCATTGGCTTGA
GTGCAGCCGCCCGCTTTAACCAGTGCAACACGACACGCGGCAACGAGGTCATCTCCGTGATGAATCGGGCCAAGAAAGCAGGGAAGTCAGTGGGAGT
GGTAACCACCACACGAGTGCAGCACGCCTCGCCAGCCGGCACCTACGCCCACACGGTGAACCGCAACTGGTACTCGGACGCCGACGTGCCTGCCTCG
GCCCGCCAGGAGGGGTGCCAGGACATCGCTACGCAGCTCATCTCCAACATGGACATTGACGTGATCCTAGGTGGAGGCCGAAAGTACATGTTTCGCA
TGGGAACCCCAGACCCTGAGTACCCAGATGACTACAGCCAAGGTGGGACCAGGCTGGACGGGAAGAATCTGGTGCAGGAATGGCTGGCGAAGCGCCA
GGGTGCCCGGTATGTGTGGAACCGCACTGAGCTCATGCAGGCTTCCCTGGACCCGTCTGTGACCCATCTCATGGGTCTCTTTGAGCCTGGAGACATG
AAATACGAGATCCACCGAGACTCCACACTGGACCCCTCCCTGATGGAGATGACAGAGGCTGCCCTGCGCCTGCTGAGCAGGAACCCCCGCGGCTTCT
TCCTCTTCGTGGAGGGTGGTCGCATCGACCATGGTCATCATGAAAGCAGGGCTTACCGGGCACTGACTGAGACGATCATGTTCGACGACGCCATTGA
GAGGGCGGGCCAGCTCACCAGCGAGGAGGACACGCTGAGCCTCGTCACTGCCGACCACTCCCACGTCTTCTCCTTCGGAGGCTACCCCCTGCGAGGG
AGCTCCATCTTCGGGCTGGCCCCTGGCAAGGCCCGGGACAGGAAGGCCTACACGGTCCTCCTATACGGAAACGGTCCAGGCTATGTGCTCAAGGACG
GCGCCCGGCCGGATGTTACCGAGAGCGAGAGCGGGAGCCCCGAGTATCGGCAGCAGTCAGCAGTGCCCCTGGACGAAGAGACCCACGCAGGCGAGGA
CGTGGCGGTGTTCGCGCGCGGCCCGCAGGCGCACCTGGTTCACGGCGTGCAGGAGCAGACCTTCATAGCGCACGTCATGGCCTTCGCCGCCTGCCTG
GAGCCCTACACCGCCTGCGACCTGGCGCCCCCCGCCGGCACCACCGACGCCGCGCACCCGGGTTACTCTAGAGTCGGGGCGGCCGGCCGCTTCGAGC
AGACATGA* 
 
*
39 nucleotide c-terminal extension in comparison to SEAP 
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Dual-Nuclear Localised GFP (dNG) | 1503 | - | pCMS28-NLS-GFP-SAMHD1-CtD (Kate 
Bishop, Francis Crick Institute) | C3.5 
ATGCCCAAGAAAAAGCGGAAAGTGGGCGGCGTGTCCAAGGGCGAGGAACTGTTTACAGGCGTGGTGCCCATCCTGGTGGAACTGGACGGGGATGTGA
ACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAAGGCGACGCCACATATGGCAAGCTGACCCTGAAGTTCATCTGCACCACCGGCAAGCTGCCCGT
GCCTTGGCCTACCCTCGTGACCACACTGACCTACGGCGTGCAGTGCTTCAGCAGATACCCCGACCATATGAAGCAGCACGACTTCTTCAAGAGCGCC
ATGCCCGAGGGCTACGTGCAGGAACGGACCATCTTCTTTAAGGACGACGGCAACTACAAGACCAGGGCCGAAGTGAAGTTCGAGGGCGACACCCTCG
TGAACCGGATCGAGCTGAAGGGCATCGACTTCAAAGAGGACGGCAACATCCTGGGCCACAAGCTGGAGTACAACTACAACAGCCACAACGTGTACAT
CATGGCCGACAAGCAGAAAAACGGCATCAAAGTGAACTTCAAGATCCGGCACAACATCGAGGACGGCTCCGTGCAGCTGGCCGACCACTACCAGCAG
AACACCCCCATCGGAGATGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCACACAGAGCGCCCTGAGCAAGGACCCCAACGAGAAGCGGGACC
ACATGGTGCTGCTGGAATTTGTGACCGCCGCTGGCATCACCCTGGGCATGGACGAGCTGTACAAGTCCGGCATGCCCAAAAAGAAAAGAAAAGTGGG
GGGAGTGTCTAAAGGGGAAGAACTGTTCACCGGGGTGGTGCCTATTCTGGTGGAACTGGATGGCGACGTGAACGGGCATAAGTTTTCCGTGTCTGGG
GAGGGGGAAGGGGATGCTACCTACGGAAAGCTGACACTGAAGTTTATCTGTACAACAGGGAAACTGCCTGTGCCCTGGCCCACACTCGTGACAACCC
TGACATATGGGGTGCAGTGTTTCTCCCGCTACCCTGATCATATGAAGCAGCATGATTTTTTCAAATCCGCTATGCCTGAGGGATATGTGCAGGAAAG
AACAATTTTCTTCAAGGATGATGGGAATTACAAAACACGCGCTGAAGTGAAATTTGAGGGGGATACACTCGTGAATCGCATTGAACTGAAGGGGATT
GATTTCAAAGAGGACGGGAATATTCTGGGGCACAAACTGGAGTATAATTACAATTCCCACAATGTGTATATTATGGCTGATAAGCAGAAAAATGGGA
TCAAAGTGAATTTCAAAATCAGACACAATATTGAGGATGGCAGTGTGCAGCTGGCTGATCATTATCAGCAGAATACTCCTATCGGCGACGGACCTGT
GCTGCTGCCTGATAATCACTATCTGTCCACCCAGTCCGCCCTGTCCAAGGACCCTAATGAGAAACGCGATCATATGGTGCTGCTGGAATTTGTGACA
GCTGCCGGAATTACACTGGGGATGGATGAACTGTATAAGAGCGGCTAA 
 
 
Dual-Nuclear Localised tdTomato (dNT) | 1542 | - | ptdTomato-Nuc (Colin Crump, 
University of Cambridge) | C3.6 
ATGGTGAGCAAGGGCGAGGAGGTCATCAAAGAGTTCATGCGCTTCAAGGTGCGCATGGAGGGCTCCATGAACGGCCACGAGTTCGAGATCGAGGGCG
AGGGCGAGGGCCGCCCCTACGAGGGCACCCAGACCGCCAAGCTGAAGGTGACCAAGGGCGGCCCCCTGCCCTTCGCCTGGGACATCCTGTCCCCCCA
GTTCATGTACGGCTCCAAGGCGTACGTGAAGCACCCCGCCGACATCCCCGATTACAAGAAGCTGTCCTTCCCCGAGGGCTTCAAGTGGGAGCGCGTG
ATGAACTTCGAGGACGGCGGTCTGGTGACCGTGACCCAGGACTCCTCCCTGCAGGACGGCACGCTGATCTACAAGGTGAAGATGCGCGGCACCAACT
TCCCCCCCGACGGCCCCGTAATGCAGAAGAAGACCATGGGCTGGGAGGCCTCCACCGAGCGCCTGTACCCCCGCGACGGCGTGCTGAAGGGCGAGAT
CCACCAGGCCCTGAAGCTGAAGGACGGCGGCCACTACCTGGTGGAGTTCAAGACCATCTACATGGCCAAGAAGCCCGTGCAACTGCCCGGCTACTAC
TACGTGGACACCAAGCTGGACATCACCTCCCACAACGAGGACTACACCATCGTGGAACAGTACGAGCGCTCCGAGGGCCGCCACCACCTGTTCCTGG
GGCATGGCACCGGCAGCACCGGCAGCGGCAGCTCCGGCACCGCCTCCTCCGAGGACAACAACATGGCCGTCATCAAAGAGTTCATGCGCTTCAAGGT
GCGCATGGAGGGCTCCATGAACGGCCACGAGTTCGAGATCGAGGGCGAGGGCGAGGGCCGCCCCTACGAGGGCACCCAGACCGCCAAGCTGAAGGTG
ACCAAGGGCGGCCCCCTGCCCTTCGCCTGGGACATCCTGTCCCCCCAGTTCATGTACGGCTCCAAGGCGTACGTGAAGCACCCCGCCGACATCCCCG
ATTACAAGAAGCTGTCCTTCCCCGAGGGCTTCAAGTGGGAGCGCGTGATGAACTTCGAGGACGGCGGTCTGGTGACCGTGACCCAGGACTCCTCCCT
GCAGGACGGCACGCTGATCTACAAGGTGAAGATGCGCGGCACCAACTTCCCCCCCGACGGCCCCGTAATGCAGAAGAAGACCATGGGCTGGGAGGCC
TCCACCGAGCGCCTGTACCCCCGCGACGGCGTGCTGAAGGGCGAGATCCACCAGGCCCTGAAGCTGAAGGACGGCGGCCACTACCTGGTGGAGTTCA
AGACCATCTACATGGCCAAGAAGCCCGTGCAACTGCCCGGCTACTACTACGTGGACACCAAGCTGGACATCACCTCCCACAACGAGGACTACACCAT
CGTGGAACAGTACGAGCGCTCCGAGGGCCGCCACCACCTGTTCCTGTACGGCATGGACGAGCTGTACAAGTCCGGACTCAGATCTCGAGCTGATCCA
AAAAAGAAGAGAAAGGTAGATCCAAAAAAGAAGAGAAAGGTAGATCCAAAAAAGAAGAGAAAGGTAGGATCGACCGGATCAAGATAA 
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LacZ | 3138 | - | pCSLZW (Edward Wright) | C4.1 
ATGGCGCCAAAAAAGAAGAGAAAGGTAGAAGACCCCAAGGACTTTCCTTCAGAATTGCTAAGTTTTTTGAGTCCAAGCTTGGCACTGGCCGTCGTTT
TACAACGTCGTGACTGGGAAAACCCTGGCGTTACCCAACTTAATCGCCTTGCAGCACATCCCCCTTTCGCCAGCTGGCGTAATAGCGAAGAGGCCCG
CACCGATCGCCCTTCCCAACAGTTGCGCAGCCTGAATGGCGAATGGCGCTTTGCCTGGTTTCCGGCACCAGAAGCGGTGCCGGAAAGCTGGCTGGAG
TGCGATCTTCCTGAGGCCGATACTGTCGTCGTCCCCTCAAACTGGCAGATGCACGGTTACGATGCGCCCATCTACACCAACGTGACCTATCCCATTA
CGGTCAATCCGCCGTTTGTTCCCACGGAGAATCCGACGGGTTGTTACTCGCTCACATTTAATGTTGATGAAAGCTGGCTACAGGAAGGCCAGACGCG
AATTATTTTTGATGGCGTTAACTCGGCGTTTCATCTGTGGTGCAACGGGCGCTGGGTCGGTTACGGCCAGGACAGTCGTTTGCCGTCTGAATTTGAC
CTGAGCGCATTTTTACGCGCCGGAGAAAACCGCCTCGCGGTGATGGTGCTGCGCTGGAGTGACGGCAGTTATCTGGAAGATCAGGATATGTGGCGGA
TGAGCGGCATTTTCCGTGACGTCTCGTTGCTGCATAAACCGACTACACAAATCAGCGATTTCCATGTTGCCACTCGCTTTAATGATGATTTCAGCCG
CGCTGTACTGGAGGCTGAAGTTCAGATGTGCGGCGAGTTGCGTGACTACCTACGGGTAACAGTTTCTTTATGGCAGGGTGAAACGCAGGTCGCCAGC
GGCACCGCGCCTTTCGGCGGTGAAATTATCGATGAGCGTGGTGGTTATGCCGATCGCGTCACACTACGTCTGAACGTCGAAAACCCGAAACTGTGGA
GCGCCGAAATCCCGAATCTCTATCGTGCGGTGGTTGAACTGCACACCGCCGACGGCACGCTGATTGAAGCAGAAGCCTGCGATGTCGGTTTCCGCGA
GGTGCGGATTGAAAATGGTCTGCTGCTGCTGAACGGCAAGCCGTTGCTGATTCGAGGCGTTAACCGTCACGAGCATCATCCTCTGCATGGTCAGGTC
ATGGATGAGCAGACGATGGTGCAGGATATCCTGCTGATGAAGCAGAACAACTTTAACGCCGTGCGCTGTTCGCATTATCCGAACCATCCGCTGTGGT
ACACGCTGTGCGACCGCTACGGCCTGTATGTGGTGGATGAAGCCAATATTGAAACCCACGGCATGGTGCCAATGAATCGTCTGACCGATGATCCGCG
CTGGCTACCGGCGATGAGCGAACGCGTAACGCGAATGGTGCAGCGCGATCGTAATCACCCGAGTGTGATCATCTGGTCGCTGGGGAATGAATCAGGC
CACGGCGCTAATCACGACGCGCTGTATCGCTGGATCAAATCTGTCGATCCTTCCCGCCCGGTGCAGTATGAAGGCGGCGGAGCCGACACCACGGCCA
CCGATATTATTTGCCCGATGTACGCGCGCGTGGATGAAGACCAGCCCTTCCCGGCTGTGCCGAAATGGTCCATCAAAAAATGGCTTTCGCTACCTGG
AGAGACGCGCCCGCTGATCCTTTGCGAATACGCCCACGCGATGGGTAACAGTCTTGGCGGTTTCGCTAAATACTGGCAGGCGTTTCGTCAGTATCCC
CGTTTACAGGGCGGCTTCGTCTGGGACTGGGTGGATCAGTCGCTGATTAAATATGATGAAAACGGCAACCCGTGGTCGGCTTACGGCGGTGATTTTG
GCGATACGCCGAACGATCGCCAGTTCTGTATGAACGGTCTGGTCTTTGCCGACCGCACGCCGCATCCAGCGCTGACGGAAGCAAAACACCAGCAGCA
GTTTTTCCAGTTCCGTTTATCCGGGCAAACCATCGAAGTGACCAGCGAATACCTGTTCCGTCATAGCGATAACGAGCTCCTGCACTGGATGGTGGCG
CTGGATGGTAAGCCGCTGGCAAGCGGTGAAGTGCCTCTGGATGTCGCTCCACAAGGTAAACAGTTGATTGAACTGCCTGAACTACCGCAGCCGGAGA
GCGCCGGGCAACTCTGGCTCACAGTACGCGTAGTGCAACCGAACGCGACCGCATGGTCAGAAGCCGGGCACATCAGCGCCTGGCAGCAGTGGCGTCT
GGCGGAAAACCTCAGTGTGACGCTCCCCGCCGCGTCCCACGCCATCCCGCATCTGACCACCAGCGAAATGGATTTTTGCATCGAGCTGGGTAATAAG
CGTTGGCAATTTAACCGCCAGTCAGGCTTTCTTTCACAGATGTGGATTGGCGATAAAAAACAACTGCTGACGCCGCTGCGCGATCAGTTCACCCGTG
CACCGCTGGATAACGACATTGGCGTAAGTGAAGCGACCCGCATTGACCCTAACGCCTGGGTCGAACGCTGGAAGGCGGCGGGCCATTACCAGGCCGA
AGCAGCGTTGTTGCAGTGCACGGCAGATACACTTGCTGATGCGGTGCTGATTACGACCGCTCACGCGTGGCAGCATCAGGGGAAAACCTTATTTATC
AGCCGGAAAACCTACCGGATTGATGGTAGTGGTCAAATGGCGATTACCGTTGATGTTGAAGTGGCGAGCGATACACCGCATCCGGCGCGGATTGGCC
TGAACTGCCAGCTGGCGCAGGTAGCAGAGCGGGTAAACTGGCTCGGATTAGGGCCGCAAGAAAACTATCCCGACCGCCTTACTGCCGCCTGTTTTGA
CCGCTGGGATCTGCCATTGTCAGACATGTATACCCCGTACGTCTTCCCGAGCGAAAACGGTCTGCGCTGCGGGACGCGCGAATTGAATTATGGCCCA
CACCAGTGGCGCGGCGACTTCCAGTTCAACATCAGCCGCTACAGTCAACAGCAACTGATGGAAACCAGCCATCGCCATCTGCTGCACGCGGAAGAAG
GCACATGGCTGAATATCGACGGTTTCCATATGGGGATTGGTGGCGACGACTCCTGGAGCCCGTCAGTATCGGCGGAATTCCAGCTGAGCGCCGGTCG
CTACCATTACCAGTTGGTCTGGTGTCAAAAATAA 
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Firefly Luciferase (FLuc) | 1653 | - | pCSFLW (Edward Wright) | C4.2 
ATGGAAGATGCCAAAAACATTAAGAAGGGCCCAGCGCCATTCTACCCACTCGAAGACGGGACCGCCGGCGAGCAGCTGCACAAAGCCATGAAGCGCT
ACGCCCTGGTGCCCGGCACCATCGCCTTTACCGACGCACATATCGAGGTGGACATTACCTACGCCGAGTACTTCGAGATGAGCGTTCGGCTGGCAGA
AGCTATGAAGCGCTATGGGCTGAATACAAACCATCGGATCGTGGTGTGCAGCGAGAATAGCTTGCAGTTCTTCATGCCCGTGTTGGGTGCCCTGTTC
ATCGGTGTGGCTGTGGCCCCAGCTAACGACATCTACAACGAGCGCGAGCTGCTGAACAGCATGGGCATCAGCCAGCCCACCGTCGTATTCGTGAGCA
AGAAAGGGCTGCAAAAGATCCTCAACGTGCAAAAGAAGCTACCGATCATACAAAAGATCATCATCATGGATAGCAAGACCGACTACCAGGGCTTCCA
AAGCATGTACACCTTCGTGACTTCCCATTTGCCACCCGGCTTCAACGAGTACGACTTCGTGCCCGAGAGCTTCGACCGGGACAAAACCATCGCCCTG
ATCATGAACAGTAGTGGCAGTACCGGATTGCCCAAGGGCGTAGCCCTACCGCACCGCACCGCTTGTGTCCGATTCAGTCATGCCCGCGACCCCATCT
TCGGCAACCAGATCATCCCCGACACCGCTATCCTCAGCGTGGTGCCATTTCACCACGGCTTCGGCATGTTCACCACGCTGGGCTACTTGATCTGCGG
CTTTCGGGTCGTGCTCATGTACCGCTTCGAGGAGGAGCTATTCTTGCGCAGCTTGCAAGACTATAAGATTCAATCTGCCCTGCTGGTGCCCACACTA
TTTAGCTTCTTCGCTAAGAGCACTCTCATCGACAAGTACGACCTAAGCAACTTGCACGAGATCGCCAGCGGCGGGGCGCCGCTCAGCAAGGAGGTAG
GTGAGGCCGTGGCCAAACGCTTCCACCTACCAGGCATCCGCCAGGGCTACGGCCTGACAGAAACAACCAGCGCCATTCTGATCACCCCCGAAGGGGA
CGACAAGCCTGGCGCAGTAGGCAAGGTGGTGCCCTTCTTCGAGGCTAAGGTGGTGGACTTGGACACCGGTAAGACACTGGGTGTGAACCAGCGCGGC
GAGCTGTGCGTCCGTGGCCCCATGATCATGAGCGGCTACGTTAACAACCCCGAGGCTACAAACGCTCTCATCGACAAGGACGGCTGGCTGCACAGCG
GCGACATCGCCTACTGGGACGAGGACGAGCACTTCTTCATCGTGGACCGGCTGAAGAGCCTGATCAAATACAAGGGCTACCAGGTAGCCCCAGCCGA
ACTGGAGAGCATCCTGCTGCAACACCCCAACATCTTCGACGCCGGGGTCGCCGGCCTGCCCGACGACGATGCCGGCGAGCTGCCCGCCGCAGTCGTC
GTGCTGGAACACGGTAAAACCATGACCGAGAAGGAGATCGTGGACTATGTGGCCAGCCAGGTTACAACCGCCAAGAAGCTGCGCGGTGGTGTTGTGT
TCGTGGACGAGGTGCCTAAAGGACTGACCGGCAAGTTGGACGCCCGCAAGATCCGCGAGATTCTCATTAAGGCCAAGAAGGGCGGCAAGATCGCCGT
GTAA 
 
 
Green Fluorescent Protein (GFP) | 720 | - | pCSFLW (Edward Wright) | C4.2 
ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCG
AGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCT
GACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGC
ACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCG
ACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCAT
CAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTG
CTGCTGCCCGACAACCACTACCTGAGCACCCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCG
CCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGTAA 
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I.3. Plasmid Maps 
 
 
Figure XVI pI.18 Expression Plasmid 
The pI.18 plasmid comprises a human cytomegalovirus (CMV) early immediate promoter, truncated 
enhancer region, intron A gene and terminator sequence. The multiple cloning site is shown. It contains an 
ampicillin resistance gene (AMP) as a selectable marker under a bacterial origin of replication (not shown).  
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Figure XVII pCAGGS Expression Plasmid 
The pCAGGS plasmid comprises a full chicken β-actin promoter and an efficient poly(A) signal from a 
rabbit β-globin gene. The multiple cloning site (MCS) is shown. It contains an ampicillin resistance gene 
(ampR) as a selectable marker under a bacterial origin of replication (pBR322). Map drawn using 
DNADynamo software.  
 
  
DNADynamo Vector Report 
CAG enhancer                   83-371 
chicken β-actin                383-662 
MCS                            1719-1766 
rabbit β-globin poly(A)        1772-2202 
SV40                           2420-2622 
Ori_pBR322                     2980-3599 
ampR                           3754-4614 
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Figure XVIII pCS[reporter]W Expression Plasmid 
The pCS[reporter]W plasmid comprises a HIV 5’LTR, packaging signal () and rev-response element 
(RRE) upstream of the reporter gene (cloned within the BamHI and NotI restriction sites) which are required 
for reverse transcription and integration. The strong spleen focus forming virus (SFFV) promoter to drives 
gene expression and a 3’LTR with a deletion in the U3 region makes the system self-inactivating (SIN). The 
central polypurine tract (cPPT) and woodchuck hepatitis virus post-transcriptional regulatory element 
(WPRE), lacking the oncogenic X protein, act to enhance transduction efficiency and expression. The 
plasmid contains an ampicillin resistance gene (ampR) as a selectable marker under a bacterial origin of 
replication (pBR322). Map drawn using DNADynamo software. 
  
DNADynamo Vector Report  
WPRE                           320-912 
3'∆U3/LTR                      1019-1252 
ampR                           2188-3048 
Ori_pBR322                     3203-3822 
SV40                           4186-4388 
5'LTR                          6911-7091 
Ψ                              7202-7246 
RRE                            7756-7989 
cPPT                           8502-8620 
SFFV                           8772-126 
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Appendix II  
II.1. Arctic-like Rabies Virus Phylogeny 
A phylogenetic tree was constructed by Dr Daniel Horton (University of Surrey) to demonstrate the 
relatedness of the Arctic-like rabies virus isolates used in this study (Figure IV). Construction 
involved the analysis of 96 RABV glycoprotein sequences (1575 nucleotides) inferred using 
MEGA6, with a GTR substitution model, gamma distribution of rate variation sites as a proportion 
of invariant sites (GTR+G+I). Established lineages were illustrated and all except the Arctic-related 
viruses collapsed for clarity. Bootstrap values (100 replicates) were illustrated at key nodes. 
 
Figure XIX Maximum Likelihood Phylogenetic Tree of 96 RABV Glycoprotein Coding 
Sequences 
Branches are labelled with bootstrap values at key nodes. Established clade, sub-clade and lineages are 
illustrated as previously defined (Pant et al., 2013) and all except the Arctic-related viruses are collapsed for 
clarity. Positions of the viruses used in this study (RV61, RV193, RV250 and RV277) are indicated. 
Constructed by Dr Daniel Horton (University of Surrey) 
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II.2. Serum Samples from Rabies Virus Vaccinated Humans and Domestic Animals 
Details are provided on the FAVN titre of serum samples from human (Table I) and domestic 
animal (Table II) vaccinees. Samples were provided by Dr Edward Wright and had been obtained 
as part of a previous study (Wright et al., 2008). 
Table III FAVN Titre Assigned to Vaccinated Human Serum Samples 
Samples from humans vaccinated with a Rabipur, Novartis vaccine and titres assigned by the fluorescent 
antibody virus neutralisation (FAVN) test 
Sample ID FAVN titre (IU/mL) 
H1 0.03 
H5 0.10 
H6 0.10 
H7 0.03 
H61 0.38 
H66 0.50 
H67 17.77 
H76 2.60 
H77 2.60 
H90 3.42 
 
Table IV FAVN Titre Assigned to Vaccinated Domestic Animal Serum Samples 
Samples from vaccinated domestic dogs and cats enrolled on the UK pet travel scheme (PETS), with titres 
assigned by the fluorescent antibody virus neutralisation (FAVN) test 
Sample ID FAVN titre (IU/mL) Vaccine Animal 
PET-5531 0.38 Nobivac, Intervet Dog 
PET-5545 0.22 Rabisin, Merial Dog 
PET-5734 0.38 Rabisin, Merial Dog 
PET-5896 0.07 Quantum, Schering Plough Dog 
PET-7649 4.50 Rabvac, Fort Dodge Cat 
PET-7653 40.50 Rabvac, Fort Dodge Cat 
PET-8418 23.38 Rabvac, Fort Dodge Cat 
PET-8742 479.71 Nobivac, Intervet Dog 
PET-9240 7.79 Nobivac, Intervet Dog 
PET-1323 159.90 Quantum, Schering Plough Dog 
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Appendix III   
III.1. Assessment of Expression Plasmid for Ebolavirus Envelope Protein 
 
 
 
Figure XX Comparison of Ebolavirus PV Titres using Different Envelope GP Expression 
Plasmids 
Lentiviral PV with a firefly luciferase reporter gene was produced by a standard three plasmid transfection, 
supplying the envelope GP of Reston or Bundibugyo ebolavirus within different expression plasmids for 
production comparison. Titres of PV were measured by a luciferase assay following infection of HEK 
293T/17 cells, reported in relative light units per ml (RLU/mL). Error bars show SD (n = 4). Data produced 
by Edward Wright  
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III.2. Morphology of Zaire ebolavirus Pseudotyped Virus 
 
 
Figure XXI Electron Microscopy of Zaire ebolavirus PV 
Samples of lentiviral PV produced with a Zaire ebolavirus GP (isolate: EBOV/Mayinga/COD/1976) were 
analysed via electron microscopy using a 4% ammonium molybdate pH6.0 with 1% trehalose composition at 
the Wellcome Trust Sanger Institute (credit: Rachael Wash, Špela Binter, Mathias Friedrich, David Goulding 
and Paul Kellam).  
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Appendix IV  
IV.1. Quantification of PV genome copies via RT-qPCR 
 
 
Figure XXII Standard Curve for RT-qPCR Genome Quantification of PV 
Standard curve composed of a 10-fold dilution series of the pCSFLW plasmid, between 1 x 10
1
 – 1 x 108 
copies for the two independent runs (n = 2). A Ct value was not assigned to quantities between 1 x 10
1
 – 1 x 
10
3
. The slope, y-intercept and efficiency of the reactions are displayed, calculated from the equation of the 
line in GraphPad Prism v.5.02.  
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IV.2. Quantification of PV core RT activity via SG-PERT Assay 
 
 
Figure XXIII Standard Curve for SG-PERT Assay Core RT Activity Quantification of PV 
Standard curve composed of a 10-fold dilution series of the HIV RT standard between 1 x 10
3
 – 1 x 109 pU 
for the two independent runs (n = 3). The slope, y-intercept and efficiency of the reactions are displayed, 
calculated from the equation of the line in GraphPad Prism v.5.02. 
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